Variant Annotation ID	Variant/Haplotypes	Drug(s)	Phenotype Category	Significance	Sentence	Allele Of Frequency In Cases	Allele Of Frequency In Controls	P Value	Ratio Stat Type	Ratio Stat	Confidence Interval Start	Confidence Interval Stop
1183684657	CYP2D6 ultrarapid metabolizer genotype	tramadol	Metabolism/PK	yes	CYP2D6 ultra-metabolizer genotype is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 poor metabolizer genotype.			< 0.001	OR			
1183684661	CYP2D6 normal metabolizer genotype	tramadol	Metabolism/PK	yes	CYP2D6 normal metabolizer genotype is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 poor metabolizer genotype.			< 0.001	OR			
982047744	CYP2D6*1xN	codeine	Metabolism/PK	not stated	CYP2D6 *1xN is associated with increased metabolism of codeine.				Unknown			
1451152848	CYP2D6 poor metabolizer phenotype	codeine	Metabolism/PK	not stated	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.							
1449296077	CYP3A4*36	fentanyl	Dosage,Efficacy	yes	CYP3A4 *36 is associated with decreased dose of fentanyl in women with Pain, Postoperative.	*36		< 0.05	OR			
1449296077	CYP3A4*36	fentanyl	Dosage,Efficacy	yes	CYP3A4 *36 is associated with decreased dose of fentanyl in women with Pain, Postoperative.			> 0.05				
1451308040	NAT2 slow acetylator	isoniazid	Metabolism/PK	no	NAT2 slow acetylator is associated with increased concentrations of isoniazid in healthy individuals as compared to NAT2 rapid acetylator.							
1451153620	CYP2D6 poor metabolizer phenotype	codeine	Metabolism/PK	not stated	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.							
1451308140	NAT2 slow acetylator	rifapentine	Metabolism/PK	not stated	NAT2 slow acetylator is associated with increased concentrations of rifapentine in people with HIV Infections.							
1451308160	CYP2B6 poor metabolizer	efavirenz	Metabolism/PK	not stated	CYP2B6 poor metabolizer is associated with increased concentrations of efavirenz in people with HIV Infections.							
1451308144	NAT2 slow acetylator	efavirenz	Metabolism/PK	not stated	NAT2 slow acetylator is associated with increased concentrations of efavirenz in people with HIV Infections.							
1451308122	NAT2 slow acetylator	nevirapine	Metabolism/PK	not stated	NAT2 slow acetylator is associated with increased concentrations of nevirapine in people with HIV Infections.							
1451161820	rs1045642	methadone	Metabolism/PK	no	Allele G is not associated with concentrations of methadone in people with Opioid-Related Disorders as compared to allele A.			= 0.352				
981240165	rs1799930	isoniazid	Toxicity,Metabolism/PK	yes	Genotype AA is associated with decreased clearance of isoniazid in people with Tuberculosis as compared to genotype GG.			= 0.04	Unknown			
1451151940	CYP2D6 poor metabolizer phenotype	dihydrocodeine	Metabolism/PK	no	CYP2D6 poor metabolizer phenotype is not associated with exposure to dihydrocodeine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.			> 0.05				
1451151966	CYP2D6 poor metabolizer phenotype	dihydromorphine	Metabolism/PK	no	CYP2D6 poor metabolizer phenotype is associated with increased concentrations of dihydromorphine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.			< 0.01				
1451163180	rs4149056	atorvastatin	Metabolism/PK	yes	Allele C is associated with increased exposure to atorvastatin as compared to allele T.			= 2.21e-6				
1451163194	rs887829	atorvastatin	Metabolism/PK	yes	Allele T is associated with increased metabolism of atorvastatin as compared to allele C.			= 7.25e-16				
1446896368	CYP2D6 ultrarapid metabolizer genotype	tramadol	Metabolism/PK	yes	CYP2D6 ultrarapid metabolizer genotype is associated with increased metabolism of tramadol.			< 0.001	OR			
1451163221	rs45446698	atorvastatin	Metabolism/PK	yes	Allele G is associated with increased metabolism of atorvastatin as compared to allele T.			= 6.18e-7				
1451334662	rs1058164	aripiprazole	Metabolism/PK	yes	Genotype GG is associated with increased concentrations of aripiprazole in healthy individuals as compared to genotypes CC + CG.	G		= 0.000				
1451163505	rs4149056	rifampin	Metabolism/PK	no	Allele C is not associated with exposure to rifampin in men as compared to allele T.			> 0.05	Unknown			
1451334680	rs28371699	aripiprazole	Metabolism/PK	yes	Genotype AA is associated with increased concentrations of aripiprazole in healthy individuals as compared to genotypes AC + CC.	C		= 0.000				
1451334722	CYP2D6 intermediate metabolizer	aripiprazole	Metabolism/PK	yes	CYP2D6 intermediate metabolizer is associated with increased concentrations of aripiprazole in healthy individuals as compared to CYP2D6 normal metabolizer.			= 0.000				
1451334781	rs1135840	aripiprazole	Metabolism/PK	yes	Genotype GG is associated with increased concentrations of aripiprazole in healthy individuals as compared to genotypes CC + CG.	G		= 0.000				
1451334860	rs28371702	aripiprazole	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of aripiprazole in healthy individuals as compared to genotypes AA + AC.	C		= 0.000				
1448099915	CYP2D6 normal metabolizer genotype	flecainide	Metabolism/PK	yes	CYP2D6 normal metabolizer genotype is associated with concentrations of flecainide in people with Tachycardia, Supraventricular as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.			< 0.0001	OR			
1451317740	CYP2C9 poor metabolizers	olanzapine	Metabolism/PK	yes	CYP2C9 poor metabolizers are associated with increased exposure to olanzapine in healthy individuals as compared to CYP2C9 intermediate metabolizer and normal metabolizer.			< 0.05				
1451335308	rs2273697	olanzapine	Metabolism/PK	no	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	A		> 0.05				
1451206861	rs1128503	morphine	Metabolism/PK	yes	Genotypes AG + GG are associated with decreased concentrations of morphine as compared to genotype AA.			= 0.04				
1451335158	rs1045642	olanzapine	Metabolism/PK	no	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	A		> 0.05				
1451335303	rs7787082	olanzapine	Metabolism/PK	no	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	G		> 0.05				
1451335460	rs2108622	olanzapine	Metabolism/PK	no	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	T		> 0.05				
1451335452	rs6314	olanzapine	Metabolism/PK	no	Genotype AG is not associated with exposure to olanzapine in healthy individuals as compared to genotype GG.	A		> 0.05				
1451335520	rs7997012	olanzapine	Metabolism/PK	no	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	A		> 0.05				
1451335447	rs6277	olanzapine	Metabolism/PK	no	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	G		> 0.05				
1451335416	rs1800497	olanzapine	Metabolism/PK	no	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	A		> 0.05				
1451335433	rs6280	olanzapine	Metabolism/PK	no	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	C		> 0.05				
1451335582	rs1137101	olanzapine	Metabolism/PK	no	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	G		> 0.05				
1451317820	rs34059508	olanzapine	Metabolism/PK	yes	Genotype AG is associated with increased exposure to olanzapine in healthy individuals as compared to genotype GG.			= 0.004				
1451317820	rs34059508	olanzapine	Metabolism/PK	yes	Genotype AG is associated with increased exposure to olanzapine in healthy individuals as compared to genotype GG.			= 0.007				
1451317900	rs5128	olanzapine	Metabolism/PK	no	Genotype CG is associated with increased exposure to olanzapine in healthy individuals as compared to genotype GG.			= 0.068				
1451317880	rs3842	olanzapine	Metabolism/PK	yes	Allele T is associated with increased clearance of olanzapine in healthy individuals as compared to allele C.			= 0.016				
1451155820	CYP2D6 poor metabolizer phenotype	tramadol	Metabolism/PK	yes	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.			< 0.05				
1451207760	CYP2D6 poor metabolizers	Dabigatran	Metabolism/PK	yes	CYP2D6 poor metabolizers are associated with decreased clearance of Dabigatran in healthy individuals.			= 0.049				
1451164966	rs2306283	atorvastatin	Metabolism/PK	no	Genotypes AA + AG are not associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to genotype GG.			> 0.05				
1451207800	rs2244613	Dabigatran	Metabolism/PK	no	Allele T is not associated with clearance of Dabigatran in healthy individuals as compared to allele G.	G						
1451207769	rs8192935	Dabigatran	Metabolism/PK	no	Allele G is not associated with clearance of Dabigatran in healthy individuals as compared to allele A.	A						
1451207900	CYP2D6 poor metabolizer	tramadol	Metabolism/PK	not stated	CYP2D6 poor metabolizer is associated with increased exposure to tramadol as compared to CYP2D6 intermediate metabolizer and normal metabolizer.							
1451156342	rs4124874	SN-38	Metabolism/PK	no	Genotypes GG + GT is not associated with metabolism of SN-38 in people with Neoplasms as compared to genotype TT.			= 0.0724	OR			
1451156580	rs4124874	bilirubin	Metabolism/PK	yes	Genotypes GG + GT is associated with increased concentrations of bilirubin in people with Neoplasms as compared to genotype TT.			= 0.0048	OR			
1451156420	rs1045642	methadone	Metabolism/PK	no	Genotype AA is not associated with concentrations of methadone as compared to genotypes AG + GG.							
1448109809	rs1045642	methadone	Metabolism/PK	yes	Genotype AG is associated with increased concentrations of methadone in men with Opioid-Related Disorders as compared to genotypes AA + GG.	A		= 0.033	OR			
1448104379	rs1045642	methadone	Metabolism/PK	yes	Genotype AA is associated with increased clearance of methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.	A		< 0.05	OR			
1451157860	CYP2D6 ultrarapid metabolizer genotype	morphine	Metabolism/PK	yes	CYP2D6 ultrarapid metabolizer genotype is associated with increased exposure to morphine in healthy individuals as compared to CYP2D6 normal metabolizer genotype.			= 0.02				
1451158023	CYP1A2 low activity	methadone	Metabolism/PK	not stated	CYP1A2 low activity is not associated with trough concentration of methadone as compared to CYP1A2 high activity.							
1451158020	CYP2D6 poor metabolizer phenotype	methadone	Metabolism/PK	not stated	CYP2D6 poor metabolizer phenotype is not associated with trough concentration of methadone as compared to CYP2D6 normal metabolizer phenotype.							
1451158041	CYP3A low activity	methadone	Metabolism/PK	yes	CYP3A low activity is associated with increased trough concentration of methadone as compared to CYP3A high activity.			< 0.001				
1451343760	rs10929303	acetaminophen glucuronide	Metabolism/PK	not stated	Genotype CC is associated with increased formation of acetaminophen glucuronide in healthy individuals as compared to genotypes CT + TT.	G						
1451342940	rs8330	acetaminophen glucuronide	Metabolism/PK	not stated	Genotype GG is associated with increased formation of acetaminophen glucuronide in healthy individuals as compared to genotypes CC + CG.	G						
1451158461	rs147055479	methylphenidate	Dosage,Efficacy	no	Genotype GG is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	A			OR			
1451158820	rs36120609	olanzapine	Metabolism/PK	yes	Genotype TCCTC/TCCTC is associated with decreased concentrations of olanzapine in healthy individuals as compared to genotypes TC/TC + TC/TCCTC.			< 0.05				
1451158825	rs36120609	olanzapine	Metabolism/PK	yes	Genotype TCCTC/TCCTC is associated with increased clearance of olanzapine in healthy individuals as compared to genotypes TC/TC + TC/TCCTC.			< 0.05				
1448997136	rs2279343	efavirenz	Metabolism/PK	yes	Genotypes AG + GG are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype AA.	G		< 0.01	OR			
1451261560	rs2279343	efavirenz	Metabolism/PK	yes	Allele G is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele A.			< 0.001				
1451352404	rs4149056	simvastatin	Metabolism/PK	no	Allele C is not associated with increased concentrations of simvastatin in healthy individuals as compared to genotype TT.							
1451352480	rs4149056	simvastatin acid	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.			< 0.0001				
1451352500	rs4149056	simvastatin acid	Metabolism/PK	not stated	Genotype CT is associated with increased exposure to simvastatin acid in healthy individuals as compared to genotype TT.				Unknown			
1451352522	rs2231142	rosuvastatin	Metabolism/PK	not stated	Genotypes GT + TT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype GG.				Unknown			
1451352820	rs4149056	atorvastatin	Metabolism/PK	yes	Genotypes CC + CT are associated with increased concentrations of atorvastatin as compared to genotype TT.			< 0.05				
1451352866	rs4149056	atorvastatin	Metabolism/PK	yes	Genotypes CC + CT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype TT.			= 0.004				
1451352886	rs1801133	atorvastatin	Metabolism/PK	yes	Genotypes AA + AG are associated with decreased concentrations of atorvastatin in healthy individuals as compared to genotype GG.			= 0.05				
1451353000	rs2306283	atorvastatin	Metabolism/PK	no	Genotypes AG + GG are not associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype AA.			= 0.977				
1451352900	rs1800629	atorvastatin	Metabolism/PK	yes	Genotypes AA + AG are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype GG.			= 0.035				
1451352892	rs6280	atorvastatin	Metabolism/PK	yes	Genotype TT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotypes CC + CT.			= 0.026				
1451352940	rs4149056	atorvastatin	Metabolism/PK	not stated	Genotypes CC + CT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype TT.			= 0.057				
1184514558	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	C		< 0.05	OR			
1183698721	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	T		< 0.05	OR			
1183698721	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	T		> 0.05	OR			
1184515373	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotype CT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	T		= 0.01	OR			
1444694284	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	C		< 0.001	OR			
1448603528	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotypes CT + TT.	C		< 0.05	OR			
1448635746	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CT is associated with decreased exposure to tacrolimus in people with Kidney Transplantation as compared to genotype CC.	C	T	= 0.033	OR			
1449575706	rs776746	tacrolimus	Metabolism/PK	not stated	Genotype TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.				OR			
1451356100	rs28379954	clozapine	Metabolism/PK	yes	Genotype CT is associated with decreased concentrations of clozapine in people with Schizophrenia as compared to genotype TT.	C		= 1.677E-8				
1451356350	rs11265549	methadone	Metabolism/PK	yes	Genotype AA is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.	A		= 0.0006				
1451230062	rs4149056	atorvastatin	Metabolism/PK	yes	Genotypes CC + CT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype TT.			= 0.000				
1184988315	rs28399499	efavirenz	Metabolism/PK	yes	Allele C is associated with decreased metabolism of efavirenz in people with HIV Infections.			= 0.001	OR			
1451230620	CYP2D6 poor metabolizers and intermediate metabolizers	o-desmethyltramadol	Metabolism/PK	yes	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased concentrations of o-desmethyltramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.			= 0.002				
1451358200	rs4149056	rosuvastatin	Metabolism/PK	yes	Genotypes CC + CT are associated with increased concentrations of rosuvastatin in children with Hypercholesterolemia as compared to genotype TT.			= 0.01				
1451358680	rs2306283	rosuvastatin	Metabolism/PK	no	Genotypes AG + GG are not associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype AA.			= 0.148				
1451358673	rs2472677	rosuvastatin	Metabolism/PK	no	Genotypes CT + TT are not associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype CC.			= 0.197				
1451358700	rs4764980	rosuvastatin	Metabolism/PK	no	Genotype AA is not associated with increased exposure to rosuvastatin in healthy individuals as compared to genotypes AG + GG.			= 0.842				
1451358668	rs2231142	rosuvastatin	Metabolism/PK	yes	Genotypes GT + TT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype GG.	T		= 0.004				
1444693888	rs2306283	rosuvastatin	Metabolism/PK	not stated	Allele G is not associated with exposure to rosuvastatin in healthy individuals as compared to allele A.	A	A		OR			
978614428	CYP2C9*2	warfarin	Dosage,Metabolism/PK	not stated	CYP2C9 *2 is associated with dose of warfarin.	*2			Unknown			
978614428	CYP2C9*2	warfarin	Dosage,Metabolism/PK	not stated	CYP2C9 *2 is associated with dose of warfarin.	*2			Unknown			
1451226263	rs4149056	pravastatin	Metabolism/PK	yes	Genotypes CC + CT are associated with increased concentrations of pravastatin in children with Hypercholesterolemia as compared to genotype TT.			= 0.03				
1296598965	rs3745274	nevirapine	Metabolism/PK	yes	Genotypes GT + TT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	T		< 0.01	OR			
827861835	rs3745274	nevirapine	Toxicity,Metabolism/PK	not stated	Genotypes GT + TT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	G			Unknown			
827823670	rs3745274	nevirapine	Dosage,Metabolism/PK	yes	Genotypes GT + TT are associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.			= 0.05	Unknown			
1296598953	rs28399499	nevirapine	Metabolism/PK	not stated	Genotype CT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype TT.	C		< 0.01	OR			
827861853	rs28399499	nevirapine	Toxicity,Metabolism/PK	not stated	Genotype CT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype TT.				Unknown			
1451228555	rs2231142	rosuvastatin	Metabolism/PK	yes	Genotypes GT + TT are associated with increased concentrations of rosuvastatin as compared to genotype GG.			= 1e-4				
1451228580	rs4149056	rosuvastatin	Metabolism/PK	no	Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT.			= 0.0184				
1448995122	rs3842	dolutegravir	Metabolism/PK	no	Allele C is not associated with concentrations of dolutegravir in people with HIV Infections as compared to allele T.			= 0.4693	OR			
1184471413	rs36118214	efavirenz	Metabolism/PK	yes	Genotype GG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.	G		= 0.001	Unknown			
1448995116	rs1045642	dolutegravir	Metabolism/PK	no	Allele A is not associated with concentrations of dolutegravir in people with HIV Infections as compared to allele G.			= 0.3428	OR			
1451141460	rs4149056	rosuvastatin	Metabolism/PK	yes	Genotypes CC + CT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype TT.			= 0.001				
1450928480	rs4646437	tacrolimus	Metabolism/PK	no	Genotypes AA + AG are not associated with concentrations of tacrolimus in children with proteinuria as compared to genotype GG.			= 0.011				
1451141481	NAT2 rapid acetylator	hydralazine	Dosage,Efficacy	not stated	NAT2 rapid acetylator is associated with increased dose of hydralazine in people with Hypertension as compared to NAT2 slow acetylator.			< 0.025				
1449716044	rs2275913	opioids	Dosage,Efficacy	yes	Allele A is associated with increased dose of opioids in people with Pain, Postoperative as compared to allele G.	A		= 0.009	OR			
1451141440	rs2231142	rosuvastatin	Metabolism/PK	yes	Genotypes GT + TT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype GG.			= 5.75e-4				
1450928448	rs10211	tacrolimus	Metabolism/PK	yes	Genotype TT are associated with increased concentrations of tacrolimus in children with null as compared to genotypes CC + CT.			= 0.0004				
1183701305	rs9923231	warfarin	Dosage,Efficacy	yes	Allele C is associated with increased dose of warfarin as compared to allele T.	A		< 0.05	OR			
1183701300	rs9923231	warfarin	Dosage,Efficacy	yes	Allele T is associated with increased response to warfarin as compared to allele C.	A		< 0.05	OR			
1447520509	rs6280	quetiapine	Metabolism/PK	yes	Genotype TT is associated with increased clearance of quetiapine in healthy individuals as compared to genotypes CC + CT.			= 0.012	OR			
1448634582	rs2273697	mycophenolic acid	Metabolism/PK	yes	Allele A is associated with decreased exposure to mycophenolic acid as compared to allele G.			= 0.006	OR			
1448634582	rs2273697	mycophenolic acid	Metabolism/PK	yes	Allele A is associated with decreased exposure to mycophenolic acid as compared to allele G.			= 0.010	OR			
1448634570	rs2273697	mycophenolic acid	Metabolism/PK	yes	Allele A is associated with decreased exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele G.			= 0.008	OR			
1448634570	rs2273697	mycophenolic acid	Metabolism/PK	yes	Allele A is associated with decreased exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele G.			= 0.013	OR			
1448634570	rs2273697	mycophenolic acid	Metabolism/PK	yes	Allele A is associated with decreased exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele G.			= 0.027	OR			
1447962788	CYP2C19*17	voriconazole	Metabolism/PK	not stated	CYP2C19 *17/*17 is associated with decreased concentrations of voriconazole in infants with Severe Combined Immunodeficiency.				OR			
1451141600	NAT2 slow acetylator	hydralazine	Metabolism/PK	not stated	NAT2 slow acetylator is associated with increased concentrations of hydralazine in men with Hypertension as compared to NAT2 rapid acetylator.							
982044124	rs776746	simvastatin	Metabolism/PK	yes	Genotype CC is associated with decreased clearance of simvastatin in healthy individuals as compared to genotype TT.	C		< 0.05	Unknown			
769278040	rs28399468	nicotine	Other,Metabolism/PK	no	Allele A is associated with decreased metabolism of nicotine as compared to allele C.				Unknown			
769278048	rs1801272	coumarin	Other,Metabolism/PK	not stated	Genotype TT is associated with decreased metabolism of coumarin as compared to genotype AT.				Unknown			
769278055	rs1801272	coumarin	Metabolism/PK	not stated	Genotype TT is associated with decreased metabolism of coumarin as compared to genotypes AA + AT.	T			Unknown			
769278059	rs5031016	nicotine	Metabolism/PK	not stated	Allele G is associated with decreased metabolism of nicotine as compared to allele A.				Unknown			
982044179	rs2032582	digoxin	Metabolism/PK	no	Allele C is not associated with clearance of digoxin in people with Heart Failure as compared to allele A.				Unknown			
982044192	rs2032582	digoxin	Metabolism/PK	no	Allele C is not associated with clearance of digoxin in people with Heart Failure as compared to allele T.				Unknown			
1183685147	CYP2C19 poor metabolizer genotype	voriconazole	Metabolism/PK	not stated	CYP2C19 poor metabolizer genotype is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 normal metabolizer genotype.				OR			
1449716257	rs1128503	fentanyl	Metabolism/PK	no	Allele G is not associated with concentrations of fentanyl in people with Neoplasms and Pain as compared to allele A.	G			OR			
1449716264	rs1045642	fentanyl	Metabolism/PK	no	Allele G is not associated with concentrations of fentanyl in people with Neoplasms and Pain as compared to allele A.	A			OR			
982044142	rs776746	simvastatin	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of simvastatin in healthy individuals as compared to genotype TT.	C		= 0.13	Unknown			
1449191972	rs776746	apixaban	Metabolism/PK	not stated	Genotypes CT + TT is associated with increased clearance of apixaban in people with Atrial Fibrillation as compared to genotype CC.	C	T		OR			
1185012200	rs4646437	cyclosporine	Metabolism/PK	yes	Genotypes AG + GG is associated with increased dose-adjusted trough concentrations of cyclosporine in people with Kidney Transplantation as compared to genotype AA.	G		< 0.05	OR			
1449716240	rs2032582	fentanyl	Metabolism/PK	no	Allele T is not associated with concentrations of fentanyl in people with Neoplasms and Pain as compared to allele A.	T			OR			
1449191978	rs1128503	apixaban	Metabolism/PK	no	Genotypes AA + AG are not associated with clearance of apixaban in people with Atrial Fibrillation as compared to genotype GG.	A	G		OR			
1449716250	rs2032582	fentanyl	Metabolism/PK	no	Allele C is not associated with concentrations of fentanyl in people with Neoplasms and Pain as compared to allele A.	C			OR			
1449191990	rs1045642	apixaban	Metabolism/PK	no	Genotypes AA + AG are not associated with clearance of apixaban in people with Atrial Fibrillation as compared to genotype GG.	A	G		OR			
1183701599	CYP2C19 poor metabolizer	citalopram	Metabolism/PK	not stated	CYP2C19 poor metabolizer is associated with decreased clearance of citalopram in healthy individuals as compared to CYP2C19 normal metabolizer.			< 0.0008	OR			
1449191984	rs2032582	apixaban	Metabolism/PK	no	Allele A is not associated with clearance of apixaban in people with Atrial Fibrillation as compared to allele C.				OR			
1183619689	CYP2D6*2	paroxetine	Metabolism/PK	not stated	CYP2D6 *2/*2 is associated with increased clearance of paroxetine in children with Depressive Disorder, Major.				Unknown			
1449732693	rs1045642	tacrolimus	Metabolism/PK	yes	Genotype GG is associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.			< 0.05	OR			
982044307	rs28365063	carvedilol	Metabolism/PK	yes	Allele G is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to allele A.			< 0.001	Unknown			
1450371753	CYP3A5 poor metabolizers	maraviroc	Metabolism/PK	yes	CYP3A5 poor metabolizers are associated with decreased concentrations of maraviroc in people with HIV as compared to CYP3A5 normal metabolizer.			= 0.048	OR			
1450371753	CYP3A5 poor metabolizers	maraviroc	Metabolism/PK	yes	CYP3A5 poor metabolizers are associated with decreased concentrations of maraviroc in people with HIV as compared to CYP3A5 normal metabolizer.			= 0.343	OR			
1450371753	CYP3A5 poor metabolizers	maraviroc	Metabolism/PK	yes	CYP3A5 poor metabolizers are associated with decreased concentrations of maraviroc in people with HIV as compared to CYP3A5 normal metabolizer.			= 0.606	OR			
982044271	rs2032582	digoxin	Metabolism/PK	yes	Genotype CC is associated with increased clearance of digoxin in people with Heart Failure as compared to genotype AC.			< 0.05	Unknown			
982044299	rs12233719	carvedilol	Metabolism/PK	yes	Allele T is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to allele G.			< 0.001	Unknown			
982044285	rs2032582	digoxin	Metabolism/PK	yes	Genotypes AA + AT are associated with decreased clearance of digoxin in people with Heart Failure as compared to genotype AC.			< 0.01	Unknown			
1451141845	NAT2 rapid acetylator	hydralazine	Dosage,Efficacy	yes	NAT2 rapid acetylator is associated with increased dose of hydralazine in people with Hypertension as compared to NAT2 slow acetylator.			< 0.05				
1450371766	CYP3A5 intermediate metabolizers	maraviroc	Metabolism/PK	no	CYP3A5 intermediate metabolizers are not associated with concentrations of maraviroc in people with HIV as compared to CYP3A5 normal metabolizer.			= 0.517	OR			
1450371766	CYP3A5 intermediate metabolizers	maraviroc	Metabolism/PK	no	CYP3A5 intermediate metabolizers are not associated with concentrations of maraviroc in people with HIV as compared to CYP3A5 normal metabolizer.			= 0.606	OR			
1450371766	CYP3A5 intermediate metabolizers	maraviroc	Metabolism/PK	no	CYP3A5 intermediate metabolizers are not associated with concentrations of maraviroc in people with HIV as compared to CYP3A5 normal metabolizer.			= 0.892	OR			
1450371807	CYP3A5 intermediate metabolizers	maraviroc	Metabolism/PK	yes	CYP3A5 intermediate metabolizers are associated with increased concentrations of maraviroc in people with HIV as compared to CYP3A5 normal metabolizer.			< 0.0036	OR			
827785745	rs776746	vardenafil	Other,Metabolism/PK	yes	Genotype TT is associated with increased clearance of vardenafil in men as compared to genotypes CC + CT.			= 0.05	Unknown			
1449192273	rs9923231	warfarin	Dosage,Other	yes	Allele T is associated with decreased dose of warfarin as compared to allele C.			= 0.001	OR			
1449192273	rs9923231	warfarin	Dosage,Other	yes	Allele T is associated with decreased dose of warfarin as compared to allele C.			= 0.001	OR			
1451141940	NAT2 slow acetylator	hydralazine	Metabolism/PK	not stated	NAT2 slow acetylator is associated with increased concentrations of hydralazine in people with Hypertension as compared to NAT2 intermediate and rapid acetylators.							
1448634086	rs8187710	lumefantrine	Metabolism/PK	yes	Genotype AA is associated with increased concentrations of lumefantrine in children with Malaria as compared to genotypes AG + GG.	A		= 0.004	OR			
1448634086	rs8187710	lumefantrine	Metabolism/PK	yes	Genotype AA is associated with increased concentrations of lumefantrine in children with Malaria as compared to genotypes AG + GG.	A			OR			
1449733021	rs2306283	rosuvastatin	Metabolism/PK	yes	Genotype GG is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotype AA.	A		= 0.0456	OR			
1449733034	rs11045854	rosuvastatin	Metabolism/PK	yes	Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.			= 0.002	OR			
1449733005	rs4149056	rosuvastatin	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotypes CT + TT.	C		= 0.001	OR			
1449733005	rs4149056	rosuvastatin	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotypes CT + TT.	C			OR			
1449733005	rs4149056	rosuvastatin	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotypes CT + TT.	C			OR			
1449733005	rs4149056	rosuvastatin	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotypes CT + TT.	C			OR			
1449749389	rs6785049	tacrolimus	Metabolism/PK	no	Genotypes AG + GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.	G			OR			
1183685485	rs1045642	voriconazole	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of voriconazole in healthy individuals as compared to genotype GG.	A		< 0.032	OR			
1449749395	rs2276707	tacrolimus	Metabolism/PK	no	Genotypes CT + TT is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T			OR			
1184471365	rs28399499	efavirenz	Metabolism/PK	yes	Allele C (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to allele T (assigned as normal metabolizer phenotype) .			< 0.001	Unknown			
1447519884	CYP2D6 ultrarapid metabolizer phenotype	nortriptyline	Metabolism/PK	yes	CYP2D6 ultrarapid metabolizer phenotype are associated with increased metabolism of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.			< 0.05	OR			
1449733067	rs34671512	rosuvastatin	Metabolism/PK	yes	Allele C is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele A.			= 0.016	OR			
1451125731	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	clozapine	Metabolism/PK	no	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of clozapine in people with Schizophrenia as compared to CYP2C19 normal metabolizer genotype.			= 0.242				
1449733045	rs12305884	rosuvastatin	Metabolism/PK	yes	Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.			= 0.002	OR			
1449733085	rs12721616	rosuvastatin	Metabolism/PK	yes	Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele C.			= 0.01	OR			
1183701955	rs140471703	nicotine	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased metabolism of nicotine as compared to genotype CC.			< 0.01	OR			
1183701959	rs143690364	nicotine	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased metabolism of nicotine as compared to genotype CC.			< 0.01	OR			
1447519878	CYP2D6 intermediate metabolizers	nortriptyline	Metabolism/PK	yes	CYP2D6 intermediate metabolizers are associated with decreased metabolism of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.			< 0.05	OR			
1183701942	rs376817657	nicotine	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased metabolism of nicotine as compared to genotype CC.			< 0.01	OR			
1448126046	rs1801159	fluorouracil	Metabolism/PK	no	Genotypes CC + CT are not associated with metabolism of fluorouracil in people with Neoplasms as compared to genotype TT.	C		= 0.35	OR			
1448126052	rs67376798	fluorouracil	Metabolism/PK	no	Genotype AT is not associated with metabolism of fluorouracil in people with Neoplasms as compared to genotype TT.	A		= 0.51	OR			
1184471369	rs3745274	efavirenz	Metabolism/PK	yes	Allele T (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to allele G (assigned as normal metabolizer phenotype) .			< 0.001	Unknown			
1449733103	rs8187692	rosuvastatin	Metabolism/PK	yes	Allele A is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele G.			= 0.003	OR			
1448126039	rs1801158	fluorouracil	Metabolism/PK	no	Genotype CT is not associated with metabolism of fluorouracil in people with Neoplasms as compared to genotype CC.	T		= 1	OR			
1449733115	rs7579275	rosuvastatin	Metabolism/PK	yes	Allele G is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele A.			= 0.03	OR			
1184472014	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GT.	G	T	< 0.001	OR	4.35	1.97	9.59
1184472014	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GT.	G	T	= 0.016	OR			
1451125750	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	clozapine	Metabolism/PK	no	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of clozapine in people with Schizophrenia as compared to CYP2D6 normal metabolizer genotype.			= 0.106				
1184473257	rs2279343	efavirenz	Metabolism/PK	no	Genotype GG is not associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AG.			< 0.059	OR			
1449733142	rs1805343	rosuvastatin	Metabolism/PK	yes	Allele A is associated with increased exposure to rosuvastatin in healthy individuals.			= 0.001	OR			
1449733184	rs8187706	rosuvastatin	Metabolism/PK	yes	Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.			= 0.002	OR			
982044755	rs1128503	digoxin	Metabolism/PK	yes	Genotype AG is associated with decreased clearance of digoxin in healthy individuals as compared to genotype AA.			< 0.05	Unknown			
982044755	rs1128503	digoxin	Metabolism/PK	yes	Genotype AG is associated with decreased clearance of digoxin in healthy individuals as compared to genotype AA.			< 0.05	Unknown			
982044755	rs1128503	digoxin	Metabolism/PK	yes	Genotype AG is associated with decreased clearance of digoxin in healthy individuals as compared to genotype AA.			< 0.05	Unknown			
1449733194	rs8187710	rosuvastatin	Metabolism/PK	yes	Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.			= 0.01	OR			
982044767	rs2032582	digoxin	Metabolism/PK	yes	Genotype CC is associated with increased clearance of digoxin in healthy individuals as compared to genotype AA.			< 0.05	Unknown			
982044767	rs2032582	digoxin	Metabolism/PK	yes	Genotype CC is associated with increased clearance of digoxin in healthy individuals as compared to genotype AA.			< 0.05	Unknown			
982044767	rs2032582	digoxin	Metabolism/PK	yes	Genotype CC is associated with increased clearance of digoxin in healthy individuals as compared to genotype AA.			< 0.05	Unknown			
1449733176	rs7899457	rosuvastatin	Metabolism/PK	yes	Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele C.			= 0.002	OR			
1451125809	CYP2C19 rapid and ultrarapid metabolizer genotypes	clozapine	Metabolism/PK	no	CYP2C19 rapid and ultrarapid metabolizer genotypes are not associated with concentrations of clozapine in people with Schizophrenia as compared to CYP2C19 normal metabolizer genotype.			= 0.242				
1449750266	rs116855232	mercaptopurine	Dosage,Toxicity	no	Allele T is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.			= 0.0082	OR			
1449750266	rs116855232	mercaptopurine	Dosage,Toxicity	no	Allele T is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.			= 0.0193	OR			
1449750266	rs116855232	mercaptopurine	Dosage,Toxicity	no	Allele T is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.			= 0.0508	OR			
769146231	rs4149015	pravastatin	Efficacy,Metabolism/PK	yes	Genotype AG is associated with decreased response to pravastatin as compared to genotype GG.			< 0.001	Unknown			
1448995933	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.			< 0.0001	OR			
1448617460	rs2740574	atazanavir	Metabolism/PK	no	Allele C is associated with decreased clearance of atazanavir in healthy individuals as compared to allele T.	C	T	= 0.0074	OR			
1448995941	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.			< 0.0001	OR			
827704966	rs28399433	efavirenz	Metabolism/PK	no	Genotype AC is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.	C		= 0.019	Unknown			
1448617452	rs4149056	atazanavir	Metabolism/PK	no	Genotype TT is not associated with clearance of atazanavir in healthy individuals as compared to genotypes CC + CT.	C	T	= 0.31	OR			
1449715608	rs1799971	alfentanil	Metabolism/PK	no	Genotypes AG + GG are associated with decreased response to alfentanil in healthy individuals as compared to genotype AA.			< 0.05	OR			
1450375846	rs537681	etonogestrel	Efficacy,Metabolism/PK	no	Genotypes CT + TT is associated with decreased steady-state concentration of etonogestrel in women as compared to genotype CC.			= 0.007	OR			
1449749631	rs1057868	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T		= 0.047	OR			
1448684682	rs4803419	levonorgestrel	Metabolism/PK	yes	Genotype CT is associated with decreased concentrations of levonorgestrel in women with HIV Infections as compared to genotype CC.			= 0.023	OR			
1448684688	rs3745274	efavirenz	Metabolism/PK	yes	Genotypes GT + TT are associated with increased concentrations of efavirenz in women with HIV Infections as compared to genotype GG.			= 0.011	OR			
1184515224	rs776746	tacrolimus	Metabolism/PK	no	Genotype CT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.			< 0.00001	OR			
982044781	rs1045642	digoxin	Metabolism/PK	yes	Genotype GG is associated with increased clearance of digoxin in healthy individuals as compared to genotype AA.			< 0.05	Unknown			
982044781	rs1045642	digoxin	Metabolism/PK	yes	Genotype GG is associated with increased clearance of digoxin in healthy individuals as compared to genotype AA.			< 0.05	Unknown			
982044781	rs1045642	digoxin	Metabolism/PK	yes	Genotype GG is associated with increased clearance of digoxin in healthy individuals as compared to genotype AA.			< 0.05	Unknown			
1449602225	rs1045642	voriconazole	Metabolism/PK	yes	Genotype AA is associated with decreased trough concentration of voriconazole in children as compared to genotypes AG + GG.	A		= 0.016	OR			
1448617361	rs2472677	atazanavir	Metabolism/PK	yes	Genotype TT is associated with decreased concentrations of atazanavir in people with HIV Infections as compared to genotypes CC + CT.	C	T	= 0.008	OR	18.0	2.1	153.9
1448617361	rs2472677	atazanavir	Metabolism/PK	yes	Genotype TT is associated with decreased concentrations of atazanavir in people with HIV Infections as compared to genotypes CC + CT.	C	T	= 0.02	OR	5.1	1.3	20.8
1447814526	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased trough concentration of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	T		= 0.011	OR			
1448617354	rs1523130	atazanavir	Metabolism/PK	no	Allele C is not associated with concentrations of atazanavir in people with HIV Infections as compared to allele T.	C	T	= 0.42	OR	0.6	0.2	2.1
1448125834	rs776746	imatinib	Metabolism/PK	yes	Genotype CC is associated with increased trough concentration of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CT + TT.	C		< 0.0001	OR			
981794208	rs760370	gemcitabine	Efficacy,Toxicity	no	Genotype GG is associated with decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + AG.	G		= 0.019	OR	3.63	1.23	10.7
1183620382	rs1045642	risperidone	Metabolism/PK	no	Allele G is not associated with increased metabolism of risperidone in people with Schizophrenia as compared to allele A.	G			Unknown			
1450814737	rs1885301	pitavastatin	Metabolism/PK	no	Allele A is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	A		= 0.028				
1450814737	rs1885301	pitavastatin	Metabolism/PK	no	Allele A is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	A		= 0.057				
1450814737	rs1885301	pitavastatin	Metabolism/PK	no	Allele A is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	A		= 0.057				
1450814737	rs1885301	pitavastatin	Metabolism/PK	no	Allele A is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	A		= 0.063				
1450814737	rs1885301	pitavastatin	Metabolism/PK	no	Allele A is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	A		= 0.103				
1450814737	rs1885301	pitavastatin	Metabolism/PK	no	Allele A is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	A		= 0.581				
1450814749	rs2273697	pitavastatin	Metabolism/PK	no	Allele A is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	A		= 0.056				
1450814749	rs2273697	pitavastatin	Metabolism/PK	no	Allele A is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	A		= 0.127				
1450814749	rs2273697	pitavastatin	Metabolism/PK	no	Allele A is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	A		= 0.147				
1450814749	rs2273697	pitavastatin	Metabolism/PK	no	Allele A is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	A		= 0.170				
1450814749	rs2273697	pitavastatin	Metabolism/PK	no	Allele A is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	A		= 0.170				
1450814749	rs2273697	pitavastatin	Metabolism/PK	no	Allele A is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	A		= 0.488				
827816385	rs9479757	methadone	Dosage,Metabolism/PK	no	Genotype AA is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.	A			Unknown			
1450044715	rs1045642	ceftriaxone	Metabolism/PK	no	Allele A is not associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to allele G.				OR			
1447984301	rs1137115	nicotine	Metabolism/PK	no	Allele C is not associated with metabolism of nicotine as compared to allele T.			= 0.0012	OR			
1447984301	rs1137115	nicotine	Metabolism/PK	no	Allele C is not associated with metabolism of nicotine as compared to allele T.			= 0.110	OR			
1450814797	rs2231142	pitavastatin	Metabolism/PK	no	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	T		= 0.235				
1450814797	rs2231142	pitavastatin	Metabolism/PK	no	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	T		= 0.296				
1450814797	rs2231142	pitavastatin	Metabolism/PK	no	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	T		= 0.620				
1450814797	rs2231142	pitavastatin	Metabolism/PK	no	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	T		= 0.620				
1450814797	rs2231142	pitavastatin	Metabolism/PK	no	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	T		= 0.650				
1450814797	rs2231142	pitavastatin	Metabolism/PK	no	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	T		= 0.900				
1450044739	rs2032582	ceftriaxone	Metabolism/PK	no	Allele A is not associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to allele C.				OR			
1450044745	rs1128503	ceftriaxone	Metabolism/PK	no	Allele A is not associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to allele G.				OR			
1450814771	rs717620	pitavastatin	Metabolism/PK	yes	Allele T is associated with decreased exposure to pitavastatin in healthy individuals as compared to allele C.	T		= 0.027				
1450814771	rs717620	pitavastatin	Metabolism/PK	yes	Allele T is associated with decreased exposure to pitavastatin in healthy individuals as compared to allele C.	T		= 0.028				
1450814771	rs717620	pitavastatin	Metabolism/PK	yes	Allele T is associated with decreased exposure to pitavastatin in healthy individuals as compared to allele C.	T		= 0.028				
1450814771	rs717620	pitavastatin	Metabolism/PK	yes	Allele T is associated with decreased exposure to pitavastatin in healthy individuals as compared to allele C.	T		= 0.034				
1450814771	rs717620	pitavastatin	Metabolism/PK	yes	Allele T is associated with decreased exposure to pitavastatin in healthy individuals as compared to allele C.	T		= 0.057				
1450814771	rs717620	pitavastatin	Metabolism/PK	yes	Allele T is associated with decreased exposure to pitavastatin in healthy individuals as compared to allele C.	T		= 0.411				
1450044772	rs13120400	ceftriaxone	Metabolism/PK	yes	Genotype TT is associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to genotypes CC + CT.			= 0.015	OR			
981502261	rs1470579	repaglinide	Dosage,Efficacy	yes	Genotypes AC + CC are associated with decreased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype AA.			< 0.05	Unknown			
1448617211	rs1045642	atazanavir	Metabolism/PK	no	Allele G is not associated with concentrations of atazanavir in people with HIV Infections as compared to allele A.	A	G	= 0.053	OR	0.32		
981502270	rs4402960	repaglinide	Dosage,Efficacy	yes	Genotypes GT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.			< 0.05	Unknown			
1450044751	rs2287622	ceftriaxone	Metabolism/PK	no	Allele G is not associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to allele A.				OR			
1450044757	rs2273697	ceftriaxone	Metabolism/PK	no	Genotype GG is associated with decreased concentrations of ceftriaxone in people with Central Nervous System Infections as compared to genotypes AA + AG.			= 0.027	OR			
827816415	rs1076560	methadone	Dosage,Metabolism/PK	no	Genotype AA is not associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype CC.	A			Unknown			
1450044786	rs10841795	ceftriaxone	Metabolism/PK	no	Allele A is not associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to allele G.				OR			
1448256709	rs17180299	methadone	Metabolism/PK	yes	Genotypes AG + GG are associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to genotype AA.	G		= 2.24E-8	OR			
827836346	rs1128503	doxorubicin	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype GG.	A		= 0.03	Unknown			
1448617129	rs2032582	lopinavir	Metabolism/PK	no	Allele C is not associated with trough concentration of lopinavir in people with HIV Infections as compared to allele A.	A	A	= 0.418	OR			
827848020	rs2279343	nevirapine	Toxicity,Metabolism/PK	no	Allele G is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele A.			= 0.16	Unknown			
1183682139	rs28365063	lamotrigine	Metabolism/PK	no	Genotype AA is not associated with increased clearance of lamotrigine as compared to genotypes AG + GG.	G			OR			
1448633511	rs3745274	efavirenz	Metabolism/PK	yes	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.			< 0.0001	OR			
1448617122	rs1045642	atazanavir	Metabolism/PK	no	Allele G is not associated with trough concentration of atazanavir in people with HIV Infections as compared to allele A.	A	G	= 0.230	OR			
1447716007	rs9282564	cyclosporine	Toxicity,Metabolism/PK	yes	Genotype CT is associated with increased concentrations of cyclosporine in people with heart transplantation as compared to genotype TT.			= 0.002	OR			
981502424	rs2304865	aripiprazole	Efficacy,Toxicity	no	Allele C is not associated with response to aripiprazole in people with Schizophrenia as compared to allele G.				Unknown			
981502420	rs2637777	aripiprazole	Efficacy,Toxicity	no	Allele A is not associated with response to aripiprazole in people with Schizophrenia as compared to allele C.				Unknown			
1448617115	rs2032582	atazanavir	Metabolism/PK	no	Allele C is not associated with trough concentration of atazanavir in people with HIV Infections as compared to allele A.	A	A	= 0.542	OR			
1448617108	rs1045642	lopinavir	Metabolism/PK	no	Allele G is not associated with trough concentration of lopinavir in people with HIV Infections as compared to allele A.	A	G	= 0.488	OR			
1448567951	rs1800629	sirolimus	Metabolism/PK	no	Allele A is not associated with dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to allele G.	A		> 0.05	OR			
1448567945	rs2740574	sirolimus	Metabolism/PK	no	Allele C is not associated with dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to allele T.	C		> 0.05	OR			
1183690887	rs7746993	busulfan	Metabolism/PK	no	Allele C is not associated with decreased clearance of busulfan in people with Neoplasms as compared to allele A.			< 0.001	OR			
1183690887	rs7746993	busulfan	Metabolism/PK	no	Allele C is not associated with decreased clearance of busulfan in people with Neoplasms as compared to allele A.			= 0.025	OR			
1448567928	rs1800896	sirolimus	Metabolism/PK	yes	Genotype CC are associated with increased dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	T		= 0.0394	OR			
981502411	rs2306987	aripiprazole	Efficacy,Toxicity	no	Allele A is not associated with response to aripiprazole in people with Schizophrenia as compared to allele T.				Unknown			
1448567921	rs1045642	sirolimus	Metabolism/PK	yes	Genotypes AA + AG are associated with increased dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to genotype GG.	A		= 0.0016	OR			
982043158	rs4149056	pravastatin	Metabolism/PK	yes	Genotype CT is associated with increased metabolism of pravastatin in children with Transplantation as compared to genotype TT.			= 0.016	Unknown			
1447814223	rs16969968	cotinine	Metabolism/PK	yes	Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G.	A	G	= 6.91E-17	OR			
1447814229	rs7170068	cotinine	Metabolism/PK	yes	Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G.	A	G	= 1.51E-9	OR			
1183690880	rs4715354	busulfan	Metabolism/PK	no	Allele G is not associated with decreased clearance of busulfan in people with Neoplasms as compared to allele A.			< 0.001	OR			
1183690880	rs4715354	busulfan	Metabolism/PK	no	Allele G is not associated with decreased clearance of busulfan in people with Neoplasms as compared to allele A.			= 0.025	OR			
1447814235	rs588765	cotinine	Metabolism/PK	no	Allele C is not associated with concentrations of cotinine in people with Tobacco Use Disorder as compared to allele T.			= 0.10	OR			
1447814206	rs10851907	cotinine	Metabolism/PK	yes	Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G.	A	G	= 5.89E-10	OR			
827816322	rs3211371	methadone	Dosage,Metabolism/PK	no	Genotype TT is not associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype CC.	T			Unknown			
1450044963	rs6961419	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	C		> 0.0001	OR			
827816336	rs1800497	methadone	Dosage,Metabolism/PK	no	Genotype AA is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.	A			Unknown			
1450044969	rs6961665	methotrexate	Metabolism/PK	no	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	A		> 0.0001	OR			
1447814214	rs57064725	cotinine	Metabolism/PK	yes	Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele C.	A	C	= 2.92E-8	OR			
1448567866	rs1045642	sirolimus	Metabolism/PK	no	Allele A is not associated with dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to allele G.	A		> 0.05	OR			
982043146	rs4149056	pravastatin	Metabolism/PK	no	Genotype CT is not associated with increased metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to genotype TT.			= 0.409	Unknown			
982043138	rs4149015	pravastatin	Metabolism/PK	yes	Genotype AG is associated with increased response to pravastatin in children with Hyperlipoproteinemia Type II as compared to genotype GG.			= 2.0E-4	Unknown			
827816288	rs1128503	methadone	Dosage,Metabolism/PK	no	Genotype AA is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.	A			Unknown			
1447814198	rs77107237	cotinine	Metabolism/PK	yes	Allele G is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele A.	A	G	= 5.89E-10	OR			
827816293	rs2032582	methadone	Dosage,Metabolism/PK	no	Genotype AA is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype CC.				Unknown			
1450044955	rs10264990	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	T		> 0.0001	OR			
1450044948	rs13233308	methotrexate	Metabolism/PK	no	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	C		> 0.0001	OR			
982043225	rs1045642	pravastatin	Metabolism/PK	no	Allele G is not associated with response to pravastatin in children with Hyperlipoproteinemia Type II as compared to allele A.			= 0.409	Unknown			
982043225	rs1045642	pravastatin	Metabolism/PK	no	Allele G is not associated with response to pravastatin in children with Hyperlipoproteinemia Type II as compared to allele A.				Unknown			
1450044994	rs1202171	methotrexate	Metabolism/PK	no	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	T		> 0.0001	OR			
1450044988	rs3789243	methotrexate	Metabolism/PK	no	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	A		> 0.0001	OR			
1450045000	rs10276036	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	C		> 0.0001	OR			
982043213	rs2032582	pravastatin	Metabolism/PK	no	Allele C is not associated with response to pravastatin in children with Hyperlipoproteinemia Type II as compared to allele A.			= 0.409	Unknown			
982043213	rs2032582	pravastatin	Metabolism/PK	no	Allele C is not associated with response to pravastatin in children with Hyperlipoproteinemia Type II as compared to allele A.				Unknown			
982046695	rs1799809	phenprocoumon	Dosage,Metabolism/PK	no	Genotype AA is not associated with increased dose of phenprocoumon as compared to genotypes AG + GG.	A		= 0.072	Unknown			
1450044975	rs10267099	methotrexate	Metabolism/PK	no	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	G		> 0.0001	OR			
1450044982	rs10808071	methotrexate	Metabolism/PK	no	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	G		> 0.0001	OR			
982046684	rs510335	phenprocoumon	Dosage,Metabolism/PK	no	Genotype GG is not associated with increased dose of phenprocoumon as compared to genotypes GT + TT.	G		= 0.193	Unknown			
1450045025	rs1128503	methotrexate	Metabolism/PK	no	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.	A		> 0.0001	OR			
982043191	rs2032582	pravastatin	Metabolism/PK	no	Allele C is not associated with metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to allele T.			= 0.409	Unknown			
982043191	rs2032582	pravastatin	Metabolism/PK	no	Allele C is not associated with metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to allele T.				Unknown			
982046680	rs510317	phenprocoumon	Dosage,Metabolism/PK	no	Genotype GG is not associated with increased dose of phenprocoumon as compared to genotypes AA + AG.	A		= 0.87	Unknown			
1450045031	rs35592	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	C		> 0.0001	OR			
1450045006	rs2235048	methotrexate	Metabolism/PK	no	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	G		> 0.0001	OR			
982043203	rs1045642	pravastatin	Metabolism/PK	no	Allele G is not associated with metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to allele A.			= 0.409	Unknown			
982043203	rs1045642	pravastatin	Metabolism/PK	no	Allele G is not associated with metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to allele A.				Unknown			
1447683061	rs2011425	lamotrigine	Metabolism/PK	yes	Genotypes GG + GT are associated with decreased steady-state concentration of lamotrigine in people with Epilepsy as compared to genotype TT.	G	T	= 0.010	OR			
1450045018	rs2235035	methotrexate	Metabolism/PK	no	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.	A		> 0.0001	OR			
982046688	rs12714145	phenprocoumon	Dosage,Metabolism/PK	no	Genotype CC is not associated with increased dose of phenprocoumon as compared to genotypes CT + TT.	C		= 0.808	Unknown			
1450045012	rs4148737	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	C		> 0.0001	OR			
1450045055	rs2002042	methotrexate	Metabolism/PK	no	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	T		> 0.0001	OR			
1450045061	rs4148398	methotrexate	Metabolism/PK	no	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.	A		> 0.0001	OR			
1450045043	rs11075291	methotrexate	Metabolism/PK	no	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	G		> 0.0001	OR			
1450045037	rs246240	methotrexate	Metabolism/PK	no	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	G		> 0.0001	OR			
1450045049	rs3784862	methotrexate	Metabolism/PK	no	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	G		> 0.0001	OR			
1450045097	rs3740063	methotrexate	Metabolism/PK	no	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	G		> 0.0001	OR			
1184753642	rs35599367	tacrolimus	Metabolism/PK	no	Genotypes AA + AG is not associated with decreased clearance of tacrolimus in children with liver transplantation as compared to genotype GG.	A		> 0.05	OR			
1448567743	rs1057868	sirolimus	Metabolism/PK	yes	Genotypes CT + TT are associated with decreased trough concentration of sirolimus in people with Kidney Transplantation as compared to genotype CC.			= 0.0197	OR			
1448996513	rs185430475	nicotine	Metabolism/PK	no	Allele G is not associated with metabolism of nicotine as compared to allele C.	G		= 1.94E-8	OR			
1448996508	rs111645190	nicotine	Metabolism/PK	no	Allele A is not associated with metabolism of nicotine as compared to allele G.	A		= 1.06E-23	OR			
1450045121	rs13120400	methotrexate	Metabolism/PK	yes	Genotype CC is associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotypes CT + TT.	C		< 10E-10	OR			
1450979020	rs9934438	warfarin	Dosage,Efficacy	yes	Genotypes AA + AG is associated with decreased dose of warfarin in people with Myocardial Infarction as compared to genotype GG.			< 0.001	Unknown			
1447682974	rs7668258	lamotrigine	Metabolism/PK	yes	Genotypes CT + TT are associated with increased steady-state concentration of lamotrigine in people with Epilepsy as compared to genotype CC.	C	T	= 0.003	OR			
1450045127	rs13137622	methotrexate	Metabolism/PK	yes	Genotypes GT + TT are associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotype GG.	T		< 10E-7	OR			
827847951	rs1045642	nevirapine	Toxicity,Metabolism/PK	no	Allele A is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele G.			= 0.4	Unknown			
1450815197	CYP2C19*2	venlafaxine	Metabolism/PK	not stated	CYP2C19 *2/*2 is associated with decreased metabolism of venlafaxine.							
1450045103	rs4148416	methotrexate	Metabolism/PK	no	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	T		> 0.0001	OR			
1450045115	rs1564481	methotrexate	Metabolism/PK	no	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	T		> 0.0001	OR			
1450045109	rs9516519	methotrexate	Metabolism/PK	no	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	G		> 0.0001	OR			
1450045151	rs2622621	methotrexate	Metabolism/PK	no	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	G		> 0.0001	OR			
982046676	rs1043550	phenprocoumon	Dosage,Metabolism/PK	no	Genotype AA is not associated with increased dose of phenprocoumon as compared to genotypes AG + GG.	A		= 0.197	Unknown			
1450045163	rs17731538	methotrexate	Metabolism/PK	no	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.	A		> 0.0001	OR			
1450045157	rs12505410	methotrexate	Metabolism/PK	yes	Genotype GG is associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotypes GT + TT.	G		< 10E-8	OR			
1450045139	rs3114018	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	C		> 0.0001	OR			
1450045133	rs2725252	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	C		> 0.0001	OR			
1450045145	rs2622604	methotrexate	Metabolism/PK	no	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	T		> 0.0001	OR			
1444668331	rs784888	metformin	Metabolism/PK	yes	Allele G is associated with decreased clearance of metformin in healthy individuals as compared to allele C.	G		= 0.03978	OR			
1450045187	rs4149081	methotrexate	Metabolism/PK	no	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	G		> 0.0001	OR			
1450045181	rs11045879	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	C		> 0.0001	OR			
982046672	rs2108622	phenprocoumon	Dosage,Metabolism/PK	no	Genotype CC is not associated with increased dose of phenprocoumon as compared to genotypes CT + TT.	C		= 0.221	Unknown			
1450045193	rs4149034	methotrexate	Metabolism/PK	no	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.	A		> 0.0001	OR			
1449295831	rs4455491	morphine	Dosage,Efficacy	no	Allele A is not associated with metabolism of morphine in people with Pain, Postoperative as compared to allele G.	A			OR			
1450045169	rs6857600	methotrexate	Metabolism/PK	no	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	T		> 0.0001	OR			
1449750257	rs1127354	mercaptopurine	Dosage,Toxicity	no	Allele A is not associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	A			OR			
1450045175	rs1051266	methotrexate	Metabolism/PK	no	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	T		> 0.0001	OR			
1450045217	rs4149026	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	C		> 0.0001	OR			
1450045211	rs1463565	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.	C		> 0.0001	OR			
1450045205	rs11045872	methotrexate	Metabolism/PK	no	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	G		> 0.0001	OR			
1450045251	rs4149057	methotrexate	Metabolism/PK	no	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	T		> 0.0001	OR			
1450045245	rs4149056	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	C		> 0.0001	OR			
1184407399	rs4253728	tacrolimus	Metabolism/PK	no	Genotype AA is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to allele G.	A	G	> 0.05	OR			
1450045257	rs4148324	methotrexate	Metabolism/PK	yes	Genotypes GG + GT are associated with decreased clearance of methotrexate in people with Osteosarcoma as compared to genotype TT.	G		> 0.0001	OR			
1444930293	rs578776	nicotine	Metabolism/PK	no	Allele A is not associated with dose of nicotine in people with Tobacco Use Disorder as compared to allele G.	A	G	< 0.19	OR		-20.24	3.93
1447944969	rs1801133	capecitabine	Metabolism/PK	yes	Genotype GG is associated with increased exposure to capecitabine in people with Neoplasms as compared to genotypes AA + AG.	A		= 0.043	OR			
1445585706	rs1051266	methotrexate	Metabolism/PK	no	Genotype TT is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.			= 0.93	OR			
1450045263	rs4148326	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	C		> 0.0001	OR			
1450045275	rs4148328	methotrexate	Metabolism/PK	no	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	T		> 0.0001	OR			
1448108791	rs28399499	nevirapine	Metabolism/PK	yes	Allele C is associated with increased concentrations of nevirapine in women as compared to allele T.			= 0.002	OR			
1448108791	rs28399499	nevirapine	Metabolism/PK	yes	Allele C is associated with increased concentrations of nevirapine in women as compared to allele T.			= 0.024	OR			
1450045269	rs10929303	methotrexate	Metabolism/PK	no	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	T		> 0.0001	OR			
982043554	rs2032582	amlodipine	Metabolism/PK	yes	Genotype CC is associated with decreased clearance of amlodipine in healthy individuals as compared to genotypes AA + AC.			< 0.01	Unknown			
982043554	rs2032582	amlodipine	Metabolism/PK	yes	Genotype CC is associated with decreased clearance of amlodipine in healthy individuals as compared to genotypes AA + AC.			< 0.01	Unknown			
982043554	rs2032582	amlodipine	Metabolism/PK	yes	Genotype CC is associated with decreased clearance of amlodipine in healthy individuals as compared to genotypes AA + AC.			< 0.01	Unknown			
982043554	rs2032582	amlodipine	Metabolism/PK	yes	Genotype CC is associated with decreased clearance of amlodipine in healthy individuals as compared to genotypes AA + AC.			< 0.05	Unknown			
1448108757	rs3745274	nevirapine	Metabolism/PK	yes	Allele T is associated with increased concentrations of nevirapine in women as compared to allele G.			= 0.00011	OR			
1448108757	rs3745274	nevirapine	Metabolism/PK	yes	Allele T is associated with increased concentrations of nevirapine in women as compared to allele G.			= 0.015	OR			
982043511	rs1045642	amlodipine	Metabolism/PK	yes	Genotype GG is associated with decreased clearance of amlodipine in healthy individuals as compared to genotypes AA + AG.			< 0.01	Unknown			
982043511	rs1045642	amlodipine	Metabolism/PK	yes	Genotype GG is associated with decreased clearance of amlodipine in healthy individuals as compared to genotypes AA + AG.			< 0.01	Unknown			
982043511	rs1045642	amlodipine	Metabolism/PK	yes	Genotype GG is associated with decreased clearance of amlodipine in healthy individuals as compared to genotypes AA + AG.			< 0.01	Unknown			
982043511	rs1045642	amlodipine	Metabolism/PK	yes	Genotype GG is associated with decreased clearance of amlodipine in healthy individuals as compared to genotypes AA + AG.			< 0.05	Unknown			
1446896329	CYP2D6 poor metabolizer	ondansetron	Metabolism/PK	no	CYP2D6 poor metabolizer is not associated with decreased metabolism of ondansetron in healthy individuals as compared to CYP2D6 normal metabolizer.			> 0.8	OR			
982022015	rs5443	risperidone	Dosage,Efficacy	no	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	C		> 0.05	Unknown			
1448256156	CYP2D6 poor metabolizer phenotype	endoxifen	Metabolism/PK	yes	CYP2D6 poor metabolizer phenotype is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer and ultra-metabolizer.			= 0.004	OR			
1183622476	rs2470890	escitalopram	Metabolism/PK	no	Allele T is not associated with metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele C.			> 0.05	Unknown			
1183622468	rs2472304	escitalopram	Metabolism/PK	no	Allele A is not associated with metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele G.			> 0.05	Unknown			
1184473116	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	G		= 0.00002	OR			
1184473116	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	G	G	= 0.009	OR			
1449750524	rs1057868	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T		< 0.05	OR			
827704679	rs1045642	efavirenz	Efficacy,Metabolism/PK	not stated	Genotype GG is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype AG.	G			Unknown			
827704671	rs1045642	efavirenz	Efficacy,Metabolism/PK	not stated	Genotype AA is associated with increased clearance of efavirenz in people with HIV Infections as compared to genotype AG.	G			Unknown			
827787027	rs1046428	dichloroacetic acid	Toxicity,Metabolism/PK	no	Allele T is associated with decreased clearance of dichloroacetic acid in children Mitochondrial Diseases.				Unknown			
827787019	rs7972	dichloroacetic acid	Toxicity,Metabolism/PK	no	Allele G is associated with decreased clearance of dichloroacetic acid in children with Mitochondrial Diseases.				Unknown			
1184997529	rs1045642	atazanavir	Metabolism/PK	yes	Genotype GG is associated with increased concentrations of atazanavir in people with HIV Infections as compared to genotypes AA + AG.			< 0.01	OR			
1184473237	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.			< 0.001	OR			
1184473241	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GT.			= 0.011	OR			
1447682570	CYP2C8*3	ibuprofen	Metabolism/PK	no	CYP2C8 *3 is associated with decreased clearance of ibuprofen in healthy individuals.	*3		= 0.01	OR			
1184473245	rs3745274	efavirenz	Metabolism/PK	yes	Genotype GT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.			< 0.001	OR			
1184473249	rs2279343	efavirenz	Metabolism/PK	yes	Genotype GG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.			< 0.003	OR			
827786999	rs7975	dichloroacetic acid	Toxicity,Metabolism/PK	no	Allele G is associated with decreased clearance of dichloroacetic acid in children with Mitochondrial Diseases.				Unknown			
1184473253	rs2279343	efavirenz	Metabolism/PK	yes	Genotype AG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.			< 0.001	OR			
827786987	rs1046428	dichloroacetic acid	Other,Metabolism/PK	yes	Allele C is associated with increased clearance of dichloroacetic acid in healthy individuals.			= 0.01	Unknown			
827786978	rs7972	dichloroacetic acid	Other,Metabolism/PK	yes	Allele G is associated with increased metabolism of dichloroacetic acid in healthy individuals.			= 0.01	Unknown			
1184473155	rs28399454	efavirenz	Metabolism/PK	yes	Allele T is associated with metabolism of efavirenz in people with HIV Infections as compared to allele C.	C		= 0.023	OR			
1184473161	rs3745274	efavirenz	Metabolism/PK	yes	Allele T is associated with metabolism of efavirenz in people with HIV Infections as compared to allele G.	G		= 0.0004	OR			
827786955	rs7975	dichloroacetic acid	Other,Metabolism/PK	yes	Allele G is associated with increased clearance of dichloroacetic acid in healthy individuals.			= 0.01	Unknown			
1184473165	rs28399499	efavirenz	Metabolism/PK	yes	Allele C is associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.	T		= 0.016	OR			
1449750688	rs116855232	thioguanine	Metabolism/PK	no	Allele T is not associated with concentrations of thioguanine in people with Autoimmune Diseases, Lupus Erythematosus, Systemic or Sjogren's Syndrome as compared to allele C.				OR			
981483665	rs2306283	methotrexate	Efficacy,Toxicity,Metabolism/PK	yes	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.			= 3.97E-11				
981483665	rs2306283	methotrexate	Efficacy,Toxicity,Metabolism/PK	yes	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.			< 0.05	Unknown			
981483656	rs4149056	methotrexate	Efficacy,Toxicity,Metabolism/PK	yes	Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.			= 5.72E-19				
981483656	rs4149056	methotrexate	Efficacy,Toxicity,Metabolism/PK	yes	Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	C		= 2.01E-10	Unknown			
1451401880	rs1045642	methadone	Metabolism/PK	yes	Genotype AA is associated with increased concentrations of methadone as compared to genotypes AG + GG.	G		= 0.0019				
1184473325	rs2307424	efavirenz	Metabolism/PK	yes	Allele G is associated with decreased metabolism of efavirenz in people with HIV Infections.	G		= 0.002	OR			
1451401900	rs1128503	methadone	Metabolism/PK	no	Allele G is not associated with concentrations of methadone as compared to allele A.	A						
1451401904	rs2032582	methadone	Metabolism/PK	no	Allele A is not associated with concentrations of methadone as compared to allele C.							
1184473329	rs2307424	efavirenz	Metabolism/PK	yes	Genotype AG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.	G		< 0.001	OR			
1184473333	rs8192726	efavirenz	Metabolism/PK	no	Allele A is not associated with metabolism of efavirenz in people with HIV Infections as compared to allele C.	A		= 0.001	OR			
1184473341	rs7439366	efavirenz	Metabolism/PK	no	Allele T is not associated with metabolism of efavirenz in people with HIV Infections as compared to allele C.	T		= 0.001	OR			
1184473345	rs28365062	efavirenz	Metabolism/PK	no	Allele G is not associated with metabolism of efavirenz in people with HIV Infections as compared to allele A.	G		= 0.001	OR			
1183703328	rs1057868	nicotine	Metabolism/PK	yes	Genotypes CT + TT is associated with increased metabolism of nicotine in CYP2A6 normal, but not reduced, metabolizers as compared to genotype CC.			= 0.03	OR			
1183703333	CYP2A6 poor metabolizer genotype	nicotine	Metabolism/PK	yes	CYP2A6 poor metabolizer genotype is associated with decreased metabolism of nicotine in nonsmokers as compared to CYP2A6 normal metabolizer genotype.			< 0.001	OR			
1448997108	rs3745274	efavirenz	Metabolism/PK	no	Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.				OR			
1184473261	rs3211371	efavirenz	Metabolism/PK	no	Genotype CC is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype CT.	C		= 0.888	OR			
1448997129	rs3745274	efavirenz	Metabolism/PK	yes	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	T		< 0.01	OR			
982043099	rs4149015	pravastatin	Metabolism/PK	yes	Genotype AG is associated with increased metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to genotype GG.			< 1.0E-4	Unknown			
1183703319	rs2266782	nicotine	Metabolism/PK	no	Genotypes AA + AG is associated with decreased metabolism of nicotine in CYP2A6 reduced, but not normal, metabolizers as compared to genotype GG.			= 0.07	OR			
1184473309	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	T		< 0.001	OR			
1448997148	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT are associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.			= 0.008	OR			
1450373388	rs1799971	morphine	Dosage,Efficacy	yes	Genotypes AG + GG are associated with increased dose of morphine in women with Pain, Postoperative as compared to genotype AA.	G		= 0.0004	OR			
1184473321	rs3745274	efavirenz	Metabolism/PK	yes	Allele T is associated with decreased metabolism of efavirenz in people with HIV Infections.	T		< 0.0001	OR			
1448112417	rs35599367	tacrolimus	Metabolism/PK	no	Genotype AG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype GG.	A		= 0.27	OR			
1448112425	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype CC.	C		< 0.001	OR			
1448112396	rs1057910	warfarin	Metabolism/PK	yes	Genotype CC is associated with decreased clearance of warfarin as compared to genotypes AA + AC.	A		= 0.002	OR	8.64	2.25	33.25
1183699264	rs12422149	montelukast	Metabolism/PK	no	Allele A is not associated with clearance of montelukast in healthy individuals as compared to allele G.	A		> 0.05	OR			
1448636679	rs2032582	everolimus	Metabolism/PK	no	Genotypes AA + AC are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype CC.	A	C	> 0.05	OR			
1183699272	rs2712807	montelukast	Metabolism/PK	no	Allele A is not associated with clearance of montelukast in healthy individuals as compared to allele G.	A		= 0.032	OR			
1183699272	rs2712807	montelukast	Metabolism/PK	no	Allele A is not associated with clearance of montelukast in healthy individuals as compared to allele G.	A		> 0.05	OR			
1183699268	rs35199625	montelukast	Metabolism/PK	no	Allele A is not associated with clearance of montelukast in healthy individuals as compared to allele G.	A		> 0.05	OR			
1448112390	rs1799853	warfarin	Metabolism/PK	yes	Genotype TT is associated with decreased clearance of warfarin as compared to genotypes CC + CT.	T		= 0.002	OR	8.64	2.25	33.25
1447948529	rs1045642	gefitinib	Metabolism/PK	no	Genotype GG is not associated with metabolism of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.				OR			
1183699250	rs2306168	montelukast	Metabolism/PK	no	Allele C is not associated with clearance of montelukast in healthy individuals as compared to allele T.	T		> 0.05	OR			
1448636661	rs11572080	everolimus	Metabolism/PK	no	Genotypes CT + TT are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype CC.	T	C	> 0.05	OR			
1447981305	rs4148157	topotecan	Metabolism/PK	yes	Genotypes AA + AG is associated with increased concentrations of topotecan in children with Brain Neoplasms as compared to genotype GG.	A		= 0.0001	OR			
1184747946	UGT1A3*2	gepirone hydrochloride	Metabolism/PK	no	UGT1A3 *2 is not associated with clearance of gepirone hydrochloride in people with Asthma.				OR			
1447948535	rs2231142	gefitinib	Metabolism/PK	no	Genotype GG is not associated with metabolism of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.				OR			
1183699255	rs776746	quetiapine	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of quetiapine in healthy individuals as compared to genotypes CT + TT.	C		= 0.0002	OR			
1184747824	rs683369	imatinib	Metabolism/PK	yes	Genotype CC is associated with decreased concentrations of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG.	G		< 0.0001	OR			
1185012370	rs1057868	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T		= 0.02	OR			
1185012370	rs1057868	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T		= 0.03	OR			
1185012370	rs1057868	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T		= 0.83	OR			
1447948523	rs2032582	gefitinib	Metabolism/PK	no	Genotype CC is not associated with metabolism of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AC + CT.				OR			
1447948516	rs1128503	gefitinib	Metabolism/PK	no	Genotype GG is not associated with metabolism of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.				OR			
1449173387	rs1799971	morphine	Metabolism/PK	no	Allele G is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele A.	G		= 0.23	OR			
1449173387	rs1799971	morphine	Metabolism/PK	no	Allele G is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele A.	G		= 0.59	OR			
1449173405	rs1045642	morphine	Metabolism/PK	no	Allele A is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele G.	G		= 0.004	OR			
1449173405	rs1045642	morphine	Metabolism/PK	no	Allele A is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele G.	G		= 0.15	OR			
1448423603	rs4244285	rilpivirine	Metabolism/PK	no	Allele A is not associated with clearance of rilpivirine in people with HIV Infections as compared to allele G.	A			OR			
1449173414	rs2032582	morphine	Metabolism/PK	no	Allele A is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele C.	A		= 0.036	OR			
1449173414	rs2032582	morphine	Metabolism/PK	no	Allele A is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele C.	A		= 0.12	OR			
1448423597	rs776746	rilpivirine	Metabolism/PK	no	Allele C is not associated with clearance of rilpivirine in people with HIV Infections as compared to allele T.				OR			
1449173422	rs2032582	morphine	Metabolism/PK	no	Allele T is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele C.	T		= 0.036	OR			
1449173422	rs2032582	morphine	Metabolism/PK	no	Allele T is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele C.	T		= 0.12	OR			
1449173430	rs4680	morphine	Metabolism/PK	no	Allele A is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele G.	A		= 0.32	OR			
1449173430	rs4680	morphine	Metabolism/PK	no	Allele A is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele G.	A		= 0.43	OR			
1448423579	rs35599367	rilpivirine	Metabolism/PK	no	Allele A is not associated with clearance of rilpivirine in people with HIV Infections as compared to allele G.	A			OR			
1448665545	rs28399499	efavirenz	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype TT.	T		= 0.028	OR			
981501360	rs2231142	sulfasalazine	Metabolism/PK	yes	Genotype TT is associated with decreased clearance of sulfasalazine in healthy individuals as compared to genotypes GG + GT.	T		< 0.05	Unknown			
1451139502	NAT2 slow acetylator	hydralazine	Metabolism/PK	no	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.			< 0.001				
1451139502	NAT2 slow acetylator	hydralazine	Metabolism/PK	no	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.							
1447948420	rs1045642	gefitinib	Metabolism/PK	no	Genotype GG are not associated with concentrations of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.			> 0.05	OR			
1447948400	rs1128503	gefitinib	Metabolism/PK	no	Genotype AA are not associated with concentrations of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.			> 0.05	OR			
1447948406	rs2032582	gefitinib	Metabolism/PK	no	Genotype CC are not associated with concentrations of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.			> 0.05	OR			
1183699485	rs2032582	risperidone	Metabolism/PK	no	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele C.	A		> 0.1	OR			
1447948394	rs2231142	gefitinib	Metabolism/PK	no	Genotype GG are not associated with concentrations of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.			> 0.05	OR			
1183699481	rs1128503	risperidone	Metabolism/PK	no	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele G.	A		> 0.1	OR			
1183699477	rs1045642	risperidone	Metabolism/PK	no	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele G.	A		> 0.1	OR			
1448112188	rs2011425	tamoxifen-n-glucuronide	Metabolism/PK	yes	Genotypes GG + GT are associated with increased concentrations of tamoxifen-n-glucuronide in women with Breast Neoplasms as compared to genotype TT.			= 0.005	OR			
982044204	rs1045642	digoxin	Metabolism/PK	no	Genotype GG is not associated with clearance of digoxin in people with Heart Failure as compared to genotypes AA + AG.	G			Unknown			
1183699460	rs776746	risperidone	Metabolism/PK	no	Allele C is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele T.	T			OR			
1333193034	rs2606345	deferasirox	Metabolism/PK	yes	Genotypes AC + CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype AA.	A		= 0.017	OR			
1333193034	rs2606345	deferasirox	Metabolism/PK	yes	Genotypes AC + CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype AA.	A		= 0.017	OR	0.13	0.02	0.7
1333193025	rs887829	deferasirox	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CC + CT.	C		= 0.045	OR			
982042188	rs2032582	digoxin	Metabolism/PK	yes	Genotype AA is associated with increased clearance of digoxin in healthy individuals as compared to genotype CC.	C		< 0.05	Unknown			
981501538	rs460000	amphetamine	Dosage,Efficacy	no	Genotype GG is associated with increased response to amphetamine in healthy individuals as compared to genotypes GT + TT.	T		= 0.096	Unknown			
1183846978	CYP2D6 poor metabolizer	fluoxetine	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of fluoxetine in healthy individuals as compared to CYP2D6 normal metabolizer.			< 0.05	OR			
1183846985	CYP2D6 poor metabolizer	fluoxetine	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of fluoxetine in healthy individuals as compared to CYP2D6 normal metabolizer.			< 0.05	OR			
982042159	rs2032582	digoxin	Metabolism/PK	yes	Genotype AT is associated with increased clearance of digoxin in healthy individuals as compared to genotype CC.	C		< 0.05	Unknown			
1183699525	rs7643645	risperidone	Metabolism/PK	no	Genotype AA is not associated with clearance of risperidone in people with Psychotic Disorders as compared to genotype GG.	G		= 0.130	OR			
1333193055	rs2273697	deferasirox	Metabolism/PK	yes	Genotype AG is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype GG.	A		= 0.032	OR			
1333193048	rs2470890	deferasirox	Metabolism/PK	yes	Genotypes CC + CT is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype TT.	C		= 0.004	OR			
1333193048	rs2470890	deferasirox	Metabolism/PK	yes	Genotypes CC + CT is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype TT.	C		= 0.037	OR	0.17	0.03	0.9
1333193041	rs762551	deferasirox	Metabolism/PK	yes	Genotypes AC + CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype AA.	A		= 0.014	OR			
1450041941	rs1080985	thioridazine	Metabolism/PK	yes	Genotypes CC + CG is associated with decreased metabolism of thioridazine as compared to genotype GG.			< 0.05	OR			
982042172	rs1045642	digoxin	Metabolism/PK	yes	Genotype AG is associated with increased clearance of digoxin in healthy individuals as compared to genotype GG.	G		< 0.05	Unknown			
1184469584	rs12248560	clopidogrel	Dosage,Efficacy	yes	Genotypes CT + TT is associated with increased response to clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	C		= 0.0005	OR			
1183699582	rs2279345	efavirenz	Metabolism/PK	yes	Genotypes CC + CT are associated with increased clearance of efavirenz in people with HIV Infections as compared to genotype TT.	C		< 0.001	OR			
1000539639	rs1045642	tacrolimus	Metabolism/PK	no	Genotype GG is not associated with metabolism of tacrolimus in children with liver transplantation as compared to genotypes AA + AG.	G			Unknown			
1448603555	rs1800872	tacrolimus	Metabolism/PK	no	Genotype TT is not associated with dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotypes GG + GT.	T		> 0.05	OR			
1448603549	rs1800896	tacrolimus	Metabolism/PK	yes	Genotype TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype CT.	C		< 0.05	OR			
1448603543	rs1946518	tacrolimus	Metabolism/PK	yes	Genotypes GG + GT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype TT.	G		< 0.05	OR			
1448603535	rs5744247	tacrolimus	Metabolism/PK	yes	Genotypes CC + CG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype GG.	C		< 0.05	OR			
1448993476	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.			< 0.001	OR			
1183699633	rs10931910	XK469	Metabolism/PK	no	Allele G is not associated with decreased clearance of XK469 in people with Neoplasms as compared to allele A.			= 0.13	OR			
1183699628	rs10931910	XK469	Metabolism/PK	yes	Allele G is associated with decreased clearance of XK469 in people with Neoplasms as compared to allele A.			= 0.003	OR			
1184174889	rs6946062	gemcitabine	Metabolism/PK	no	Genotype TT is not associated with metabolism of gemcitabine as compared to genotypes CC + CT.	T	C	> 0.05	OR			
981862168	rs7287550	morphine	Dosage,Efficacy	yes	Allele C is associated with decreased dose of morphine in people with Neoplasms as compared to allele T.	C		= 0.055	Unknown			
1184174886	rs747199	gemcitabine	Metabolism/PK	no	Genotype GG is not associated with metabolism of gemcitabine as compared to genotypes CC + CG.	G	C	> 0.05	OR			
981862160	rs737866	morphine	Dosage,Efficacy	yes	Allele T is associated with decreased dose of morphine in people with Neoplasms as compared to allele C.	T		= 0.055	Unknown			
1333193325	CYP2C8*3	rosiglitazone	Dosage,Metabolism/PK	yes	CYP2C8 *3 is associated with increased metabolism of rosiglitazone in healthy individuals.			= 0.02	Unknown			
1184174878	rs1048977	gemcitabine	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of gemcitabine as compared to genotypes CC + CT.	T	C	< 0.05	OR			
1184174881	rs11598702	gemcitabine	Metabolism/PK	yes	Genotype TT is associated with decreased clearance of gemcitabine as compared to genotypes CC + CT.	C	T	< 0.05	OR			
981862185	rs740603	morphine	Dosage,Efficacy	yes	Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.	A		= 0.055	Unknown			
981862176	rs5746849	morphine	Dosage,Efficacy	yes	Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.	A		= 0.055	Unknown			
981501734	rs2740574	carbamazepine	Metabolism/PK	yes	Genotype TT is associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.			= 0.027	Unknown			
981501734	rs2740574	carbamazepine	Metabolism/PK	yes	Genotype TT is associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	C			Unknown			
981501734	rs2740574	carbamazepine	Metabolism/PK	yes	Genotype TT is associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	C			Unknown			
1447980873	rs762551	carbamazepine	Metabolism/PK	yes	Genotype AA is associated with increased clearance of carbamazepine in children with Epilepsy as compared to genotypes AC + CC.	A	C	= 0.0004	OR			
1448993561	CYP2D6 poor metabolizer genotype	aripiprazole	Metabolism/PK	yes	CYP2D6 poor metabolizer genotype is associated with increased dose-adjusted trough concentrations of aripiprazole in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer genotype.	*22		< 0.0001	OR			
981862151	rs2075507	morphine	Dosage,Efficacy	yes	Allele G is associated with decreased dose of morphine in people with Neoplasms as compared to allele A.	G		= 0.055	Unknown			
1448993578	CYP2D6 poor metabolizer genotype	risperidone	Metabolism/PK	yes	CYP2D6 poor metabolizer genotype is associated with increased dose-adjusted trough concentrations of risperidone in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer genotype.	*22		< 0.0001	OR			
981501779	rs2234922	carbamazepine	Metabolism/PK	no	Genotype GG is not associated with clearance of carbamazepine in people with Epilepsy as compared to genotypes AA + AG.				Unknown			
981501779	rs2234922	carbamazepine	Metabolism/PK	no	Genotype GG is not associated with clearance of carbamazepine in people with Epilepsy as compared to genotypes AA + AG.				Unknown			
981501779	rs2234922	carbamazepine	Metabolism/PK	no	Genotype GG is not associated with clearance of carbamazepine in people with Epilepsy as compared to genotypes AA + AG.				Unknown			
1184748403	rs1523130	ritonavir	Metabolism/PK	yes	Genotypes CC + CT are associated with increased concentrations of ritonavir in people with HIV Infections as compared to genotype TT.			= 0.02	OR			
981862234	rs2239393	morphine	Dosage,Efficacy	yes	Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.	A		= 0.055	Unknown			
1184748409	rs6785049	ritonavir	Metabolism/PK	yes	Genotypes AA + AG is associated with concentrations of ritonavir in people with HIV Infections as compared to genotype GG.			= 0.042	OR			
981501792	rs1128503	carbamazepine	Metabolism/PK	yes	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.			= 0.036	Unknown			
981501792	rs1128503	carbamazepine	Metabolism/PK	yes	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.				Unknown			
981419860	rs1800566	epirubicin	Efficacy,Toxicity	yes	Genotype AA is associated with decreased response to epirubicin in Breast Cancer Cell Lines as compared to genotype GG.			= 0.01	Unknown			
981862244	rs174699	morphine	Dosage,Efficacy	yes	Allele T is associated with decreased dose of morphine in people with Neoplasms as compared to allele C.	C		= 0.055	Unknown			
1448636182	rs28399499	efavirenz	Metabolism/PK	not stated	Genotypes CC + CT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype TT.				OR			
981501801	rs4148739	carbamazepine	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotype CT.			= 0.023	Unknown			
981501801	rs4148739	carbamazepine	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotype CT.				Unknown			
1451139946	NAT2 slow acetylator	hydralazine	Metabolism/PK	yes	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.			< 0.05				
1448636173	rs3745274	efavirenz	Metabolism/PK	not stated	Genotypes GT + TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.				OR			
981862203	rs4680	morphine	Dosage,Efficacy	yes	Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.	A		= 0.055	Unknown			
1184748428	rs1799971	ethanol	Metabolism/PK	yes	Genotypes AG + GG is associated with increased concentrations of ethanol in healthy individuals as compared to genotype AA.			= 0.02	OR			
1184748428	rs1799971	ethanol	Metabolism/PK	yes	Genotypes AG + GG is associated with increased concentrations of ethanol in healthy individuals as compared to genotype AA.			= 0.02	OR			
1184748428	rs1799971	ethanol	Metabolism/PK	yes	Genotypes AG + GG is associated with increased concentrations of ethanol in healthy individuals as compared to genotype AA.			= 0.03	OR			
981501753	rs1051740	carbamazepine	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.			= 0.026	Unknown			
981501753	rs1051740	carbamazepine	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.				Unknown			
981862194	rs6269	morphine	Dosage,Efficacy	yes	Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.	A		= 0.055	Unknown			
981862218	rs4818	morphine	Dosage,Efficacy	yes	Allele C is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.	C		= 0.055	Unknown			
1446899452	rs71647871	quinapril	Metabolism/PK	no	Genotype CT is not associated with metabolism of quinapril in healthy individuals as compared to genotype CC.	C	T	= 0.136	OR			
1446899452	rs71647871	quinapril	Metabolism/PK	no	Genotype CT is not associated with metabolism of quinapril in healthy individuals as compared to genotype CC.	C	T	= 0.334	OR			
1446899465	rs71647871	quinapril	Metabolism/PK	no	Genotype CT is not associated with clearance of quinapril in healthy individuals as compared to genotype CC.	C	T	= 0.756	OR			
1184174892	rs11853372	gemcitabine	Metabolism/PK	no	Genotype TT is not associated with metabolism of gemcitabine as compared to genotypes GG + GT.	T	G	> 0.05	OR			
1184174895	rs4877831	gemcitabine	Metabolism/PK	no	Genotype GG is not associated with metabolism of gemcitabine as compared to genotypes CC + CG.	G	C	> 0.05	OR			
981501842	rs4148386	carbamazepine	Metabolism/PK	yes	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.			= 0.012	Unknown			
981501842	rs4148386	carbamazepine	Metabolism/PK	yes	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.				Unknown			
1448993645	rs2242480	haloperidol	Metabolism/PK	no	Genotype CT is associated with increased concentrations of haloperidol in people with Psychotic Disorders as compared to genotype CC.				OR			
981501851	rs7643645	carbamazepine	Metabolism/PK	yes	Allele G is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele A.			= 0.04	Unknown			
982042511	rs1045642	digoxin	Metabolism/PK	yes	Genotype AA is associated with increased clearance of digoxin in healthy individuals as compared to genotype GG.	G		< 0.05	Unknown			
1184748352	rs4149056	ritonavir	Metabolism/PK	yes	Genotypes CC + CT is associated with increased concentrations of ritonavir in people with HIV Infections as compared to genotype TT.			= 0.01	OR			
1184748352	rs4149056	ritonavir	Metabolism/PK	yes	Genotypes CC + CT is associated with increased concentrations of ritonavir in people with HIV Infections as compared to genotype TT.			= 0.077	OR			
1448308434	rs1045642	tacrolimus	Metabolism/PK	no	Genotype GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.	A		> 0.05	OR			
981501862	rs2461817	carbamazepine	Metabolism/PK	yes	Allele C is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele A.			= 0.006	Unknown			
1450943400	rs2306168	atenolol	Metabolism/PK	no	Genotype TT is not associated with increased exposure to atenolol in healthy individuals as compared to genotype CC.							
1184748358	rs2032582	ritonavir	Metabolism/PK	yes	Genotypes AC + CC is associated with concentrations of ritonavir in people with HIV Infections as compared to genotype AA.			= 0.007	OR			
1184748358	rs2032582	ritonavir	Metabolism/PK	yes	Genotypes AC + CC is associated with concentrations of ritonavir in people with HIV Infections as compared to genotype AA.			= 0.043	OR			
1451409712	rs12471326	cotinine glucuronide	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of cotinine glucuronide as compared to genotype TT.	C		= 0.030				
981501809	rs4148740	carbamazepine	Metabolism/PK	yes	Genotype AG is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotype AA.			= 0.026	Unknown			
981501809	rs4148740	carbamazepine	Metabolism/PK	yes	Genotype AG is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotype AA.				Unknown			
1451409700	rs145014075	nicotine	Metabolism/PK	yes	Genotype GT is associated with increased concentrations of nicotine as compared to genotype GG.	T		= 0.035				
1451409980	rs35599367	everolimus	Metabolism/PK	no	Genotype AG is not associated with trough concentration of everolimus in people with Breast Neoplasms, Kidney Neoplasms or Neuroendocrine Tumors as compared to genotype GG.	A		= 0.63				
981501817	rs2273697	carbamazepine	Metabolism/PK	yes	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.			= 0.047	Unknown			
981501817	rs2273697	carbamazepine	Metabolism/PK	yes	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.				Unknown			
981862254	rs165728	morphine	Dosage,Efficacy	yes	Allele T is associated with decreased dose of morphine in people with Neoplasms as compared to allele C.	T		= 0.055	Unknown			
1451410001	rs776746	everolimus	Metabolism/PK	yes	Genotype CT is associated with decreased trough concentration of everolimus in people with Breast Neoplasms, Kidney Neoplasms or Neuroendocrine Tumors as compared to genotype CC.	T		= 0.004				
981501834	rs3740066	carbamazepine	Metabolism/PK	yes	Genotypes CT + TT are associated with decreased metabolism of carbamazepine in men with Epilepsy as compared to genotype CC.			= 0.008	Unknown			
1448993707	rs3745274	nevirapine	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of nevirapine in people with HIV Infections as compared to genotypes GG + GT.			< 0.001	OR			
1451156401	rs1045642	quetiapine	Metabolism/PK	no	Genotype AA is not associated with concentrations of quetiapine as compared to genotypes AG + GG.							
981501871	rs4688040	carbamazepine	Metabolism/PK	yes	Allele T is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele G.			= 0.04	Unknown			
1184470036	rs4244285	clopidogrel	Dosage,Efficacy	yes	Genotypes AA + AG is associated with decreased response to clopidogrel in people with percutaneous coronary intervention as compared to genotype GG.	A		= 0.01	OR			
1184175032	rs2072671	gemcitabine	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AC + CC.	A	C	= 0.028	OR			
981501889	rs28365063	carbamazepine	Metabolism/PK	yes	Genotype AA is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to genotypes AG + GG.			= 0.004	Unknown			
981501889	rs28365063	carbamazepine	Metabolism/PK	yes	Genotype AA is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to genotypes AG + GG.				Unknown			
1451411280	rs3781727	voriconazole	Metabolism/PK	not stated	Genotypes CC + CT are associated with decreased exposure to voriconazole in healthy individuals as compared to genotype TT.							
1447947867	rs1057910	irbesartan	Metabolism/PK	yes	Genotype AC is associated with increased concentrations of irbesartan in people with Essential hypertension as compared to genotype AA.	C	A	< 0.0001	OR			
1447947867	rs1057910	irbesartan	Metabolism/PK	yes	Genotype AC is associated with increased concentrations of irbesartan in people with Essential hypertension as compared to genotype AA.	C	A	< 0.0001	OR			
1447947839	rs72558187	irbesartan	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of irbesartan in healthy individuals as compared to genotype TT.			< 0.05	OR			
1447947832	rs72558187	irbesartan	Metabolism/PK	yes	Genotype CT is associated with decreased clearance of irbesartan in healthy individuals as compared to genotype TT.			< 0.01	OR			
1448125824	rs1045642	imatinib	Metabolism/PK	yes	Genotype AG is associated with decreased trough concentration of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + GG.	A		< 0.0001	OR			
1448125824	rs1045642	imatinib	Metabolism/PK	yes	Genotype AG is associated with decreased trough concentration of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + GG.	A		= 0.048	OR			
1447947817	rs1057910	irbesartan	Metabolism/PK	yes	Genotype AC is associated with decreased metabolism of irbesartan in healthy individuals as compared to genotype AA.			< 0.01	OR			
1447947817	rs1057910	irbesartan	Metabolism/PK	yes	Genotype AC is associated with decreased metabolism of irbesartan in healthy individuals as compared to genotype AA.			< 0.01	OR			
1451415192	rs2032582	lamotrigine	Metabolism/PK	no	Allele T is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele A.							
1451415180	rs1128503	lamotrigine	Metabolism/PK	no	Allele G is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele A.	A						
1451415152	rs1045642	lamotrigine	Metabolism/PK	no	Allele A is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele G.	A						
1451415186	rs2032582	lamotrigine	Metabolism/PK	no	Allele C is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele A.							
1451415220	rs2231142	lamotrigine	Metabolism/PK	no	Allele T is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele G.	T						
1451415252	rs3114020	lamotrigine	Metabolism/PK	no	Allele C is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele T.	T						
1451415080	rs28365063	lamotrigine	Metabolism/PK	no	Genotype AG is not associated with concentrations of lamotrigine in people with Epilepsy as compared to genotype AA.	G						
1451417063	rs1128503	temozolomide	Metabolism/PK	yes	Genotypes AA + AG are associated with decreased concentrations of temozolomide in people with Glioma as compared to genotype GG.	G		< 0.05				
1449275102	rs3745274	efavirenz	Metabolism/PK	not stated	Genotype TT is associated with increased concentrations of efavirenz in people with Hepatitis B and HIV Infections as compared to genotypes GG + GT.				OR			
1451415258	rs628031	lamotrigine	Metabolism/PK	no	Allele G is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele A.	A						
1184473123	rs3745274	efavirenz	Metabolism/PK	yes	Genotype GT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	G		= 0.037	OR			
1184473123	rs3745274	efavirenz	Metabolism/PK	yes	Genotype GT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	G	G	= 0.073	OR			
1451415020	rs7668258	lamotrigine	Metabolism/PK	no	Allele T is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele C.	T						
1451415500	rs2740574	tacrolimus	Metabolism/PK	yes	Allele C is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.	C		< 10E-4				
1451415506	rs35599367	tacrolimus	Metabolism/PK	yes	Allele A is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	A		< 10E-3				
1451415515	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT are associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	C		< 0.007				
1449162629	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	desvenlafaxine	Metabolism/PK	not stated	CYP2C19 poor metabolizer and intermediate metabolizer genotypes is not associated with increased concentrations of desvenlafaxine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer and ultra-metabolizer genotypes.				OR			
1184754633	TLR4 poor metabolizer genotype	tacrolimus	Metabolism/PK	yes	TLR4 poor metabolizer genotype is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to TLR4 intermediate metabolizer and normal metabolizer.			< 0.0001	OR			
1184754633	TLR4 poor metabolizer genotype	tacrolimus	Metabolism/PK	yes	TLR4 poor metabolizer genotype is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to TLR4 intermediate metabolizer and normal metabolizer.			= 0.0026	OR			
1184754633	TLR4 poor metabolizer genotype	tacrolimus	Metabolism/PK	yes	TLR4 poor metabolizer genotype is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to TLR4 intermediate metabolizer and normal metabolizer.			= 0.0047	OR			
1184754633	TLR4 poor metabolizer genotype	tacrolimus	Metabolism/PK	yes	TLR4 poor metabolizer genotype is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to TLR4 intermediate metabolizer and normal metabolizer.			= 0.0116	OR			
1450371773	CYP3A5 poor metabolizers	maraviroc	Metabolism/PK	no	CYP3A5 poor metabolizers are not associated with concentrations of maraviroc in people with HIV as compared to CYP3A5 intermediate metabolizers.			= 0.071	OR			
1450371773	CYP3A5 poor metabolizers	maraviroc	Metabolism/PK	no	CYP3A5 poor metabolizers are not associated with concentrations of maraviroc in people with HIV as compared to CYP3A5 intermediate metabolizers.			= 0.1370	OR			
1450371773	CYP3A5 poor metabolizers	maraviroc	Metabolism/PK	no	CYP3A5 poor metabolizers are not associated with concentrations of maraviroc in people with HIV as compared to CYP3A5 intermediate metabolizers.			= 0.280	OR			
1450371773	CYP3A5 poor metabolizers	maraviroc	Metabolism/PK	no	CYP3A5 poor metabolizers are not associated with concentrations of maraviroc in people with HIV as compared to CYP3A5 intermediate metabolizers.			= 0.904	OR			
1449154923	SLC22A1 deficiency	o-desmethyltramadol	Metabolism/PK	not stated	SLC22A1 deficiency is associated with increased concentrations of o-desmethyl-tramadol in infants with Pain.				OR		2.01	2.48
1184754350	CYP3A5 poor metabolizer genotype	tacrolimus	Metabolism/PK	yes	CYP3A5 poor metabolizer genotype is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 intermediate metabolizer and normal metabolizer.			< 0.0001	OR			
1184754350	CYP3A5 poor metabolizer genotype	tacrolimus	Metabolism/PK	yes	CYP3A5 poor metabolizer genotype is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 intermediate metabolizer and normal metabolizer.			= 0.0026	OR			
1184754350	CYP3A5 poor metabolizer genotype	tacrolimus	Metabolism/PK	yes	CYP3A5 poor metabolizer genotype is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 intermediate metabolizer and normal metabolizer.			= 0.0047	OR			
1184754350	CYP3A5 poor metabolizer genotype	tacrolimus	Metabolism/PK	yes	CYP3A5 poor metabolizer genotype is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 intermediate metabolizer and normal metabolizer.			= 0.0116	OR			
1448631663	FMO3 normal metabolizer genotype	olanzapine	Metabolism/PK	no	FMO3 normal metabolizer genotype is not associated with clearance of olanzapine in people with Schizophrenia as compared to FMO3 intermediate metabolizer genotype.				OR			
1183699383	CYP2D6 ultrarapid metabolizer phenotype	risperidone	Metabolism/PK	yes	CYP2D6 ultrarapid metabolizer phenotype is associated with increased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 (assigned as intermediate metabolizer phenotype) .			= 0.006	OR			
1183699383	CYP2D6 ultrarapid metabolizer phenotype	risperidone	Metabolism/PK	yes	CYP2D6 ultrarapid metabolizer phenotype is associated with increased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 (assigned as intermediate metabolizer phenotype) .			= 0.007	OR			
1183699383	CYP2D6 ultrarapid metabolizer phenotype	risperidone	Metabolism/PK	yes	CYP2D6 ultrarapid metabolizer phenotype is associated with increased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 (assigned as intermediate metabolizer phenotype) .			> 0.1	OR			
1183699383	CYP2D6 ultrarapid metabolizer phenotype	risperidone	Metabolism/PK	yes	CYP2D6 ultrarapid metabolizer phenotype is associated with increased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 (assigned as intermediate metabolizer phenotype) .			> 0.7	OR			
1450371799	CYP3A5 poor metabolizers	maraviroc	Metabolism/PK	yes	CYP3A5 poor metabolizers are associated with increased concentrations of maraviroc in people with HIV as compared to CYP3A5 normal metabolizer.			< 0.0001	OR			
1184748530	CYP2D6 poor metabolizer	risperidone	Metabolism/PK	yes	CYP2D6 poor metabolizer are associated with decreased clearance of risperidone in healthy individuals.			< 0.011	OR			
1447947578	NAT2 poor metabolizer genotype	efavirenz	Metabolism/PK	not stated	NAT2 poor metabolizer genotype is associated with increased clearance of efavirenz in people with HIV and Tuberculosis as compared to NAT2 normal metabolizer genotype.				OR			
1448993570	CYP2D6 poor metabolizer genotype	haloperidol	Metabolism/PK	yes	CYP2D6 poor metabolizer genotype is associated with increased dose-adjusted trough concentrations of haloperidol in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer genotype.	*22		< 0.0001	OR			
1449170923	CYP3A5 poor metabolizer and intermediate metabolizer genotypes	tamoxifen	Metabolism/PK	no	CYP3A5 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of tamoxifen in women with Breast Neoplasms.			= 0.7050	OR			
1449170929	CYP2C9 poor metabolizer and intermediate metabolizer genotypes	tamoxifen	Metabolism/PK	no	CYP2C9 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of tamoxifen in women with Breast Neoplasms.			= 0.4447	OR			
1449576659	CYP2D6 intermediate metabolizer and normal metabolizer	tamsulosin	Metabolism/PK	yes	CYP2D6 intermediate metabolizer and normal metabolizer are associated with decreased concentrations of tamsulosin in healthy individuals as compared to CYP2D6 poor metabolizers.			= 0.005	OR			
1449576659	CYP2D6 intermediate metabolizer and normal metabolizer	tamsulosin	Metabolism/PK	yes	CYP2D6 intermediate metabolizer and normal metabolizer are associated with decreased concentrations of tamsulosin in healthy individuals as compared to CYP2D6 poor metabolizers.			= 0.005	OR			
1449170911	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	tamoxifen	Metabolism/PK	no	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of tamoxifen in women with Breast Neoplasms.			= 0.5731	OR			
1449576669	CYP2D6 intermediate metabolizer and normal metabolizer	tamsulosin	Metabolism/PK	yes	CYP2D6 intermediate metabolizer and normal metabolizer are associated with decreased concentrations of tamsulosin in healthy individuals as compared to CYP2D6 poor metabolizers.			< 0.001	OR			
1449576669	CYP2D6 intermediate metabolizer and normal metabolizer	tamsulosin	Metabolism/PK	yes	CYP2D6 intermediate metabolizer and normal metabolizer are associated with decreased concentrations of tamsulosin in healthy individuals as compared to CYP2D6 poor metabolizers.			< 0.001	OR			
1449003201	CYP2D6 poor metabolizer genotype	noroxymorphone	Metabolism/PK	yes	CYP2D6 poor metabolizer genotype is associated with decreased concentrations of noroxymorphone in healthy individuals as compared to CYP2D6 normal metabolizer genotype.			= 1.3E-5	OR			
1449003196	CYP2D6 poor metabolizer genotype	oxymorphone	Metabolism/PK	yes	CYP2D6 poor metabolizer genotype is associated with decreased exposure to oxymorphone in healthy individuals as compared to CYP2D6 ultrarapid metabolizer genotype.			= 0.007	OR			
1449003191	CYP2D6 poor metabolizer genotype	oxymorphone	Metabolism/PK	yes	CYP2D6 poor metabolizer genotype is associated with decreased exposure to oxymorphone in healthy individuals as compared to CYP2D6 normal metabolizer genotype.			= 0.013	OR			
1449170893	CYP3A4 poor metabolizer and intermediate metabolizer genotypes	n-desmethyltamoxifen	Metabolism/PK	no	CYP3A4 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of n-desmethyltamoxifen in women with Breast Neoplasms.			= 0.9651	OR			
1449170868	CYP3A4 poor metabolizer and intermediate metabolizer genotypes	4-hydroxytamoxifen	Metabolism/PK	no	CYP3A4 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of 4-hydroxytamoxifen in women with Breast Neoplasms.			= 0.8200	OR			
1449170875	CYP3A5 poor metabolizer and intermediate metabolizer genotypes	4-hydroxytamoxifen	Metabolism/PK	no	CYP3A5 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of 4-hydroxytamoxifen in women with Breast Neoplasms.			= 0.5061	OR			
1449170881	CYP2C9 poor metabolizer and intermediate metabolizer genotypes	4-hydroxytamoxifen	Metabolism/PK	no	CYP2C9 poor metabolizer and intermediate metabolizer genotypes are associated with concentrations of 4-hydroxytamoxifen in women with Breast Neoplasms.			= 0.1983	OR			
1449170862	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	4-hydroxytamoxifen	Metabolism/PK	no	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of 4-hydroxytamoxifen in women with Breast Neoplasms.			= 0.0074	OR			
1449170844	CYP3A4 poor metabolizer and intermediate metabolizer genotypes	endoxifen	Metabolism/PK	no	CYP3A4 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of endoxifen in women with Breast Neoplasms.			= 0.6818	OR			
1451436960	rs2740574	cyclosporine	Metabolism/PK	no	Allele T is associated with increased concentrations of cyclosporine in people with Kidney Transplantation as compared to allele C.			= 0.25				
1451439620	rs2740574	vincristine	Metabolism/PK	no	Genotype CT is not associated with clearance of vincristine in children with Neoplasms as compared to genotype TT.	*1B			Unknown			
1451439700	rs2740574	tacrolimus	Metabolism/PK	yes	Genotype CT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT.			< 0.005	OR			
1451440440	rs2740574	risperidone	Metabolism/PK	no	Allele C is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele T.	*1B			OR			
1451440480	rs2740574	(S)-methadone	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of (S)-methadone in people with Opioid-Related Disorders as compared to genotype TT.			> 0.3	OR			
1451440540	rs2740574	everolimus	Metabolism/PK	no	Genotype TT is not associated with dose-adjusted trough concentrations of everolimus in people with lung transplantation as compared to genotypes CC + CT.	*1		= 0.6	OR			
1451440560	rs2740574	fentanyl	Metabolism/PK	yes	Allele C is associated with decreased clearance of fentanyl in people with Burns as compared to allele T.			< 0.01				
1451441660	rs2740574	tacrolimus	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of tacrolimus in children with Kidney Transplantation as compared to genotype CT.	*1B		< 0.05	OR			
1451443220	rs2740574	tacrolimus	Metabolism/PK	no	Allele C is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.			= 0.79	OR			
1451463720	rs717620	methotrexate	Metabolism/PK	yes	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	T		= 0.017				
1451463760	rs4149056	methotrexate	Metabolism/PK	no	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	C		= 0.254				
1451463726	rs4948496	methotrexate	Metabolism/PK	no	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	C		= 0.11				
1451463740	rs1801133	methotrexate	Metabolism/PK	no	Allele A is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	A		= 0.623				
1451465029	rs1801133	methotrexate	Metabolism/PK	no	Genotype AA is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.			= 0.427	OR	0.53	0.17	1.64
1451465038	rs1801131	methotrexate	Metabolism/PK	no	Genotype GG is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT.			= 0.260	OR	0.21	0.03	1.69
1451465080	rs4149081	methotrexate	Metabolism/PK	no	Genotype AA is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.			= 0.260	Unknown			
1451465052	rs1979277	methotrexate	Metabolism/PK	no	Genotype GG is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.			= 0.749	OR	1.15	0.49	2.67
1451465061	rs1045642	methotrexate	Metabolism/PK	no	Genotype AA is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.			= 0.260	OR	2.19	0.86	5.61
1451465067	rs2231142	methotrexate	Metabolism/PK	no	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.			= 0.749	OR	1.19	0.41	3.46
1451465086	rs11045879	methotrexate	Metabolism/PK	no	Genotype CC is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.			= 0.008	Unknown			
1451465086	rs11045879	methotrexate	Metabolism/PK	no	Genotype CC is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.			= 0.08	Unknown			
1451451120	rs4149056	pravastatin	Metabolism/PK	yes	Allele C is associated with decreased clearance of pravastatin in healthy individuals as compared to allele T.			< 0.01				
1451451140	rs2306283	pravastatin	Metabolism/PK	yes	is associated with decreased clearance of pravastatin in healthy individuals as compared to allele A.			< 0.01				
1451451180	rs2296651	pravastatin	Metabolism/PK	yes	Allele A is associated with increased clearance of pravastatin in healthy individuals as compared to allele G.			< 0.01				
1451484060	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	risperidone	Metabolism/PK	yes	CYP2D6 poor metabolizer and intermediate metabolizer genotypes is associated with increased exposure to risperidone in people with Psychotic Disorders or Schizophrenia as compared to CYP2D6 normal metabolizer genotype.			< 0.0001				
1451487800	rs25678	daunorubicin	Metabolism/PK	no	Genotypes CG + GG is associated with increased exposure to daunorubicin in people with Leukemia, Myeloid, Acute as compared to genotype CC.			= 0.188				
1451503688	rs2266780	teneligliptin	Metabolism/PK	yes	Genotypes AG + GG is associated with decreased clearance of teneligliptin in men as compared to genotype AA.	A		= 0.0026				
1451516560	rs2032582	(R)-methadone	Metabolism/PK	yes	Genotype AA is associated with decreased clearance of (R)-methadone in people with HIV Infections as compared to genotypes AT + TT.							
1451503720	rs2266782	teneligliptin	Metabolism/PK	yes	Genotypes AG + GG is associated with decreased clearance of teneligliptin in men as compared to genotype AA.	A		= 0.0026				
1451503700	rs909530	teneligliptin	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased clearance of teneligliptin in men as compared to genotype CC.	C		= 0.0002				
1451503760	rs2242480	teneligliptin	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased concentrations of teneligliptin in men as compared to genotype CC.	C		= 0.0332				
1451516600	rs2279343	(S)-methadone	Metabolism/PK	not stated	Allele G is associated with decreased clearance of (S)-methadone in people with HIV Infections as compared to allele A.							
1451516606	rs2307424	(R)-methadone	Metabolism/PK	yes	Genotype GG is associated with increased clearance of (R)-methadone in people with HIV Infections.							
1451516640	rs3003596	(R)-methadone	Metabolism/PK	yes	Genotype GG is associated with increased clearance of (R)-methadone in people with HIV Infections.							
1451502800	rs72846714	mercaptopurine	Metabolism/PK	yes	Genotypes AA + AG are associated with decreased metabolism of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.			= 6.77e-4				
1451502800	rs72846714	mercaptopurine	Metabolism/PK	yes	Genotypes AA + AG are associated with decreased metabolism of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.			= 6.24e-3				
1451502880	rs58700372	mercaptopurine	Metabolism/PK	yes	Genotypes CC + CT are associated with decreased metabolism of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.			= 9.58e-5				
1451502880	rs58700372	mercaptopurine	Metabolism/PK	yes	Genotypes CC + CT are associated with decreased metabolism of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.			= 6.69e-4				
1451504580	rs1801133	methotrexate	Metabolism/PK	yes	Genotypes AA + AG are associated with increased exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	A		= 0.027				
1451511420	rs1801133	methotrexate	Metabolism/PK	yes	Genotypes AA + AG are associated with increased concentrations of methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GG.	A		= 0.003				
1451505540	rs4646453	sirolimus	Metabolism/PK	yes	Genotype CC is associated with increased trough concentration of sirolimus in people with Kidney Transplantation as compared to genotypes AA + AC.			< 0.0001				
1451505550	rs15524	sirolimus	Metabolism/PK	yes	Genotype AA is associated with increased trough concentration of sirolimus in people with Kidney Transplantation as compared to genotypes AG + GG.			< 0.0001				
1451506360	rs1051266	methotrexate	Metabolism/PK	not stated	Genotype TT is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	C						
1451582502	CYP2B6*6	hydroxybupropion	Metabolism/PK	yes	CYP2B6 *6 is associated with decreased exposure to hydroxybupropion in healthy individuals.			< 0.01				
1451582540	CYP2B6 poor metabolizer and intermediate metabolizer genotypes	hydroxybupropion	Metabolism/PK	yes	CYP2B6 poor metabolizer and intermediate metabolizer genotypes is associated with decreased exposure to hydroxybupropion in healthy individuals as compared to CYP2B6 normal metabolizer genotype.			< 0.01				
1451582540	CYP2B6 poor metabolizer and intermediate metabolizer genotypes	hydroxybupropion	Metabolism/PK	yes	CYP2B6 poor metabolizer and intermediate metabolizer genotypes is associated with decreased exposure to hydroxybupropion in healthy individuals as compared to CYP2B6 normal metabolizer genotype.			< 0.01				
1451546960	rs2372536	methotrexate	Metabolism/PK	no	Allele G is not associated with concentrations of methotrexate in children with Osteosarcoma as compared to allele C.	G		= 0.833				
1448104442	rs2032582	methadone	Metabolism/PK	yes	Genotype AC is associated with increased concentrations of methadone in men with Opioid-Related Disorders as compared to genotypes AA + CC.	T		= 0.033	OR			
1451547000	rs1801133	methotrexate	Metabolism/PK	no	Allele A is not associated with concentrations of methotrexate in children with Osteosarcoma as compared to allele G.	A		= 0.821				
1451547020	rs1051266	methotrexate	Metabolism/PK	yes	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to genotype CC.	C		= 0.030				
1451547006	rs1801131	methotrexate	Metabolism/PK	no	Allele G is not associated with concentrations of methotrexate in children with Osteosarcoma as compared to allele T.	G		= 0.521				
1451547383	rs1544105	methotrexate	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	C		= 0.023				
1451547383	rs1544105	methotrexate	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	C		= 0.055				
1451548140	rs11568563	celiprolol	Metabolism/PK	yes	Allele G is associated with decreased concentrations of Celiprolol in healthy individuals as compared to allele T.			= 6.19E-3				
1451548145	rs1045642	celiprolol	Metabolism/PK	yes	Allele G is associated with decreased concentrations of Celiprolol in healthy individuals as compared to allele A.			= 0.03				
1451548340	rs4149009	methotrexate	Metabolism/PK	yes	Genotypes CC + CT are associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	T		= 0.0326	RR	1.3	1.138	1.485
1451548340	rs4149009	methotrexate	Metabolism/PK	yes	Genotypes CC + CT are associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	T		= 0.0576	RR	1.255	1.103	1.428
1451548506	rs1801133	methotrexate	Metabolism/PK	no	Allele A is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	A						
1451511100	rs2231142	methotrexate	Metabolism/PK	no	Allele T is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	T		= 0.321				
1451511100	rs2231142	methotrexate	Metabolism/PK	no	Allele T is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	T		= 0.398				
1451511100	rs2231142	methotrexate	Metabolism/PK	no	Allele T is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	T		= 0.672				
1451511100	rs2231142	methotrexate	Metabolism/PK	no	Allele T is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	T		= 0.672				
1451511160	rs3758149	methotrexate	Metabolism/PK	yes	Genotype GG is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.	A		< 0.05				
1451511171	rs1801133	methotrexate	Metabolism/PK	no	Genotypes AA + AG are associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	C		= 0.27				
1451511171	rs1801133	methotrexate	Metabolism/PK	no	Genotypes AA + AG are associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	C		= 0.58				
1451511164	rs1544105	methotrexate	Metabolism/PK	no	Genotypes CT + TT are associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	C		= 0.16				
1451511164	rs1544105	methotrexate	Metabolism/PK	no	Genotypes CT + TT are associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	C		= 0.96				
1451511320	rs1051296	methotrexate	Metabolism/PK	yes	Genotypes AC + CC are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	A		= 0.04				
1451511320	rs1051296	methotrexate	Metabolism/PK	yes	Genotypes AC + CC are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	A		= 0.10				
1451552561	rs3745274	tramadol	Metabolism/PK	yes	Genotype TT is associated with increased exposure to tramadol in healthy individuals as compared to genotypes GG + GT.	T		= 0.012				
1451552548	rs4680	tramadol	Metabolism/PK	no	Allele A is not associated with concentrations of tramadol in healthy individuals as compared to allele G.	A		= 0.708				
1451552752	rs45445694	methotrexate	Metabolism/PK	no	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased steady-state concentration of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.			> 0.05				
1451552723	rs1801133	methotrexate	Metabolism/PK	yes	Genotypes AG + GG are associated with increased steady-state concentration of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	A		= 0.0007				
1451614958	rs2074087	methotrexate	Metabolism/PK	no	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	G		= 0.706				
1451614946	rs1045642	methotrexate	Metabolism/PK	no	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	G		= 0.706				
1451614940	rs2231142	methotrexate	Metabolism/PK	no	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	T		= 0.789				
1451615000	rs3784862	methotrexate	Metabolism/PK	no	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	A		= 0.610				
1451615006	rs2273697	methotrexate	Metabolism/PK	no	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	A		= 0.546				
1451615012	rs3740065	methotrexate	Metabolism/PK	no	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	G		= 0.646				
1451615018	rs717620	methotrexate	Metabolism/PK	no	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	T		= 0.988				
1451552740	rs1051266	methotrexate	Metabolism/PK	yes	Genotype TT is associated with increased steady-state concentration of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	A		= 0.0467				
1451614952	rs1128503	methotrexate	Metabolism/PK	no	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	G		= 0.587				
1451614974	rs2230671	methotrexate	Metabolism/PK	no	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	A		= 0.385				
1451615024	rs2274407	methotrexate	Metabolism/PK	no	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	A		= 0.883				
1451465044	rs45445694	methotrexate	Metabolism/PK	no	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.			= 0.749	OR	1.31	0.47	3.69
1451553338	rs1801133	methotrexate	Metabolism/PK	yes	Genotype AA is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	A		= 0.005	OR	8.654	1.625	46.078
1451615120	rs4149056	methotrexate	Metabolism/PK	no	Allele C is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	C		= 0.073				
1451615128	rs4149081	methotrexate	Metabolism/PK	no	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	A		= 0.812				
1451553370	rs1045642	methotrexate	Metabolism/PK	yes	Genotype AG is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	A		= 0.022	OR	4.235	1.177	15.24
1451613242	rs2306283	methotrexate	Metabolism/PK	yes	Genotypes AA + AG are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	G		= 0.001				
1451613242	rs2306283	methotrexate	Metabolism/PK	yes	Genotypes AA + AG are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	G		< 0.001				
1451613242	rs2306283	methotrexate	Metabolism/PK	yes	Genotypes AA + AG are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	G		= 0.036				
1451553466	rs1801131	methotrexate	Metabolism/PK	no	Allele G is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	T		> 0.05	Unknown			
1451615134	rs4149009	methotrexate	Metabolism/PK	no	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	T		= 0.752				
1451615140	rs1051266	methotrexate	Metabolism/PK	no	Allele C is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	C		= 0.433				
1451553460	rs2231142	methotrexate	Metabolism/PK	yes	Genotype GT is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	T		= 0.025	OR	4.211	1.126	15.74
1451615146	rs1801131	methotrexate	Metabolism/PK	no	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	G		= 0.661				
1451615216	rs10464903	methotrexate	Metabolism/PK	no	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	T		= 0.948				
1451615152	rs1801133	methotrexate	Metabolism/PK	no	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	A		= 0.878				
1451553477	rs1051266	methotrexate	Metabolism/PK	no	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	C		> 0.05	Unknown			
1451615306	rs1800909	methotrexate	Metabolism/PK	no	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	G		= 0.349				
1451615343	rs1544105	methotrexate	Metabolism/PK	no	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	T		= 0.463				
1451615160	rs2372536	methotrexate	Metabolism/PK	no	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	G		= 0.940				
1451615200	rs1650697	methotrexate	Metabolism/PK	no	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	G		= 0.337				
1451615317	rs719235	methotrexate	Metabolism/PK	no	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	A		= 0.865				
1451615300	rs12681874	methotrexate	Metabolism/PK	no	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	T		= 0.669				
1451615349	rs9344	methotrexate	Metabolism/PK	no	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	A		= 0.304				
1451568920	CYP2D6 poor metabolizer phenotype	morphine	Metabolism/PK	yes	CYP2D6 poor metabolizer phenotype is associated with decreased exposure to morphine in infants as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.			< 0.001				
1451568920	CYP2D6 poor metabolizer phenotype	morphine	Metabolism/PK	yes	CYP2D6 poor metabolizer phenotype is associated with decreased exposure to morphine in infants as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.			< 0.014				
1451569080	rs1045642	methadone	Metabolism/PK	no	Allele G is not associated with metabolism of methadone in men with Heroin Dependence as compared to allele A.	A		= 0.3772				
1451569101	rs3745274	methadone	Metabolism/PK	no	Allele T is not associated with metabolism of methadone in men with Heroin Dependence as compared to allele G.	T		= 0.6909				
1451569107	rs2242480	methadone	Metabolism/PK	no	Allele T is not associated with metabolism of methadone in men with Heroin Dependence as compared to allele C.	T		= 0.4313				
981502416	rs2306990	aripiprazole	Efficacy,Toxicity	no	Allele C is not associated with response to aripiprazole in people with Schizophrenia as compared to allele T.				Unknown			
1451639680	rs2740574	erythromycin	Metabolism/PK	no	Genotype CC is not associated with metabolism of erythromycin in healthy individuals as compared to genotype TT.							
1451639740	rs2740574	nifedipine	Metabolism/PK	no	Genotype CC is not associated with metabolism of nifedipine in healthy individuals as compared to genotype TT.							
1451639883	rs35599367	pazopanib	Metabolism/PK	yes	Genotype AG is associated with decreased clearance of pazopanib in people with Neoplasms as compared to genotype GG.			= 0.002				
1451639920	rs2231142	pazopanib	Metabolism/PK	no	Genotypes GT + TT is not associated with decreased clearance of pazopanib in people with Neoplasms as compared to genotype GG.			= 0.67				
1451639980	rs2231137	pazopanib	Metabolism/PK	no	Genotype CT is not associated with decreased clearance of pazopanib in people with Neoplasms as compared to genotype CC.			= 0.86				
1451640080	rs35599367	tenofovir alafenamide	Metabolism/PK	yes	Genotype AG is associated with decreased concentrations of tenofovir alafenamide in healthy individuals as compared to genotype GG.	A		= 0.033				
1451648640	rs12208357	morphine	Metabolism/PK	no	Allele T is not associated with exposure to morphine in people with Pain, Postoperative as compared to allele C.			= 0.3				
1451648703	rs34059508	morphine	Metabolism/PK	no	Allele A is not associated with exposure to morphine in people with Pain, Postoperative as compared to allele G.			= 0.3				
1451643703	rs4253728	2-hydroxyatorvastatin	Metabolism/PK	yes	Genotypes AA + AG is associated with decreased concentrations of 2-hydroxyatorvastatin in healthy individuals as compared to genotype GG.			= 0.0013				
1451643703	rs4253728	2-hydroxyatorvastatin	Metabolism/PK	yes	Genotypes AA + AG is associated with decreased concentrations of 2-hydroxyatorvastatin in healthy individuals as compared to genotype GG.			= 0.044				
1451648709	rs72552763	morphine	Metabolism/PK	no	Allele del is not associated with exposure to morphine in people with Pain, Postoperative as compared to allele GAT.			= 0.3				
1451644760	rs35599367	2-hydroxyatorvastatin	Metabolism/PK	yes	Genotype AG is associated with decreased concentrations of 2-hydroxyatorvastatin in healthy individuals as compared to genotype GG.			< 0.001				
1451644829	rs258747	2-hydroxyatorvastatin	Metabolism/PK	no	Genotype AA is not associated with decreased concentrations of 2-hydroxyatorvastatin in healthy individuals as compared to genotypes AG + GG.			= 0.0029				
1451644829	rs258747	2-hydroxyatorvastatin	Metabolism/PK	no	Genotype AA is not associated with decreased concentrations of 2-hydroxyatorvastatin in healthy individuals as compared to genotypes AG + GG.							
1451644868	rs3733260	2-hydroxyatorvastatin	Metabolism/PK	no	Genotype TT is not associated with decreased concentrations of 2-hydroxyatorvastatin in healthy individuals as compared to genotypes GG + GT.			= 0.0038				
1451644868	rs3733260	2-hydroxyatorvastatin	Metabolism/PK	no	Genotype TT is not associated with decreased concentrations of 2-hydroxyatorvastatin in healthy individuals as compared to genotypes GG + GT.							
1451652240	rs6714486	mycophenolic acid	Metabolism/PK	yes	Genotypes AA + AT is associated with decreased dose-adjusted trough concentrations of mycophenolic acid in children with Kidney Transplantation as compared to genotype TT.			= 0.05				
1451647385	CYP2C19 poor metabolizers and intermediate metabolizers	oxycodone	Metabolism/PK	yes	CYP2C19 poor metabolizers and intermediate metabolizers are associated with decreased metabolism of oxycodone as compared to CYP2C19 normal metabolizer and ultrarapid metabolizer.			= 1.97E-14				
1451647381	CYP2D6 poor metabolizers and intermediate metabolizers	oxycodone	Metabolism/PK	yes	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased metabolism of oxycodone as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.			= 8.68E-129				
1451678340	rs1045642	fentanyl	Metabolism/PK	no	Allele G is not associated with clearance of fentanyl in children as compared to allele A (assigned as normal metabolizer genotype phenotype) .							
1451679529	rs55944529	methadone	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of methadone in people with Heroin Dependence as compared to genotypes CC + CT.	T		= 0.003				
1451679535	rs11114083	methadone	Metabolism/PK	no	Genotypes AA + AC are not associated with concentrations of methadone in people with Heroin Dependence as compared to genotype CC.	A		= 0.88				
1451679553	rs2070586	methadone	Metabolism/PK	no	Genotypes AG + GG are not associated with concentrations of methadone in people with Heroin Dependence as compared to genotype AA.	A		= 0.91				
1451679559	rs2070587	methadone	Metabolism/PK	no	Genotypes GT + TT are not associated with concentrations of methadone in people with Heroin Dependence as compared to genotype GG.	G		= 0.90				
1451681600	rs2472297	clozapine	Metabolism/PK	yes	Allele T is associated with decreased concentrations of clozapine in people with Schizophrenia as compared to allele C.			= 4.35e-10				
1451682560	rs61750900	n-desmethylclozapine	Metabolism/PK	yes	Allele T is associated with decreased concentrations of n-desmethylclozapine in people with Schizophrenia as compared to allele G.			= 3.17e-17				
1451682566	rs2011425	n-desmethylclozapine	Metabolism/PK	yes	Allele G is associated with decreased concentrations of n-desmethylclozapine in people with Schizophrenia as compared to allele T.			= 3.34e-9				
1451682620	rs61750900	clozapine	Metabolism/PK	yes	Allele T is associated with decreased metabolism of clozapine in people with Schizophrenia as compared to allele G.			= 5.01e-70				
1451682582	rs1126545	clozapine	Metabolism/PK	yes	Allele T is associated with decreased metabolism of clozapine in people with Schizophrenia as compared to allele C.			= 5.96e-14				
1451663080	rs28399454	nicotine	Metabolism/PK	not stated	Genotypes CT + TT are associated with decreased metabolism of nicotine as compared to genotype CC.							
1450823491	rs58310495	fluvastatin	Metabolism/PK	yes	Allele T is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele C.			= 3.07e-10				
1451664500	CYP2D6*4	duloxetine	Metabolism/PK	not stated	CYP2D6 *4/*4 is associated with increased concentrations of duloxetine in women with Depressive Disorder.							
1451684680	CYP3A4 low activity	n-desmethylclozapine	Metabolism/PK	yes	CYP3A4 low activity is associated with decreased concentrations of n-desmethylclozapine in people with Schizophrenia as compared to CYP3A4 high activity.			< 0.0001				
1451664485	CYP2D6*4	desvenlafaxine	Metabolism/PK	not stated	CYP2D6 *4/*4 is associated with decreased concentrations of desvenlafaxine in women with Depressive Disorder.							
1451684740	CYP1A2 low activity	n-desmethylclozapine	Metabolism/PK	yes	CYP1A2 low activity is associated with decreased concentrations of n-desmethylclozapine in people with Schizophrenia as compared to CYP1A2 high activity.			= 0.0007				
1451685290	rs762551	clozapine	Metabolism/PK	not stated	Genotype AA is associated with decreased concentrations of clozapine in people with Schizophrenia and Tobacco Use Disorder as compared to genotypes AC + CC.							
1451685223	rs762551	clozapine	Metabolism/PK	yes	Genotype AA is associated with increased concentrations of clozapine in people with Schizophrenia as compared to genotypes AC + CC.			= 0.005				
1451686760	CYP2B6*6	efavirenz	Metabolism/PK	not stated	CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV Infections.	*1/*6	*6/*6					
1451692484	CYP3A5*3	tacrolimus	Metabolism/PK	no	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in men with liver transplantation and Obesity.							
1451692802	UGT1A1*28	clozapine	Metabolism/PK	no	UGT1A1 *28/*28 is associated with increased concentrations of clozapine in men with Schizophrenia.							
1451697420	rs3735451	hydroxychloroquine	Metabolism/PK	yes	Genotype CC is associated with decreased concentrations of hydroxychloroquine in people with Arthritis, Rheumatoid or Lupus Erythematosus, Systemic as compared to genotypes CT + TT.	C		= 0.017				
1451674420	rs2231142	pitavastatin	Metabolism/PK	no	Allele T is not associated with increased concentrations of pitavastatin in healthy individuals as compared to allele G.			> 0.05				
1451700040	rs2331559	nicotine	Metabolism/PK	no	Allele C is not associated with clearance of nicotine as compared to allele G.			= 0.48				
1451700080	rs835309	nicotine	Metabolism/PK	no	Allele G is not associated with clearance of nicotine as compared to allele T.			= 0.07				
1451700101	rs11726322	nicotine	Metabolism/PK	no	Allele G is not associated with clearance of nicotine as compared to allele C.			= 0.70				
1451700120	rs2942857	nicotine	Metabolism/PK	no	Allele A is not associated with clearance of nicotine as compared to allele C.			= 0.08				
1451674520	rs4149056	pitavastatin	Metabolism/PK	yes	Genotypes CC + CT are associated with increased concentrations of pitavastatin in healthy individuals as compared to genotype TT.			< 0.05				
1451707240	rs2279345	efavirenz	Metabolism/PK	no	Allele C is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele T.	C		= 0.0001				
1451707240	rs2279345	efavirenz	Metabolism/PK	no	Allele C is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele T.	C		= 0.341				
1451714340	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.							
1451707041	rs28399499	efavirenz	Metabolism/PK	yes	Allele C is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele T.	T		= 0.0001				
1451707041	rs28399499	efavirenz	Metabolism/PK	yes	Allele C is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele T.	T		= 0.002				
1451714346	rs35599367	tacrolimus	Metabolism/PK	yes	Genotypes AA + AG are associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype GG.							
1451706780	rs2279343	efavirenz	Metabolism/PK	no	Allele G is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele A.	A		= 0.0001				
1451706780	rs2279343	efavirenz	Metabolism/PK	no	Allele G is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele A.	A		= 0.886				
1451715780	rs4244285	citalopram	Metabolism/PK	yes	Genotype AG is associated with increased concentrations of citalopram in men with Alcoholism and Depressive Disorder, Major as compared to genotype GG.			< 0.001				
1451707340	rs3745274	efavirenz	Metabolism/PK	yes	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.	G		= 0.0001				
1451707340	rs3745274	efavirenz	Metabolism/PK	yes	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.	G		= 0.018				
1451707346	rs8192719	efavirenz	Metabolism/PK	yes	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele C.	C		= 0.0001				
1451707346	rs8192719	efavirenz	Metabolism/PK	yes	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele C.	C		= 0.0001				
1451720320	rs762551	clozapine	Metabolism/PK	yes	Genotype AA is associated with decreased dose-adjusted trough concentrations of clozapine in people with Schizophrenia and Tobacco Use Disorder as compared to genotypes AC + CC.			= 0.047				
1451144700	rs35599367	alprazolam	Metabolism/PK	yes	Genotype AG is associated with increased concentrations of alprazolam in men with Alcoholism and Anxiety Disorders as compared to genotype GG.	A		= 0.001				
1451726920	rs1045642	lamotrigine	Metabolism/PK	no	Genotype AA is not associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes AG + GG.							
1451726360	rs6755571	lamotrigine	Metabolism/PK	yes	Genotype CC is associated with decreased concentrations of lamotrigine in women with Epilepsy as compared to genotype AC.	A		< 0.05				
1451726360	rs6755571	lamotrigine	Metabolism/PK	yes	Genotype CC is associated with decreased concentrations of lamotrigine in women with Epilepsy as compared to genotype AC.	A		< 0.05				
1451726491	rs7439366	lamotrigine	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes CC + CT.			< 0.05				
1451726778	rs1902023	lamotrigine	Metabolism/PK	yes	Genotype AA is associated with decreased concentrations of lamotrigine in women with Epilepsy as compared to genotypes AC + CC.	A		< 0.05				
1451726778	rs1902023	lamotrigine	Metabolism/PK	yes	Genotype AA is associated with decreased concentrations of lamotrigine in women with Epilepsy as compared to genotypes AC + CC.	A		< 0.05				
1451726901	rs1128503	lamotrigine	Metabolism/PK	no	Genotype AA is not associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes AG + GG.							
1451727960	rs77235035	ticagrelor	Metabolism/PK	no	Genotype AA is associated with decreased concentrations of ticagrelor in healthy individuals as compared to genotypes AC + CC.	A						
1450930992	rs2242480	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in children with Nephrotic Syndrome as compared to genotype CT.			< 0.0001				
1444935523	rs2242480	carbamazepine	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	C		= 0.027	OR			
1444935523	rs2242480	carbamazepine	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	C		= 0.042	OR			
1451732760	rs2231142	rosuvastatin	Metabolism/PK	yes	Genotypes GT + TT is associated with increased concentrations of rosuvastatin as compared to genotype GG.			< 0.00001				
1451734000	rs4728709	rivaroxaban	Metabolism/PK	not stated	Genotypes AA + AG is associated with increased clearance of rivaroxaban in people with Atrial Fibrillation as compared to genotype GG.	A						
1451735420	rs4986893	voriconazole	Metabolism/PK	yes	Genotypes AA + AG is associated with increased dose-adjusted trough concentrations of voriconazole in children as compared to genotype GG.			= 0.004				
1451735380	rs4244285	voriconazole	Metabolism/PK	yes	Genotypes AA + AG is associated with increased dose-adjusted trough concentrations of voriconazole in children as compared to genotype GG.	A		< 0.0001				
1451735460	rs1057910	voriconazole	Metabolism/PK	no	Genotypes AA + AC is not associated with increased dose-adjusted trough concentrations of voriconazole in children as compared to genotype CC.			= 0.293				
1451735563	rs4646437	voriconazole	Metabolism/PK	no	Genotypes AA + AG is not associated with increased dose-adjusted trough concentrations of voriconazole in children as compared to genotype GG.	A		= 0.942				
769257715	rs1045642	carbamazepine	Other,Metabolism/PK	no	Allele A is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele G.				Unknown			
1451774660	rs2231142	dolutegravir	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of dolutegravir in people with HIV Infections as compared to genotypes GG + GT.	T		= 0.047				
1451775480	rs2472677	dolutegravir	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of dolutegravir in people with HIV Infections as compared to genotypes CC + CT.	C		= 0.033				
1451140186	NAT2 rapid acetylator	hydralazine	Dosage,Efficacy	yes	NAT2 rapid acetylator is associated with increased dose of hydralazine in people with Hypertension as compared to NAT2 slow acetylator.			< 0.05				
1451760640	rs2069514	clozapine	Metabolism/PK	no	Genotype AG is not associated with concentrations of clozapine in people with Schizophrenia as compared to genotype GG.	A		= 0.65				
1451760610	rs762551	clozapine	Metabolism/PK	yes	Genotypes AA + AC are associated with decreased concentrations of clozapine in people with Schizophrenia as compared to genotype CC.	A		< 0.001				
1451760660	rs4244285	clozapine	Metabolism/PK	no	Genotype AG is not associated with concentrations of clozapine in people with Schizophrenia as compared to genotype GG.	A		= 0.93				
1451807340	rs11188059	escitalopram	Metabolism/PK	yes	Allele G is associated with decreased concentrations of escitalopram as compared to allele A.			< 0.001				
1451807320	rs2860840	escitalopram	Metabolism/PK	yes	Allele T is associated with decreased concentrations of escitalopram as compared to allele C.			< 0.001				
1451809180	rs34130495	morphine	Metabolism/PK	no	Allele A is not associated with exposure to morphine in people with Pain, Postoperative as compared to allele G.			= 0.3				
1451140180	NAT2 slow acetylator	hydralazine	Metabolism/PK	yes	NAT2 slow acetylator is associated with increased concentrations of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.			= 0.001				
1451140180	NAT2 slow acetylator	hydralazine	Metabolism/PK	yes	NAT2 slow acetylator is associated with increased concentrations of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.			< 0.02				
1451768280	rs1532268	methotrexate	Metabolism/PK	yes	Genotypes CT + TT is associated with increased exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.			= 0.04				
1451769360	rs17004785	methotrexate	Metabolism/PK	yes	Genotype CG is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.							
1451769300	rs4148416	methotrexate	Metabolism/PK	yes	Genotype TT is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.							
1451770441	rs2011425	clozapine 5-N-glucuronide	Metabolism/PK	no	Genotype GT is associated with decreased exposure to clozapine 5-N-glucuronide as compared to genotype TT.	G		= 0.14				
1451771272	rs1513559	clozapine N+ glucuronide	Metabolism/PK	no	Genotypes AG + GG is associated with decreased exposure to clozapine N+ glucuronide as compared to genotype AA.							
1451771820	rs416593	clozapine N+ glucuronide	Metabolism/PK	no	Genotypes AA + AT is associated with decreased exposure to clozapine N+ glucuronide as compared to genotype AA.							
1446901646	CYP2D6 poor metabolizers	amitriptyline	Metabolism/PK	not stated	CYP2D6 poor metabolizers are associated with decreased metabolism of amitriptyline in people with Depression as compared to CYP2D6 normal metabolizers.				OR			
1448684673	rs3745274	levonorgestrel	Metabolism/PK	yes	Genotypes GT + TT are associated with decreased concentrations of levonorgestrel in women with HIV Infections as compared to genotype GG.			= 0.021	OR			
1447947794	rs1057910	irbesartan	Metabolism/PK	yes	Genotype AC is associated with decreased clearance of irbesartan in healthy individuals as compared to genotype AA.			< 0.001	OR			
769258956	rs717620	erythromycin	Other,Metabolism/PK	yes	Genotype TT is associated with increased metabolism of erythromycin as compared to genotypes CC + CT.			= 0.013	Unknown			
1184470183	rs11265572	tacrolimus	Metabolism/PK	yes	Genotypes GT + TT are associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to genotype GG.	G		< 0.01	OR			
1184470183	rs11265572	tacrolimus	Metabolism/PK	yes	Genotypes GT + TT are associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to genotype GG.	G			OR			
1183700136	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.			< 0.0001	OR			
981502104	rs286913	ziprasidone	Dosage,Efficacy	yes	Allele A is associated with increased response to ziprasidone in people with Schizophrenia as compared to allele G.	A		= 0.034	Unknown			
981502111	rs11240594	olanzapine	Dosage,Efficacy	yes	Allele A is associated with increased response to olanzapine in people with Schizophrenia as compared to allele G.	A		= 0.068	Unknown			
1445391811	rs1045642	phenytoin	Metabolism/PK	no	Genotype AG is not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy as compared to genotype AA.	A		= 0.18	OR			
981502120	rs11677416	olanzapine	Dosage,Efficacy	yes	Allele C is associated with increased response to olanzapine in people with Schizophrenia as compared to allele T.	C		= 0.32	Unknown			
1448993933	rs8192709	efavirenz	Metabolism/PK	no	Genotypes CT + TT are not associated with concentrations of efavirenz in people with HIV Infections as compared to genotype CC.	T		= 0.371	OR			
1448603074	rs2231142	felodipine	Metabolism/PK	yes	Genotype TT is associated with increased exposure to felodipine in healthy individuals as compared to genotypes GG + GT.			= 0.034	OR			
699642204	rs12422149	montelukast	Efficacy,Metabolism/PK	yes	Genotype AG is associated with decreased response to montelukast in people with Asthma as compared to genotype GG.			= 0.019	Unknown			
1448603069	rs1045642	sirolimus	Metabolism/PK	yes	Genotype AG is associated with increased concentrations of sirolimus as compared to genotypes AA + GG.			= 0.038	OR			
769259039	rs28365062	zidovudine	Metabolism/PK	yes	Allele G is associated with increased metabolism of zidovudine as compared to allele A.			= 0.004	Unknown			
1448993954	rs8100458	efavirenz	Metabolism/PK	no	Genotypes CT + TT are not associated with concentrations of efavirenz in people with HIV Infections as compared to genotype CC.	T		= 0.1454	OR			
1451140220	NAT2 slow acetylator	hydralazine	Metabolism/PK	yes	NAT2 slow acetylator is associated with increased concentrations of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.			< 0.005				
1448258995	DPYD deficiency	fluorouracil	Metabolism/PK	not stated	DPYD deficiency is associated with decreased metabolism of fluorouracil in women with Breast Neoplasms.				OR			
1447947686	rs1523130	atazanavir	Metabolism/PK	no	Genotype CC (assigned as deficiency phenotype) is not associated with concentrations of atazanavir in people with HIV Infections as compared to genotypes CT + TT.	C		= 0.82	OR			
1447947662	rs4149056	atazanavir	Metabolism/PK	no	Genotype CT (assigned as deficiency phenotype) is not associated with concentrations of atazanavir in people with HIV Infections as compared to genotype TT.	C		= 0.57	OR			
1447947668	rs2472677	atazanavir	Metabolism/PK	yes	Genotype CT (assigned as deficiency phenotype) is associated with decreased concentrations of atazanavir in people with HIV Infections as compared to genotypes CC + TT.	C		= 0.03	OR			
1184470283	rs4253728	cyclosporine	Metabolism/PK	no	Genotype AA is not associated with metabolism of cyclosporine in people with Kidney Transplantation as compared to allele G.	A	G	> 0.05	OR			
1184470287	rs35599367	cyclosporine	Metabolism/PK	yes	Allele A is associated with decreased metabolism of cyclosporine in people with Kidney Transplantation as compared to allele G.	A	G	< 0.01	OR			
981502125	rs2975226	clozapine	Dosage,Efficacy	yes	Allele A is associated with increased response to clozapine in people with Schizophrenia as compared to allele T.			= 0.00404	OR	2.866	1.536	5.348
1444936640	rs1045642	sunitinib	Metabolism/PK	yes	Genotype GG is associated with increased exposure to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AG.	G		< 0.05	OR			
1448262608	rs1142345	azathioprine	Metabolism/PK	yes	Genotype CT is associated with decreased metabolism of azathioprine in people with Inflammatory Bowel Diseases as compared to genotype TT.			= 0.016	OR			
1448262608	rs1142345	azathioprine	Metabolism/PK	yes	Genotype CT is associated with decreased metabolism of azathioprine in people with Inflammatory Bowel Diseases as compared to genotype TT.			= 0.028	OR			
1450342045	rs4148412	morphine-3-glucuronide	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of morphine-3-glucuronide in children with tonsillectomy as compared to genotypes CC + CT.			< 0.05	OR			
1450342045	rs4148412	morphine-3-glucuronide	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of morphine-3-glucuronide in children with tonsillectomy as compared to genotypes CC + CT.			= 0.06	OR			
749069601	rs2472677	atazanavir	Metabolism/PK	yes	Genotype TT is associated with increased metabolism of atazanavir in people with HIV Infections as compared to genotypes CC + CT.				Unknown			
1444707128	rs9934438	acenocoumarol	Dosage,Efficacy	yes	Genotypes AA + AG is associated with decreased dose of acenocoumarol as compared to genotype GG.			= 0.004	OR			
982029098	rs28399504	mephenytoin	Metabolism/PK	yes	Allele G is associated with decreased metabolism of mephenytoin as compared to allele A.				Unknown			
1446902590	CYP2C19 poor metabolizers	imipramine	Metabolism/PK	yes	CYP2C19 poor metabolizers are associated with decreased metabolism of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.			< 0.01	OR			
1450112795	rs717620	mycophenolic acid	Metabolism/PK	yes	Genotype TT is associated with increased dose-adjusted trough concentrations of mycophenolic acid in people with Kidney Transplantation as compared to genotypes CC + CT.			= 0.043	OR			
1451128662	rs56107638	clozapine	Toxicity,Metabolism/PK	no	Genotype AG is associated with increased concentrations of clozapine in women with schizoaffective disorder as compared to genotype GG.							
1450342277	SLC22A1 low activity	morphine	Metabolism/PK	yes	SLC22A1 low activity is associated with increased concentrations of morphine in healthy individuals as compared to SLC22A1 high activity.			= 0.03	OR			
1449162717	rs11265572	tacrolimus	Metabolism/PK	no	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.				OR			
1449162725	rs1800872	tacrolimus	Metabolism/PK	no	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.				OR			
1448639083	rs2013249	bupropion	Metabolism/PK	no	Genotype CC is not associated with metabolism of bupropion in healthy individuals as compared to genotypes CG + GG.	C	G	> 0.05	OR			
1449162739	rs1800896	tacrolimus	Metabolism/PK	no	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.				OR			
1449162732	rs1800871	tacrolimus	Metabolism/PK	no	Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.				OR			
1449162751	rs16840252	tacrolimus	Metabolism/PK	no	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.				OR			
1448639061	rs2231198	bupropion	Metabolism/PK	no	Genotype CC is not associated with metabolism of bupropion in healthy individuals as compared to genotypes CT + TT.	C	T	> 0.05	OR			
1449162758	rs1128503	tramadol	Metabolism/PK	yes	Genotype AA is associated with increased exposure to tramadol as compared to genotype GG.	A		= 0.05	OR			
1449162769	rs1045642	tramadol	Metabolism/PK	yes	Genotype AA is associated with increased exposure to tramadol as compared to genotype GG.	A		= 0.03	OR			
1448639049	rs12248560	bupropion	Metabolism/PK	no	Genotype CC is not associated with metabolism of bupropion in healthy individuals as compared to genotypes CT + TT.	A	T	> 0.05	OR			
1448098367	rs16935279	antiepileptics	Metabolism/PK	yes	Genotypes CC + CT are associated with decreased metabolism of antiepileptics in people with Bipolar Disorder and Psychotic Disorders as compared to genotype TT.	C		= 4.76E-10	OR			
1449162764	rs2032582	tramadol	Metabolism/PK	yes	Genotype AA is associated with increased exposure to tramadol as compared to genotype CC.	A		= 0.04	OR			
1448639039	rs2279343	bupropion	Metabolism/PK	no	Genotype AA is not associated with metabolism of bupropion in healthy individuals as compared to genotypes AG + GG.	A	G	> 0.05	OR			
1448639034	rs3745274	bupropion	Metabolism/PK	no	Genotype TT is not associated with metabolism of bupropion in healthy individuals as compared to genotypes GG + GT.	G	T	> 0.05	OR			
1446902332	CYP2C19 poor metabolizers	imipramine	Metabolism/PK	yes	CYP2C19 poor metabolizers are associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.			< 0.01	OR			
1448639028	rs8192709	bupropion	Metabolism/PK	no	Genotype TT is not associated with metabolism of bupropion in healthy individuals as compared to genotypes CC + CT.	C	T	> 0.05	OR			
1183680593	CYP2D6*4	codeine	Metabolism/PK	not stated	CYP2D6 *4/*4 is associated with decreased metabolism of codeine in healthy individuals.				OR			
1447983631	rs28365063	lamotrigine	Metabolism/PK	yes	Genotype GG is associated with increased clearance of lamotrigine in people with Epilepsy as compared to genotypes AA + AG.	G		< 0.05	OR			
1447983614	rs628031	lamotrigine	Metabolism/PK	no	Genotype GG is associated with increased dose of lamotrigine in people with Epilepsy as compared to genotypes AA + AG.	A		= 0.6	OR			
1447983624	rs7668258	lamotrigine	Metabolism/PK	yes	Genotype TT is associated with decreased clearance of lamotrigine in people with Epilepsy as compared to genotypes CC + CT.	T		< 0.05	OR			
1449162841	rs3814055	tacrolimus	Metabolism/PK	no	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.				OR			
655386824	rs60369023	gemcitabine	Other,Metabolism/PK	yes	Allele A is associated with decreased metabolism of gemcitabine in people with Neoplasms as compared to allele G.			= 0.001	Unknown			
655386820	rs2072671	gemcitabine	Toxicity,Metabolism/PK	no	Allele C is not associated with decreased metabolism of gemcitabine in people with Neoplasms as compared to allele A.				Unknown			
1449162849	rs6785049	tacrolimus	Metabolism/PK	no	Allele G is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele A.				OR			
1449162856	rs3814057	tacrolimus	Metabolism/PK	no	Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.				OR			
827923820	rs71647871	methylphenidate	Dosage,Metabolism/PK	yes	Genotype CT is associated with decreased dose of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.			= 0.022	Unknown			
1449162891	rs657075	tacrolimus	Metabolism/PK	no	Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.				OR			
1449162909	rs1524107	tacrolimus	Metabolism/PK	no	Allele C is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation.				OR			
1184467044	TPMT*3A	mercaptopurine	Dosage,Efficacy,Toxicity	not stated	TPMT *3A/*3A is associated with decreased dose of mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.				OR			
1449146532	CYP1A2*1F	clozapine	Dosage,Metabolism/PK	no	CYP1A2 *1F/*1F is associated with increased dose of clozapine in women with Schizophrenia.				OR			
1448573355	rs1128503	tacrolimus	Metabolism/PK	no	Genotypes AG + GG is not associated with metabolism of tacrolimus in people with Colitis, Ulcerative as compared to genotype AA.	G			OR			
1449588912	rs4149117	voriconazole	Metabolism/PK	yes	Genotypes GT + TT is associated with decreased trough concentration of voriconazole in children as compared to genotype GG.	T		= 0.046	OR			
1451178201	rs2032582	aripiprazole	Metabolism/PK	yes	Genotype AA is associated with decreased dose-adjusted trough concentrations of aripiprazole in children as compared to genotypes AC + CC.			= 0.019	Unknown			
1449162946	rs1057868	tacrolimus	Metabolism/PK	no	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.				OR			
1451178160	rs1045642	aripiprazole	Metabolism/PK	yes	Genotype AA is associated with decreased dose-adjusted trough concentrations of aripiprazole in children as compared to genotypes AG + GG.			= 0.019	Unknown			
827661941	rs1057910	warfarin	Dosage,Metabolism/PK	yes	Genotypes AC + CC are associated with decreased dose of warfarin as compared to genotype AA.			= 4.4E-13	Unknown			
1450375434	rs1045642	tramadol	Metabolism/PK	no	Allele A is associated with increased concentrations of tramadol in healthy individuals as compared to allele G.	A		= 0.04	OR			
1450375434	rs1045642	tramadol	Metabolism/PK	no	Allele A is associated with increased concentrations of tramadol in healthy individuals as compared to allele G.	A		= 0.09	OR			
1450375434	rs1045642	tramadol	Metabolism/PK	no	Allele A is associated with increased concentrations of tramadol in healthy individuals as compared to allele G.	A		= 0.56	OR			
1445296452	rs13253389	cotinine	Metabolism/PK	yes	Genotypes AG + GG is associated with increased concentrations of cotinine in children as compared to genotype AA.	G		= 0.0006	OR			
1449752869	CYP2D6 ultrarapid metabolizer	o-desmethyltramadol	Metabolism/PK	yes	CYP2D6 ultrarapid metabolizer is associated with increased concentrations of o-desmethyl-tramadol in people with Low Back Pain or Osteoarthritis as compared to CYP2D6 normal metabolizer.			< 0.0001	OR			
981505272	rs1544410	midazolam	Metabolism/PK	yes	Allele C is associated with increased clearance of midazolam as compared to allele T.	T		= 0.03	Unknown			
1450375444	rs1045642	o-desmethyltramadol	Metabolism/PK	no	Allele A is not associated with concentrations of o-desmethyltramadol in healthy individuals as compared to allele G.	A		= 0.19	OR			
1450375444	rs1045642	o-desmethyltramadol	Metabolism/PK	no	Allele A is not associated with concentrations of o-desmethyltramadol in healthy individuals as compared to allele G.	A		= 0.19	OR			
1450375444	rs1045642	o-desmethyltramadol	Metabolism/PK	no	Allele A is not associated with concentrations of o-desmethyltramadol in healthy individuals as compared to allele G.	A		= 0.42	OR			
1450375444	rs1045642	o-desmethyltramadol	Metabolism/PK	no	Allele A is not associated with concentrations of o-desmethyltramadol in healthy individuals as compared to allele G.	A		= 0.56	OR			
1448261943	rs1045642	sunitinib	Metabolism/PK	yes	Genotypes AA + AG is associated with increased clearance of sunitinib in people with Carcinoma, Renal Cell and Neoplasm Metastasis as compared to genotype GG.			= 0.06	OR			
1444694255	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with hemopoietic stem cell transplant as compared to genotype CC.			< 0.05	OR	32.2	1.32	786.0
1444694255	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with hemopoietic stem cell transplant as compared to genotype CC.			< 0.05	OR	33.0	1.34	814.0
1184233832	rs3745274	efavirenz	Metabolism/PK	yes	Genotype GT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	G	T	< 0.001	OR			
1184233832	rs3745274	efavirenz	Metabolism/PK	yes	Genotype GT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	G	T	< 0.001	OR	4.35	1.97	9.59
1449560375	rs1128503	lamotrigine	Metabolism/PK	no	Allele A is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele G.			> 0.0125	OR			
1449560369	rs7668258	lamotrigine	Metabolism/PK	no	Allele T is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele C.			> 0.0125	OR			
1449003329	rs11045879	methotrexate	Metabolism/PK	no	Genotypes CC + CT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.			= 0.287	OR			
1447676175	rs9561778	cyclophosphamide	Efficacy,Toxicity,Metabolism/PK	no	Genotype GG is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotypes GT + TT.	A		= 1	OR			
1450936672	rs17376019	ethanol	Metabolism/PK	yes	Genotype CT is associated with decreased concentrations of ethanol in healthy individuals as compared to genotype CC.	T		< 0.0081				
1449003337	rs4149056	methotrexate	Metabolism/PK	no	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.			= 0.441	OR			
1447676180	rs3957357	cyclophosphamide	Efficacy,Toxicity,Metabolism/PK	no	Genotype GG is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotypes AA + AG.	A		= 0.3	OR			
1184512390	rs3211371	efavirenz	Metabolism/PK	no	Genotype TT is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype CC.	T		= 0.37	OR			
1450936677	rs671	ethanol	Metabolism/PK	yes	Genotype AG is associated with increased concentrations of ethanol in healthy individuals as compared to genotype GG.	A		< 0.008				
1449560381	rs2231142	lamotrigine	Metabolism/PK	no	Allele G is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele T.			> 0.0125	OR			
1447676185	rs1695	cyclophosphamide	Efficacy,Toxicity,Metabolism/PK	no	Genotype AA is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotypes AG + GG.	A		= 0.39	OR			
1449003343	rs10841753	methotrexate	Metabolism/PK	yes	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.			= 0.017	OR			
1447676170	rs4148350	cyclophosphamide	Efficacy,Toxicity,Metabolism/PK	no	Genotype GG is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype GT.	G		= 0.20	OR			
1449003351	rs1051266	methotrexate	Metabolism/PK	no	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.			= 0.384	OR			
1449003357	rs3788200	methotrexate	Metabolism/PK	no	Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.			= 0.491	OR			
1449003369	rs1131596	methotrexate	Metabolism/PK	no	Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.			= 0.219	OR			
1447676150	rs4244285	cyclophosphamide	Efficacy,Toxicity,Metabolism/PK	no	Genotype GG is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotypes AA + AG.	A		= 0.57	OR			
1447676154	rs776746	cyclophosphamide	Efficacy,Toxicity,Metabolism/PK	no	Genotype CC is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotypes CT + TT.	C		= 0.15	OR			
1450936718	rs671	acetaldehyde	Metabolism/PK	yes	Genotype AG is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotype GG.	A		< 0.001				
1450936723	rs4643	acetaldehyde	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotypes AA + AC.	C		> 0.0330				
1449003375	rs2838958	methotrexate	Metabolism/PK	no	Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.			= 0.259	OR			
1449003387	rs1128503	methotrexate	Metabolism/PK	no	Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.			= 0.149	OR			
1450936730	rs1229984	acetaldehyde	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotypes CC + TT.	C		> 0.0340				
1449003393	rs1045642	methotrexate	Metabolism/PK	no	Genotypes AA + AG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.			= 0.340	OR			
1444694209	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	C			OR			
1447676115	rs2279343	cyclophosphamide	Efficacy,Toxicity,Metabolism/PK	no	Genotype AA is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotypes AG + GG.	A		= 0.25	OR			
1449003399	rs2231137	methotrexate	Metabolism/PK	no	Genotypes CC + CT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.			= 0.688	OR			
1450936684	rs1229976	ethanol	Metabolism/PK	no	Genotype CT is not associated with concentrations of ethanol in healthy individuals as compared to genotype TT.	C		> 0.0842				
1450936689	rs4643	ethanol	Metabolism/PK	yes	Genotype CC is associated with decreased concentrations of ethanol in healthy individuals as compared to genotypes AA + AC.	C		< 0.0369				
1450936696	rs1229984	ethanol	Metabolism/PK	no	Genotypes CC + CT are not associated with concentrations of ethanol in healthy individuals as compared to genotype TT.	C		> 0.0837				
827892661	rs67376798	fluorouracil	Toxicity,Metabolism/PK	yes	Genotype AT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	A		< 0.002	Unknown			
1450936711	rs1229976	acetaldehyde	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotype TT.	C		< 0.0270				
827892647	rs3918290	fluorouracil	Toxicity,Metabolism/PK	yes	Genotype CT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	T		< 0.001	Unknown			
1449003438	rs2306283	methotrexate	Metabolism/PK	no	Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.			= 0.294	OR			
1444694133	rs1057868	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype CC.	C		< 0.05	OR			
1447987342	rs56324128	ticagrelor	Metabolism/PK	yes	Genotype CC is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to genotype CT.	C		= 8.64E-12	OR			
1184512532	rs3732356	efavirenz	Metabolism/PK	no	Genotype GG is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype TT.			> 0.05	OR			
1184512536	rs12721616	efavirenz	Metabolism/PK	no	Genotype CC is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype TT.			> 0.05	OR			
1447676042	rs3957356	cyclophosphamide	Efficacy,Toxicity,Metabolism/PK	yes	Genotype CT is associated with decreased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype CC.	C	C	= 0.005	OR			
1448265859	rs3745274	efavirenz	Metabolism/PK	yes	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.			= 0.02	OR			
1444694176	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	C		= 0.03	OR			
1184512548	rs1464602	efavirenz	Metabolism/PK	no	Genotype GG is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype AA.			> 0.05	OR			
1449003493	rs776746	lumefantrine	Metabolism/PK	yes	Allele C is associated with increased concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele T.			= 0.04	OR			
1184512552	rs2502815	efavirenz	Metabolism/PK	no	Genotype AA is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype GG.			> 0.05	OR			
1444694062	rs11959113	fentanyl	Dosage,Efficacy	yes	Genotype AA is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG.			= 0.042	OR			
1449003506	rs3745274	lumefantrine	Metabolism/PK	no	Allele T is not associated with concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele G.			= 0.85	OR			
1183693340	rs2032582	tacrolimus	Metabolism/PK	no	Genotype CC is not associated with clearance of tacrolimus in people with Kidney Transplantation.	C		< 0.001	OR			
1447987282	rs4149056	ticagrelor	Metabolism/PK	yes	Allele T is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele C.	C		= 2.13E-12	OR			
1447987289	rs61361928	ticagrelor	Metabolism/PK	yes	Genotype TT is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to genotype CT.	C		= 7.7E-14	OR			
1183693336	rs1128503	tacrolimus	Metabolism/PK	no	Genotype AA is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	A		< 0.001	OR			
1183693332	rs1045642	tacrolimus	Metabolism/PK	no	Genotype AA is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	A		< 0.001	OR			
1449003524	rs10264272	lumefantrine	Metabolism/PK	yes	Allele T is associated with increased concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele C.			= 0.039	OR			
1444694094	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype CC.	C		< 0.002	OR			
1449003535	rs41303343	lumefantrine	Metabolism/PK	no	Allele A is associated with increased concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele del.			= 0.039	OR			
1449003545	rs2740574	lumefantrine	Metabolism/PK	yes	Allele C is associated with increased concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele T.			= 0.24	OR			
1447987275	rs113681054	ticagrelor	Metabolism/PK	yes	Allele C is associated with increased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele T.	C		= 3.63E-13	OR			
1184512470	rs3745274	efavirenz	Metabolism/PK	not stated	Genotype TT is associated with decreased clearance of efavirenz in children with HIV Infections as compared to genotype GG.				OR			
827695929	rs1057910	glimepiride	Dosage,Metabolism/PK	no	Genotype AC is associated with decreased dose of glimepiride in people with Diabetes Mellitus, Type 2 as compared to genotype AA.			= 0.07	Unknown			
1444694110	rs776746	tacrolimus	Metabolism/PK	no	Genotypes CT + TT is not associated with concentrations of tacrolimus in people with heart transplantation as compared to genotype CC.	C		> 0.05	OR			
827925294	rs2032582	digoxin	Metabolism/PK	yes	Genotype CC is associated with increased metabolism of digoxin as compared to genotype AA.			= 0.05	Unknown			
827811113	rs2740574	midazolam	Other,Metabolism/PK	no	Allele C is not associated with increased clearance of midazolam in people with Carcinoma, Renal Cell as compared to allele T.	T			Unknown			
1448265747	rs1045642	azithromycin	Metabolism/PK	yes	Genotype AA is associated with decreased concentrations of azithromycin in healthy individuals as compared to genotype GG.	A		= 0.013	OR			
1444694036	rs3845446	fentanyl	Dosage,Efficacy	no	Genotype TT is not associated with dose of fentanyl in people with Pain, Postoperative as compared to genotypes CC + CT.			> 0.05	OR			
1449003619	rs3842	lumefantrine	Metabolism/PK	no	Allele C is not associated with concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele T.			= 0.28	OR			
1444694050	rs2835859	fentanyl	Dosage,Efficacy	yes	Genotype TT is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes CC + CT.			= 0.003	OR			
1444694056	rs2952768	fentanyl	Dosage,Efficacy	yes	Genotype CC is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes CT + TT.			= 1.3E-6	OR			
1184512556	rs2307424	efavirenz	Metabolism/PK	no	Genotype GG is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype AG.			> 0.05	OR			
1444693964	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.				OR			
1184168575	rs145450955	lamivudine	Metabolism/PK	no	Genotype GG is not associated with clearance of lamivudine in healthy individuals as compared to genotype AG.	A		> 0.05	OR			
1444693992	rs9384179	fentanyl	Dosage,Efficacy	yes	Genotype AA is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG.			= 0.042	OR			
1444693880	rs4149056	rosuvastatin	Metabolism/PK	not stated	Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele C.	T	T		OR			
1444693893	rs2231142	rosuvastatin	Metabolism/PK	not stated	Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele G.	T	T		OR			
1448265615	CYP2D6 poor metabolizers and intermediate metabolizers	endoxifen	Metabolism/PK	yes	Genotypes *3 + *4 + *5 + *6 + *9 + *10 + *17 + *29 + *41 (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to genotypes *1 + *2 + *35 (assigned as normal metabolizers phenotype) .			< 0.05	OR			
1184987905	rs3745274	efavirenz	Dosage,Metabolism/PK	not stated	Genotype TT is associated with decreased dose of efavirenz in people with HIV Infections.				OR			
769171459	rs1045642	loperamide	Other,Metabolism/PK	no	Genotype AA is not associated with metabolism of loperamide as compared to genotype GG.	A			Unknown			
1444693914	rs1045642	tacrolimus	Metabolism/PK	no	Genotypes AA + AG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.				OR			
1449593570	rs13120400	voriconazole	Metabolism/PK	yes	Genotype CC is associated with increased trough concentration of voriconazole in children as compared to genotypes CT + TT.	C		= 0.029	OR			
1451100940	rs28375964	morphine	Metabolism/PK	no	Allele T is not associated with metabolism of morphine in children as compared to allele C.							
982036220	rs2032582	verapamil	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of verapamil in healthy individuals as compared to genotypes AA + AC.			< 0.03	Unknown			
1451100985	rs62296959	morphine	Metabolism/PK	no	Allele A is not associated with metabolism of morphine in children as compared to allele G.							
1451100980	rs10006452	morphine	Metabolism/PK	no	Allele C is not associated with metabolism of morphine in children as compared to allele T.							
1184988061	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.	G		< 0.0001	OR			
982036359	rs776746	amlodipine	Metabolism/PK	yes	Genotype CC is associated with increased metabolism of amlodipine in healthy individuals as compared to genotypes CT + TT.	C		= 0.029	Unknown			
982036359	rs776746	amlodipine	Metabolism/PK	yes	Genotype CC is associated with increased metabolism of amlodipine in healthy individuals as compared to genotypes CT + TT.	C		= 0.034	Unknown			
982036359	rs776746	amlodipine	Metabolism/PK	yes	Genotype CC is associated with increased metabolism of amlodipine in healthy individuals as compared to genotypes CT + TT.	C		= 0.037	Unknown			
1451101160	rs184199168	tramadol	Metabolism/PK	not stated	Allele A is associated with decreased metabolism of tramadol as compared to allele T.	A		= 8.675E-10				
1451101160	rs184199168	tramadol	Metabolism/PK	not stated	Allele A is associated with decreased metabolism of tramadol as compared to allele T.			> 0.05				
981954525	rs776746	ondansetron	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of ondansetron as compared to genotypes CT + TT.			< 0.001	Unknown			
981954525	rs776746	ondansetron	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of ondansetron as compared to genotypes CT + TT.	T		= 0.003	Unknown			
1448101515	rs1045642	clopidogrel	Metabolism/PK	no	Allele A is not associated with metabolism of clopidogrel in men with Coronary Artery Disease as compared to allele G.	A	G		OR			
769171171	rs1800562	epoetin alfa	Dosage,Metabolism/PK	yes	Allele A is associated with decreased dose of epoetin alfa in people with hemodialysis treatment as compared to allele G.			= 0.01	Unknown			
1451101220	rs9384825	tramadol	Metabolism/PK	not stated	Allele T is associated with decreased metabolism of tramadol as compared to allele C.	T		= 5.479E-9				
1451101220	rs9384825	tramadol	Metabolism/PK	not stated	Allele T is associated with decreased metabolism of tramadol as compared to allele C.			> 0.05				
1451101168	rs72732317	tramadol	Metabolism/PK	not stated	Allele T is associated with decreased metabolism of tramadol as compared to allele G.	T		= 1.987E-10				
1451101168	rs72732317	tramadol	Metabolism/PK	not stated	Allele T is associated with decreased metabolism of tramadol as compared to allele G.			> 0.05				
769171145	rs1799945	epoetin alfa	Dosage,Metabolism/PK	yes	Allele G is associated with decreased dose of epoetin alfa in people with hemodialysis treatment as compared to allele C.			= 0.01	Unknown			
1451101180	rs62435418	tramadol	Metabolism/PK	not stated	Allele A is associated with decreased metabolism of tramadol as compared to allele G.	A		= 1.288E-10				
1451101180	rs62435418	tramadol	Metabolism/PK	not stated	Allele A is associated with decreased metabolism of tramadol as compared to allele G.			> 0.05				
827925284	rs1045642	digoxin	Metabolism/PK	yes	Genotype GG is associated with increased metabolism of digoxin as compared to genotype AA.			= 0.05	Unknown			
827695410	rs4244285	nelfinavir	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of nelfinavir in people with HIV Infections as compared to genotype GG.	A		< 0.001	Unknown			
827695410	rs4244285	nelfinavir	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of nelfinavir in people with HIV Infections as compared to genotype GG.	A		< 0.001	Unknown			
827695410	rs4244285	nelfinavir	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of nelfinavir in people with HIV Infections as compared to genotype GG.	A		< 0.001	Unknown			
827695410	rs4244285	nelfinavir	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of nelfinavir in people with HIV Infections as compared to genotype GG.	A		= 0.05	Unknown			
1446905415	CYP2C19 poor metabolizers	imipramine	Metabolism/PK	yes	CYP2C19 poor metabolizers are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.			= 0.0027	OR			
769170859	rs1045642	digoxin	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of digoxin as compared to genotype GG.			= 0.006	Unknown			
1184988306	rs3745274	efavirenz	Metabolism/PK	yes	Allele T is associated with decreased metabolism of efavirenz in people with HIV Infections.			= 0.012	OR			
1448101363	rs887929	deferasirox	Metabolism/PK	no	Genotype TT is not associated with concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.			= 0.057	OR	5.211	0.955	28.435
1448101346	rs4646903	deferasirox	Metabolism/PK	no	Genotypes AA + AG are not associated with concentrations of deferasirox in people with beta-Thalassemia as compared to genotype GG.			= 0.326	OR	0.323	0.034	3.08
1184349348	rs3745274	efavirenz	Metabolism/PK	yes	Genotypes GT + TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.			< 0.01	OR			
1448101354	rs2606345	deferasirox	Metabolism/PK	no	Genotype AA is not associated with concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes AC + CC.			= 0.202	OR	0.498	0.171	1.453
1448101330	rs2470890	deferasirox	Metabolism/PK	no	Genotype TT is not associated with concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CC + CT.			= 0.493	OR	1.455	0.498	4.25
1448101324	rs1135840	deferasirox	Metabolism/PK	no	Genotypes CG + GG are not associated with concentrations of deferasirox in people with beta-Thalassemia as compared to genotype CC.			= 0.078	OR	2.667	0.896	7.939
1448101336	rs762551	deferasirox	Metabolism/PK	no	Genotypes AC + CC are not associated with concentrations of deferasirox in people with beta-Thalassemia as compared to genotype AA.			= 0.931	OR	0.818	0.1777	3.792
1448101311	rs2231142	deferasirox	Metabolism/PK	no	Genotype GG is not associated with concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes GT + TT.			= 0.931	OR	0.818	0.1777	3.792
1448428998	rs776746	everolimus	Metabolism/PK	yes	Genotypes CC + CT is associated with decreased clearance of everolimus in people with heart transplantation as compared to genotype TT.	C		= 0.031	OR			
1448101296	rs3806596	deferasirox	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.			= 0.002	OR	2.287	43.728	
1448101303	rs13120400	deferasirox	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.			= 0.027	OR	7.5	1.253	44.885
1451134163	CYP2D6 poor metabolizers and intermediate metabolizers	tramadol	Metabolism/PK	not stated	CYP2D6 poor metabolizers and intermediate metabolizers are associated with increased concentrations of tramadol in healthy individuals as compared to CYP2D6 normal metabolizers.							
1451134168	CYP2D6 poor metabolizers and intermediate metabolizers	o-desmethyltramadol	Metabolism/PK	not stated	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased concentrations of o-desmethyltramadol in healthy individuals as compared to CYP2D6 normal metabolizers.							
981954791	rs11134178	methylphenidate	Dosage,Efficacy	no	Allele T is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.			= 0.959	Unknown			
1448592786	rs2279343	propofol	Metabolism/PK	yes	Genotypes AA + AG is associated with decreased clearance of propofol as compared to genotype GG.			= 0.0014	OR			
981954785	rs9627183	methylphenidate	Dosage,Efficacy	no	Allele G is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.			= 0.959	Unknown			
1446905210	rs28399499	efavirenz	Metabolism/PK	yes	Allele C is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele T.	C	T	< 0.0001	OR			
769170937	rs1045642	tacrolimus	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype GG.			< 0.01	Unknown			
1446905219	rs4803419	efavirenz	Metabolism/PK	yes	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele C.	T	C	= 0.04	OR			
1446905219	rs4803419	efavirenz	Metabolism/PK	yes	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele C.	T	T	= 0.340	OR			
769170930	rs1045642	etoposide	Metabolism/PK	yes	Genotype GG is associated with increased metabolism of etoposide in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.			= 0.002	Unknown			
981479695	rs472660	olanzapine	Dosage,Efficacy,Toxicity,Metabolism/PK	yes	Genotype AA is associated with increased clearance of olanzapine in people with Schizophrenia as compared to genotypes AG + GG.	A		= 1.5E-5	Unknown			
981479707	rs472660	ziprasidone	Metabolism/PK	no	Allele A is not associated with increased clearance of ziprasidone in people with Schizophrenia as compared to allele G.	A		= 0.176	Unknown			
1184988338	CYP2B6*6	efavirenz	Metabolism/PK	yes	CYP2B6 *6/*6 is associated with decreased metabolism of efavirenz in people with HIV.			= 0.016	OR			
1446905193	rs3745274	efavirenz	Metabolism/PK	yes	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.	T		< 0.0001	OR			
981479718	rs2472300	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
769170882	rs1045642	tacrolimus	Metabolism/PK	yes	Genotype GG is associated with increased dose of tacrolimus in people with Transplantation as compared to genotypes AA + AG.			< 0.05	Unknown			
982036737	rs4148323	carvedilol	Metabolism/PK	yes	Allele A is associated with decreased metabolism of carvedilol in people with Angina Pectoris as compared to allele G.			< 0.05	Unknown			
1446905104	CYP2D6 poor metabolizers	imipramine	Metabolism/PK	no	CYP2D6 poor metabolizers are not associated with metabolism of imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.			> 0.05	OR			
1449266478	CYP1A2*1B	methadone	Metabolism/PK	no	CYP1A2 *1B is not associated with concentrations of methadone in people with Opioid-Related Disorders.			= 0.048	OR			
1446905111	CYP2D6 poor metabolizers	desipramine	Metabolism/PK	yes	CYP2D6 poor metabolizers are associated with decreased metabolism of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.			< 0.01	OR			
1448494366	rs1043657	exemestane	Metabolism/PK	no	Genotypes CT + TT are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to genotype CC.	T		= 0.94	OR			
1449266505	rs7439366	methadone	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to genotypes CC + TT.	T		= 0.015	OR			
981477680	rs2231142	acetaminophen	Metabolism/PK	no	Genotype GT is not associated with clearance of acetaminophen as compared to genotype GG.				Unknown			
1449266520	rs9282564	methadone	Metabolism/PK	yes	Allele C is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to allele T.			< 0.02	OR			
1449266512	rs1045642	methadone	Metabolism/PK	yes	Allele A is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to allele G.			< 0.03	OR			
1449266539	CYP3A5*3	methadone	Metabolism/PK	no	CYP3A5 *3 is not associated with concentrations of methadone in people with Opioid-Related Disorders.			> 0.1	OR			
1449266567	CYP2D6 poor metabolizer genotype	methadone	Metabolism/PK	no	CYP2D6 poor metabolizer genotype is not associated with concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2D6 intermediate metabolizer and normal metabolizer.			> 0.2	OR			
1450806689	CYP2C19 poor metabolizers	omeprazole	Metabolism/PK	yes	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.				OR			
1449266559	CYP2D6 ultrarapid metabolizer genotype	(S)-methadone	Metabolism/PK	yes	CYP2D6 ultrarapid metabolizer genotype is associated with decreased concentrations of s-methadone in people with Opioid-Related Disorders as compared to CYP2D6 intermediate metabolizer and normal metabolizer.			= 0.03	OR			
981477860	rs1057910	sulfamethoxazole	Metabolism/PK	no	Genotype AC is not associated with metabolism of sulfamethoxazole in people with Kidney Transplantation as compared to genotype AA.			= 0.7019	Unknown			
1446904957	CYP2D6 poor metabolizers	desipramine	Metabolism/PK	not stated	CYP2D6 poor metabolizers are associated with increased concentrations of desipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.				OR			
1450806823	CYP2C19 poor metabolizers	lansoprazole	Metabolism/PK	yes	CYP2C19 poor metabolizers are associated with decreased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 normal metabolizers.			< 0.001	OR			
1448100931	rs2244613	Dabigatran	Metabolism/PK	yes	Genotype GG is associated with decreased concentrations of Dabigatran in people with Atrial Fibrillation as compared to genotype TT.	G		= 0.040	OR			
1448100925	rs4148738	Dabigatran	Metabolism/PK	no	Genotypes CT + TT are associated with decreased concentrations of Dabigatran in people with Atrial Fibrillation as compared to genotype CC.	T		= 0.033	OR			
1449004578	rs1751034	tenofovir	Metabolism/PK	not stated	Genotype TT is associated with decreased clearance of tenofovir in people with HIV Infections as compared to genotypes CC + CT.	C			OR			
1449004602	rs1045642	trazodone	Metabolism/PK	yes	Genotype AA is associated with increased clearance of trazodone in healthy individuals as compared to genotypes AG + GG.	A		= 0.03	OR			
1447674863	rs2076222	fentanyl	Dosage,Efficacy	yes	Allele G is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to allele T.	G		= 0.0001	OR			
981478035	rs10994982	methotrexate	Metabolism/PK	yes	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.			= 0.021	Unknown			
1447986129	rs4149045	lopinavir	Metabolism/PK	no	Genotypes AG + GG is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype AA.	A			OR			
1450806946	CYP2C19 poor metabolizers	omeprazole	Metabolism/PK	not stated	CYP2C19 poor metabolizers are associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.				OR			
1447986136	rs4149057	lopinavir	Metabolism/PK	no	Genotypes CC + CT is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype TT.	C			OR			
1447986111	rs2306283	lopinavir	Metabolism/PK	no	Genotypes AA + AG is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype GG.	A			OR			
1447986122	rs4149044	lopinavir	Metabolism/PK	no	Genotypes AA + AT is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype TT.	A			OR			
1447986096	rs4149056	lopinavir	Metabolism/PK	no	Allele C is not associated with concentrations of lopinavir in people with HIV Infections.	C			OR			
1448100784	rs8192935	Dabigatran	Metabolism/PK	yes	Genotype GG is associated with increased concentrations of Dabigatran in people with Atrial Fibrillation as compared to genotypes AA + AG.	A		= 0.033	OR			
1447986105	rs7910642	lopinavir	Metabolism/PK	no	Genotypes AA + AG is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype GG.	A			OR			
1450806923	CYP2C19 poor metabolizers	omeprazole	Metabolism/PK	yes	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.			< 0.05	OR			
1447986089	rs35599367	lopinavir	Metabolism/PK	no	Allele A is not associated with concentrations of lopinavir in people with HIV Infections.	A			OR			
1450807008	CYP2C19 poor metabolizers	pantoprazole	Metabolism/PK	yes	Genotypes *2/*2 + *2/*3 + *3/*3 are associated with decreased metabolism of pantoprazole in healthy individuals as compared to genotypes *1/*1 + *1/*2 + *1/*3.			< 0.01	OR			
608178490	rs1045642	lansoprazole	Other,Metabolism/PK	yes	Allele G is associated with increased metabolism of lansoprazole as compared to genotype AA.			= 0.05	Unknown			
608178494	rs2740574	indinavir	Metabolism/PK	not stated	Genotype CC is associated with decreased metabolism of indinavir in people with HIV Infections as compared to genotypes CT + TT.			= 0.04	Unknown			
1448624896	rs2487032	clopidogrel	Metabolism/PK	yes	Allele A is associated with increased metabolism of clopidogrel as compared to genotype GG.			= 0.0441	OR			
1450823480	rs77760615	fluvastatin	Metabolism/PK	yes	Allele G is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele A.			= 8.5e-11				
1448624885	rs12456693	clopidogrel	Metabolism/PK	no	Genotype CT is associated with increased metabolism of clopidogrel as compared to genotype CC.			= 0.0521	OR			
1447674588	rs2032582	sirolimus	Metabolism/PK	yes	Allele A is associated with increased concentrations of sirolimus in people with hematopoietic stem cell transplantation.			= 0.01	OR			
1449004944	rs776746	4-hydroxycyclophosphamide	Metabolism/PK	yes	Genotypes CC + CT is associated with decreased concentrations of 4-hydroxycyclophosphamide in people with Lupus Nephritis as compared to genotype TT.			< 0.01	OR			
1184989031	BCHE deficiency	succinylcholine	Toxicity,Other	no	BCHE deficiency is associated with decreased metabolism of succinylcholine.				OR			
1185234929	rs35303484	efavirenz	Metabolism/PK	yes	Allele G is associated with concentrations of efavirenz in people with HIV Infections as compared to allele A.			< 0.05	OR			
1449004981	rs2248359	deferasirox	Metabolism/PK	not stated	Genotype TT is associated with metabolism of deferasirox in children with beta-Thalassemia as compared to genotypes CC + CT.				OR			
613978582	rs1057910	phenytoin	Dosage,Metabolism/PK	yes	Allele C is associated with increased dose of phenytoin in people with Epilepsy as compared to allele A.			= 0.0066	Unknown			
1449004990	rs7975232	deferasirox	Metabolism/PK	yes	Genotype AA is associated with metabolism of deferasirox in children with beta-Thalassemia as compared to genotypes AC + CC.			= 0.007	OR			
1185234940	rs3842	efavirenz	Metabolism/PK	yes	Allele C is associated with concentrations of efavirenz in people with HIV Infections as compared to allele T.			< 0.05	OR			
1449004998	rs2228570	deferasirox	Metabolism/PK	yes	Allele G is associated with metabolism of deferasirox in children with beta-Thalassemia as compared to allele A.			= 0.003	OR			
1449004998	rs2228570	deferasirox	Metabolism/PK	yes	Allele G is associated with metabolism of deferasirox in children with beta-Thalassemia as compared to allele A.			= 0.008	OR			
1449004998	rs2228570	deferasirox	Metabolism/PK	yes	Allele G is associated with metabolism of deferasirox in children with beta-Thalassemia as compared to allele A.			= 0.010	OR			
1448641151	rs1045642	tacrolimus	Metabolism/PK	no	Genotype GG is not associated with concentrations of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to genotypes AA + AG.	A		= 0.135	OR			
1448641151	rs1045642	tacrolimus	Metabolism/PK	no	Genotype GG is not associated with concentrations of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to genotypes AA + AG.	A		= 0.785	OR			
1185234889	rs1934969	losartan	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of losartan in healthy individuals as compared to genotype TT.	T		= 0.021	OR			
827811153	rs1045642	midazolam	Other,Metabolism/PK	no	Allele A is not associated with increased clearance of midazolam in people with Carcinoma, Renal Cell as compared to allele G.	A			Unknown			
1185234900	rs3745274	efavirenz	Metabolism/PK	yes	Genotypes GT + TT is associated with concentrations of efavirenz in people with HIV Infections as compared to genotype GG.			< 0.05	OR			
827811136	rs776746	midazolam	Other,Metabolism/PK	no	Allele T is not associated with increased clearance of midazolam in people with Carcinoma, Renal Cell as compared to allele C.	T			Unknown			
769169833	rs2279343	nicotine	Metabolism/PK	not stated	Allele G is associated with increased metabolism of nicotine in people with Tobacco Use Disorder as compared to allele A.			= 0.01	Unknown			
1184137318	CYP2D6 poor metabolizers	paroxetine	Metabolism/PK	yes	CYP2D6 poor metabolizers is associated with decreased clearance of paroxetine in healthy individuals as compared to CYP2D6 normal metabolizers.			= 0.0001	OR			
1184137318	CYP2D6 poor metabolizers	paroxetine	Metabolism/PK	yes	CYP2D6 poor metabolizers is associated with decreased clearance of paroxetine in healthy individuals as compared to CYP2D6 normal metabolizers.			= 0.027	OR			
769169810	rs2032582	paclitaxel	Metabolism/PK	yes	Genotype CT is associated with increased metabolism of paclitaxel in people with Ovarian Neoplasms.				Unknown			
1184137305	CYP2D6 poor metabolizers	paroxetine	Metabolism/PK	not stated	CYP2D6 poor metabolizers is associated with decreased clearance of paroxetine in people with Depressive Disorder, Major.			= 0.002	OR			
1184137305	CYP2D6 poor metabolizers	paroxetine	Metabolism/PK	not stated	CYP2D6 poor metabolizers is associated with decreased clearance of paroxetine in people with Depressive Disorder, Major.			= 0.008	OR			
1184137305	CYP2D6 poor metabolizers	paroxetine	Metabolism/PK	not stated	CYP2D6 poor metabolizers is associated with decreased clearance of paroxetine in people with Depressive Disorder, Major.			= 0.02	OR			
1184137305	CYP2D6 poor metabolizers	paroxetine	Metabolism/PK	not stated	CYP2D6 poor metabolizers is associated with decreased clearance of paroxetine in people with Depressive Disorder, Major.			= 0.08	OR			
769235406	rs762551	leflunomide	Other,Metabolism/PK	no	Allele A is not associated with metabolism of leflunomide in people with Arthritis as compared to genotype CC.				Unknown			
769235409	rs12720461	leflunomide	Other,Metabolism/PK	no	Allele T is not associated with metabolism of leflunomide in people with Arthritis as compared to genotype CC.				Unknown			
1449005177	rs10950022	warfarin	Dosage,Metabolism/PK	no	Genotypes CC + CT is associated with decreased dose of warfarin as compared to genotype TT.			= 0.059	OR			
1184137368	rs8027174	darunavir	Metabolism/PK	not stated	Genotypes GT + TT is associated with decreased clearance of darunavir in people with HIV Infections as compared to genotypes GG + TT.				OR			
1447674287	rs1045642	tacrolimus	Metabolism/PK	no	Genotypes AG + GG is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype AA.	A			OR			
1450954880	rs1801159	fluorouracil	Metabolism/PK	yes	Genotypes CC + CT is associated with increased concentrations of fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.			= 0.01	OR			
1450954880	rs1801159	fluorouracil	Metabolism/PK	yes	Genotypes CC + CT is associated with increased concentrations of fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.			= 0.046	OR			
1449005259	rs2231142	risperidone	Metabolism/PK	yes	Genotypes GT + TT is associated with decreased dose-adjusted trough concentrations of risperidone in children as compared to genotype GG.			= 0.007	OR			
1449169100	rs7439366	valproic acid	Metabolism/PK	yes	Genotype TT is associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.02	OR			
1449169100	rs7439366	valproic acid	Metabolism/PK	yes	Genotype TT is associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.02	OR			
1449169100	rs7439366	valproic acid	Metabolism/PK	yes	Genotype TT is associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.49	OR			
1449169100	rs7439366	valproic acid	Metabolism/PK	yes	Genotype TT is associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.65	OR			
1449169116	rs7439366	valproic acid	Metabolism/PK	no	Genotype CT is not associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.09	OR			
1449169116	rs7439366	valproic acid	Metabolism/PK	no	Genotype CT is not associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.13	OR			
1449169116	rs7439366	valproic acid	Metabolism/PK	no	Genotype CT is not associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.24	OR			
1449169116	rs7439366	valproic acid	Metabolism/PK	no	Genotype CT is not associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.28	OR			
1449169116	rs7439366	valproic acid	Metabolism/PK	no	Genotype CT is not associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.40	OR			
1449169125	rs7668258	valproic acid	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.002	OR			
1449169125	rs7668258	valproic acid	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.09	OR			
1449169125	rs7668258	valproic acid	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.35	OR			
1451249860	rs4149056	simvastatin acid	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotypes CT + TT.			< 0.001				
1450807565	rs1799930	isoniazid	Metabolism/PK	yes	Genotype AA is associated with increased exposure to isoniazid in people with HIV Infections and Tuberculosis as compared to genotypes AG + GG.			= 0.009	OR			
1449169135	rs7668258	valproic acid	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.004	OR			
1449169135	rs7668258	valproic acid	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.01	OR			
1449169135	rs7668258	valproic acid	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CC.			= 0.10	OR			
1449169145	rs12233719	valproic acid	Metabolism/PK	yes	Genotype GG is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype TT.			= 0.0006	OR			
1449169145	rs12233719	valproic acid	Metabolism/PK	yes	Genotype GG is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype TT.			= 0.01	OR			
1449169145	rs12233719	valproic acid	Metabolism/PK	yes	Genotype GG is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype TT.			= 0.58	OR			
769218940	rs762551	paroxetine	Metabolism/PK	yes	Allele A is associated with increased dose of paroxetine in people with Depressive Disorder, Major as compared to allele C.	C		= 0.0028	Unknown			
1449169153	rs12233719	valproic acid	Metabolism/PK	no	Genotype GG is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype GT.			< 0.00001	OR			
1449169153	rs12233719	valproic acid	Metabolism/PK	no	Genotype GG is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype GT.			< 0.00001	OR			
1449169153	rs12233719	valproic acid	Metabolism/PK	no	Genotype GG is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype GT.			= 0.15	OR			
1450807585	rs4149032	isoniazid	Metabolism/PK	yes	Genotype CC is associated with decreased exposure to isoniazid in people with HIV Infections and Tuberculosis as compared to genotypes CT + TT.			= 0.015	OR			
1447678220	rs3812718	carbamazepine	Metabolism/PK	yes	Genotype TT is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	C	T	= 0.002	OR			
1447678220	rs3812718	carbamazepine	Metabolism/PK	yes	Genotype TT is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	C	T	= 0.021	OR			
1449165120	rs12208357	metformin	Metabolism/PK	yes	Allele T is associated with increased exposure to metformin in healthy individuals as compared to allele C.	T	C	= 0.038	OR			
1449165132	rs1867351	metformin	Metabolism/PK	no	Allele C is not associated with exposure to metformin as compared to allele T.	T	C	> 0.15	OR			
1449165143	rs72552763	metformin	Metabolism/PK	no	Allele del is not associated with exposure to metformin as compared to allele GAT.	del	GAT	> 0.15	OR			
1449165153	rs316019	metformin	Metabolism/PK	no	Allele C is not associated with exposure to metformin as compared to allele A.	A	C	> 0.15	OR			
1449165148	rs34059508	metformin	Metabolism/PK	no	Allele A is not associated with exposure to metformin as compared to allele G.	A	G	> 0.15	OR			
1451114894	rs4149056	ritonavir	Metabolism/PK	no	Allele C is not associated with exposure to ritonavir in children with HIV Infections as compared to allele T.	C		= 0.3453				
1447678164	rs3812718	carbamazepine	Metabolism/PK	yes	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	C	T	= 0.028	OR			
1447678164	rs3812718	carbamazepine	Metabolism/PK	yes	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	C	T	= 0.033	OR			
1449165218	rs784888	metformin	Metabolism/PK	no	Allele C is not associated with exposure to metformin as compared to allele G.	C	G	> 0.15	OR			
1449165213	rs12943590	metformin	Metabolism/PK	no	Allele A is not associated with exposure to metformin as compared to allele G.	A	G	> 0.15	OR			
1449296299	rs1801133	folic acid	Metabolism/PK	not stated	Allele A is associated with decreased metabolism of folic acid.				OR			
1451114889	rs4149056	lopinavir	Metabolism/PK	yes	Genotype CT is associated with increased exposure to lopinavir in children with HIV Infections as compared to genotype TT.	C		= 0.042				
827812782	rs1799883	valproic acid	Dosage,Metabolism/PK	no	Genotype TT is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes CC + CT.	T			Unknown			
827812774	rs7439366	valproic acid	Dosage,Metabolism/PK	no	Genotype CC is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes CT + TT.	C			Unknown			
827812768	rs28365062	valproic acid	Dosage,Metabolism/PK	no	Genotype GG is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AG.	G			Unknown			
1449296305	rs1801131	folic acid	Metabolism/PK	not stated	Allele G is associated with decreased metabolism of folic acid.				OR			
1451114966	rs4149056	ritonavir	Metabolism/PK	no	Allele C is not associated with clearance of ritonavir in children with HIV Infections as compared to allele T.	C						
827812759	rs7668258	valproic acid	Dosage,Metabolism/PK	no	Genotype TT is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes CC + CT.	T			Unknown			
827812746	rs2741049	valproic acid	Dosage,Metabolism/PK	no	Genotype CC is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes CT + TT.	C			Unknown			
827812732	rs6731242	valproic acid	Dosage,Metabolism/PK	no	Genotype GG is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes GG + GT.	G			Unknown			
827812721	rs1019385	valproic acid	Dosage,Metabolism/PK	yes	Genotype AC is associated with decreased dose of valproic acid in people with Epilepsy as compared to genotype AA.	C		< 1.0E-4	Unknown			
827812715	rs1019385	valproic acid	Dosage,Metabolism/PK	yes	Genotype CC is associated with decreased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AC.	C		< 1.0E-4	Unknown			
769169634	rs1057910	losartan	Metabolism/PK	yes	Allele C is associated with decreased metabolism of losartan in people with no disease as compared to allele A.			< 0.05	Unknown			
827812695	rs1105879	valproic acid	Dosage,Metabolism/PK	yes	Genotype AC is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype AA.	C		< 1.0E-4	Unknown			
827812675	rs2070959	valproic acid	Dosage,Metabolism/PK	yes	Genotype AG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype AA.	G		< 1.0E-4	Unknown			
1444712547	rs2289669	metformin	Metabolism/PK	yes	Genotype AA is associated with decreased clearance of metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AG + GG.			< 0.01	OR			
1449296415	rs1045642	fentanyl	Dosage,Efficacy	yes	Genotype GG is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AA + AG.	G		< 0.01	OR			
827812655	rs6759892	valproic acid	Dosage,Metabolism/PK	yes	Genotype GT is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype TT.	G		< 1.0E-4	Unknown			
1446907885	rs3745274	cyclophosphamide	Metabolism/PK	no	Allele G is not associated with metabolism of cyclophosphamide in people with as compared to allele T.	G	T	= 0.606	OR			
827567361	rs9923231	warfarin	Dosage,Metabolism/PK	yes	Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.			= 1.0E-4	Unknown			
1446907901	rs1695	cyclophosphamide	Metabolism/PK	no	Allele G is not associated with metabolism of cyclophosphamide in people with as compared to allele A.	G	A	= 0.231	OR			
1444712484	CYP2D6 poor metabolizers	endoxifen	Metabolism/PK	no	CYP2D6 poor metabolizers are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.				OR			
1444712484	CYP2D6 poor metabolizers	endoxifen	Metabolism/PK	no	CYP2D6 poor metabolizers are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.				OR			
1450934909	rs10841753	estrone sulfate	Metabolism/PK	yes	Allele C is associated with decreased estrone sulfate in women with Breast Neoplasms as compared to allele T.			= 0.004				
1450984121	rs1128503	atazanavir	Metabolism/PK	yes	Genotypes AG + GG is associated with decreased clearance of atazanavir in healthy individuals as compared to genotype AA.			= 0.01	OR			
1444712354	CYP2D6 poor metabolizers	endoxifen	Metabolism/PK	yes	CYP2D6 poor metabolizers are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.			= 0.003	OR			
1448821487	rs2231142	tenofovir	Metabolism/PK	yes	Genotypes GT + TT are associated with increased concentrations of tenofovir in women with HIV Infections as compared to genotype GG.	T		= 1.7E-5	OR			
1450984205	rs1045642	atazanavir	Metabolism/PK	yes	Genotypes AG + GG is associated with decreased clearance of atazanavir in healthy individuals as compared to genotype AA.			= 0.01	OR			
1451115303	rs4149056	lopinavir	Metabolism/PK	yes	Allele C is associated with increased trough concentration of lopinavir in people with HIV Infections as compared to allele T.	C		= 0.01				
1446907707	rs7254579	cyclophosphamide	Metabolism/PK	yes	Allele C is associated with metabolism of cyclophosphamide in people with Lupus erythematosus as compared to allele T.	C	T	< 0.001	OR			
1449001754	rs3745274	nevirapine	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of nevirapine in people with HIV Infections as compared to genotypes GG + GT.			< 0.00005	OR			
1449001754	rs3745274	nevirapine	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of nevirapine in people with HIV Infections as compared to genotypes GG + GT.			= 0.0004	OR			
1446907717	rs13059232	cyclophosphamide	Metabolism/PK	no	Allele C is not associated with metabolism of cyclophosphamide in people with as compared to allele T.	C	T	= 0.028	OR			
981755649	rs9409929	vitamin d and analogues	Metabolism/PK	no	Allele A is associated with increased metabolism of vitamin d and analogues in people with Adenoma as compared to allele G.			= 0.222	Unknown			
1450984200	rs2032582	atazanavir	Metabolism/PK	yes	Genotypes AC + CC is associated with decreased clearance of atazanavir in healthy individuals as compared to genotype AA.			= 0.01	OR			
827566630	rs2276332	ethanol	Toxicity,Metabolism/PK	yes	Allele C is associated with metabolism of ethanol.	A	C	= 0.048	Unknown			
827566623	rs1229976	ethanol	Toxicity,Metabolism/PK	yes	Allele C is associated with metabolism of ethanol.	T	C	= 0.033	Unknown			
1448821568	rs3745274	efavirenz	Metabolism/PK	yes	Genotypes GT + TT is associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.			= 0.0009	OR			
1449165643	rs237025	tacrolimus	Metabolism/PK	yes	Genotype AA is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AG + GG.	G			OR			
1449165643	rs237025	tacrolimus	Metabolism/PK	yes	Genotype AA is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AG + GG.	G			OR			
827566611	rs1154461	ethanol	Toxicity,Metabolism/PK	yes	Allele C is associated with metabolism of ethanol.	G	C	= 3.0E-4	Unknown			
1446907684	rs4803419	cyclophosphamide	Metabolism/PK	no	Allele T is not associated with metabolism of cyclophosphamide in people with as compared to allele C.	C	T	= 0.017	OR			
1444843284	rs2231142	sulfasalazine	Metabolism/PK	not stated	Genotype TT is associated with decreased clearance of sulfasalazine in healthy individuals as compared to genotypes GG + GT.	G	T		OR			
1446907636	rs4802101	cyclophosphamide	Metabolism/PK	yes	Allele C is associated with decreased metabolism of cyclophosphamide in people with Lupus erythematosus as compared to allele T.	C	T	< 0.001	OR			
1444843306	rs72552713	sulfasalazine	Metabolism/PK	not stated	Genotype AG is associated with decreased metabolism of sulfasalazine in healthy individuals.				OR			
1449165670	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	T			OR			
1449165670	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	T			OR			
1449165670	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	T			OR			
1449165670	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	T			OR			
1449165678	CYP3A4*22	cyclosporine	Metabolism/PK	not stated	CYP3A4 *22 is not associated with concentrations of cyclosporine in children with Kidney Transplantation.				OR			
1449165693	rs1057868	cyclosporine	Metabolism/PK	yes	Allele T is associated with increased concentrations of cyclosporine in children with Kidney Transplantation as compared to allele C.			= 0.01	OR			
1446907621	rs4244285	cyclophosphamide	Metabolism/PK	yes	Allele A is associated with decreased metabolism of cyclophosphamide in people with Lupus erythematosus as compared to allele G.	A	G	< 0.001	OR			
1446907580	rs4149056	simvastatin acid	Metabolism/PK	yes	Allele C is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.			= 0.001	OR			
1450984320	rs1128503	atazanavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of atazanavir in healthy individuals as compared to genotypes AG + GG.			< 0.007	OR			
1450984320	rs1128503	atazanavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of atazanavir in healthy individuals as compared to genotypes AG + GG.			< 0.02	OR			
1445400123	rs2297595	fluorouracil	Metabolism/PK	yes	Genotypes CC + CT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype TT.	C		< 0.03	OR			
1445400112	rs2032582	phenytoin	Metabolism/PK	no	Allele A is not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy as compared to allele C.	T		= 0.54	OR			
1445400136	rs1801265	fluorouracil	Metabolism/PK	yes	Genotype GG is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotypes AA + AG.	G		= 0.046	OR			
769169111	rs2231142	imatinib	Other,Metabolism/PK	yes	Genotype GT is associated with decreased metabolism of imatinib in people with Neoplasms as compared to genotype GG.			< 0.05	Unknown			
1450984482	rs1045642	atazanavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of atazanavir in healthy individuals as compared to genotypes AG + GG.			< 0.007	OR			
1450984482	rs1045642	atazanavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of atazanavir in healthy individuals as compared to genotypes AG + GG.			< 0.02	OR			
1445400130	rs3918290	fluorouracil	Metabolism/PK	yes	Genotype CT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype CC.	T		< 0.0001	OR			
1449165830	rs1128503	tacrolimus	Metabolism/PK	no	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	A		> 0.05	OR			
1448496718	rs1056827	exemestane	Metabolism/PK	no	Genotypes AA + AC are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to genotype CC.	A		= 0.91	OR			
1449165839	rs2032582	tacrolimus	Metabolism/PK	no	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele C.	T		> 0.05	OR			
769250961	rs1045642	doxorubicin	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype GG.	A		= 0.03	Unknown			
1449001996	rs28898617	valproic acid	Metabolism/PK	yes	Allele G is associated with increased concentrations of valproic acid in children with Epilepsy as compared to allele A.			= 0.0089	OR			
1449165851	rs3842689	tacrolimus	Metabolism/PK	no	Allele GAGAAG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele del.	GAGAAG		> 0.05	OR			
1445400142	rs1801160	fluorouracil	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype CC.	T		= 0.029	OR			
1448821786	rs1045642	efavirenz	Metabolism/PK	no	Genotypes AA + AG are not associated with concentrations of efavirenz in children with HIV Infections as compared to genotype GG.			= 0.0827	OR			
1449165845	rs1045642	tacrolimus	Metabolism/PK	no	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	A		> 0.05	OR			
769250973	rs2032582	doxorubicin	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype CC.	A		= 0.03	Unknown			
1448821794	rs4149056	efavirenz	Metabolism/PK	no	Genotypes CC + CT are not associated with concentrations of efavirenz in children with HIV Infections as compared to genotype TT.			= 0.639	OR			
1450984448	rs2032582	atazanavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of atazanavir in healthy individuals as compared to genotypes AC + CC.			< 0.007	OR			
1450984448	rs2032582	atazanavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of atazanavir in healthy individuals as compared to genotypes AC + CC.			< 0.02	OR			
1448821800	rs3745274	lopinavir	Metabolism/PK	no	Genotypes GT + TT are not associated with concentrations of lopinavir in children with HIV Infections as compared to genotype GG.			= 0.1415	OR			
1448821806	rs1045642	lopinavir	Metabolism/PK	no	Genotypes AA + AG are not associated with concentrations of lopinavir in children with HIV Infections as compared to genotype GG.			= 0.1966	OR			
1184511084	rs7643645	donepezil	Metabolism/PK	no	Genotype AA is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype GG.			> 0.01	OR			
1451131980	rs3745274	efavirenz	Metabolism/PK	not stated	Genotype TT is associated with decreased metabolism of efavirenz in women with HIV Infections as compared to genotype GG.							
1184511092	rs2032582	donepezil	Metabolism/PK	no	Genotype CC is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype AA.			> 0.01	OR			
827812640	rs1105879	valproic acid	Dosage,Metabolism/PK	yes	Genotype CC is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AC.		C	< 1.0E-4	Unknown			
1448821812	rs4149056	lopinavir	Metabolism/PK	no	Genotypes CC + CT are not associated with concentrations of lopinavir in children with HIV Infections as compared to genotype TT.			= 0.0918	OR			
1448821818	rs3745274	ritonavir	Metabolism/PK	no	Genotypes GT + TT are not associated with concentrations of ritonavir in children with HIV Infections as compared to genotype GG.			= 0.1807	OR			
1184511096	rs1128503	donepezil	Metabolism/PK	no	Genotype AA is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype GG.			> 0.01	OR			
1448821824	rs1045642	ritonavir	Metabolism/PK	no	Genotypes AA + AG are not associated with concentrations of ritonavir in children with HIV Infections as compared to genotype GG.			= 0.512	OR			
827812626	rs2070959	valproic acid	Dosage,Metabolism/PK	yes	Genotype GG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AG.	G		< 1.0E-4	Unknown			
1448821830	rs4149056	ritonavir	Metabolism/PK	no	Genotypes CC + CT are not associated with concentrations of ritonavir in children with HIV Infections as compared to genotype TT.			= 0.3951	OR			
827812612	rs6759892	valproic acid	Dosage,Metabolism/PK	yes	Genotype GG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes GT + TT.	G		= 1.0E-4	Unknown			
1449182301	rs1051660	morphine	Dosage,Efficacy	yes	Allele A is associated with decreased dose of morphine in people with Pain as compared to allele C.	A		= 0.0278	OR	0.34	0.12	0.98
1449182322	rs1799971	morphine	Dosage,Efficacy	no	Allele G is not associated with dose of morphine in people with Pain as compared to allele A.	G		= 0.1490	OR	1.92	0.79	4.66
1449182316	rs17174629	morphine	Dosage,Efficacy	no	Allele G is not associated with dose of morphine in people with Pain as compared to allele A.	G		= 0.0984	OR	0.19	0.02	1.8
1449182334	rs1799972	morphine	Dosage,Efficacy	no	Allele T is not associated with dose of morphine in people with Pain as compared to allele C.	T		= 0.3441	OR	0.44	0.08	2.55
1184511048	rs2740574	donepezil	Metabolism/PK	no	Genotype TT is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype CC.			> 0.01	OR			
1184511052	rs4646437	donepezil	Metabolism/PK	no	Genotype GG is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype AA.			> 0.01	OR			
1184511056	rs35599367	donepezil	Metabolism/PK	no	Genotype GG is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype AA.			> 0.01	OR			
1449182349	rs4680	morphine	Dosage,Efficacy	no	Allele G is not associated with dose of morphine in people with Pain as compared to allele A.	A		= 0.2928	OR	0.76	0.45	1.27
1184511060	rs776746	donepezil	Metabolism/PK	no	Genotype TT is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype CC.			> 0.01	OR			
1184511072	rs1057868	donepezil	Metabolism/PK	no	Genotype TT is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype CC.			> 0.01	OR			
1184511076	rs1523130	donepezil	Metabolism/PK	no	Genotype CC is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype TT.			> 0.01	OR			
1184511080	rs2472677	donepezil	Metabolism/PK	no	Genotype TT is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype CC.			> 0.01	OR			
1449002165	rs4244285	clopidogrel thiol metabolite H4	Metabolism/PK	yes	Allele A is associated with exposure to clopidogrel thiol metabolite H4 as compared to allele G.	A	G	= 0.004	OR			
1449002191	rs4244285	clopidogrel	Metabolism/PK	no	Allele A is not associated with exposure to clopidogrel as compared to allele G.	A	G	> 0.05	OR			
981477559	rs7311358	mycophenolate mofetil	Metabolism/PK	yes	Allele A is associated with decreased clearance of mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.				Unknown			
981477567	rs7311358	mycophenolate mofetil	Metabolism/PK	no	Allele A is not associated with clearance of mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.				Unknown			
827812467	rs776746	tacrolimus	Other,Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	C		< 0.001	Unknown			
981477575	rs4149117	mycophenolate mofetil	Metabolism/PK	no	Allele G is not associated with clearance of mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.				Unknown			
827566695	rs283416	ethanol	Toxicity,Metabolism/PK	yes	Allele A is associated with metabolism of ethanol.	A	G	= 0.015	Unknown			
827566688	rs283411	ethanol	Toxicity,Metabolism/PK	yes	Allele A is associated with metabolism of ethanol.	A		= 0.015	Unknown			
1451164960	rs4149056	atorvastatin	Metabolism/PK	yes	Genotypes CC + CT are associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to genotype TT.			< 0.01				
827566681	rs1662060	ethanol	Toxicity,Metabolism/PK	yes	Allele C is associated with metabolism of ethanol.	C	T	= 0.003	Unknown			
1451164971	rs2231142	atorvastatin	Metabolism/PK	no	Genotypes GG + GT are not associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to genotype TT.			> 0.05				
827566660	rs17033	ethanol	Toxicity,Metabolism/PK	yes	Allele C is associated with metabolism of ethanol.	C	T	= 0.029	Unknown			
827566667	rs1229985	ethanol	Toxicity,Metabolism/PK	yes	Allele G is associated with metabolism of ethanol.	G	A	= 0.003	Unknown			
827566652	rs931635	ethanol	Toxicity,Metabolism/PK	yes	Allele A is associated with metabolism of ethanol.	A	G		Unknown	0.041		
1184167161	rs4244285	clopidogrel	Metabolism/PK	yes	Allele A (assigned as poor metabolizer phenotype) is associated with increased dose of clopidogrel in healthy individuals as compared to allele G (assigned as normal metabolizer phenotype) .	A		< 0.05	OR			
827566637	rs1229967	ethanol	Toxicity,Metabolism/PK	yes	Allele C is associated with metabolism of ethanol.	G	C	= 0.041	Unknown			
827813931	rs41303343	cyclosporine	Dosage,Metabolism/PK	no	Allele A is not associated with clearance of cyclosporine in people with Kidney Transplantation as compared to allele del.	A			Unknown			
827813909	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Allele C is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to allele T.	C		= 1.0E-4	Unknown			
1451115880	rs4149056	amprenavir	Metabolism/PK	yes	Allele C is associated with decreased trough concentration of amprenavir in people with HIV Infections as compared to allele T.	C		= 0.03				
827813894	rs41303343	tacrolimus	Dosage,Metabolism/PK	yes	Allele A is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to allele del.	A		= 1.0E-4	Unknown			
827813880	rs10264272	tacrolimus	Dosage,Metabolism/PK	yes	Allele T is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to allele C.	T		= 1.0E-4	Unknown			
827830252	rs1045642	cyclosporine	Dosage,Metabolism/PK	no	Allele G is not associated with increased dose of cyclosporine in people with Kidney Transplantation as compared to allele A.	G			Unknown			
1450935696	rs771237265	tolbutamide	Metabolism/PK	yes	Allele C is associated with decreased clearance of tolbutamide as compared to allele A.			< 0.01				
1450935701	rs761895497	tolbutamide	Metabolism/PK	yes	Allele C is associated with decreased clearance of tolbutamide as compared to allele T.			< 0.05				
827830235	rs4986910	tacrolimus	Dosage,Metabolism/PK	yes	Allele G is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to allele A.				Unknown			
827813847	rs2740574	tacrolimus	Dosage,Metabolism/PK	no	Allele C is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele T.				Unknown			
1450935713	rs144928727	mephenytoin	Metabolism/PK	no	Allele G is associated with decreased clearance of mephenytoin as compared to allele A.			> 0.05				
1450935720	rs145119820	mephenytoin	Metabolism/PK	yes	Allele A is associated with decreased clearance of mephenytoin as compared to allele G.			< 0.05				
827813837	rs2032582	tacrolimus	Dosage,Metabolism/PK	no	Allele T is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.				Unknown			
1444695245	rs1057868	clobazam	Metabolism/PK	not stated	Genotype TT is associated with increased clearance of clobazam in people with Epilepsy as compared to genotype CC.	T			OR			
827830210	rs2740574	cyclosporine	Dosage,Metabolism/PK	no	Genotypes CC + CT are not associated with increased dose of cyclosporine in people with Kidney Transplantation as compared to genotype TT.	T			Unknown			
827813827	rs2032582	tacrolimus	Dosage,Metabolism/PK	no	Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.				Unknown			
827617217	rs762551	caffeine	Other,Metabolism/PK	yes	Genotype AA is associated with increased metabolism of caffeine in people with Tobacco Use Disorder as compared to genotypes AC + CC.	A		= 0.04	Unknown			
827830204	rs2740574	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes CC + CT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype TT.	T		= 0.027	Unknown			
827617207	rs762551	caffeine	Other,Metabolism/PK	yes	Genotype AA is associated with increased metabolism of caffeine in people with heavy coffee consumption as compared to genotypes AC + CC.			= 0.016	Unknown			
827617207	rs762551	caffeine	Other,Metabolism/PK	yes	Genotype AA is associated with increased metabolism of caffeine in people with heavy coffee consumption as compared to genotypes AC + CC.	A		= 0.022	Unknown			
827813819	rs1045642	tacrolimus	Dosage,Metabolism/PK	no	Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele G.				Unknown			
1444842728	rs2740574	tacrolimus	Metabolism/PK	yes	Allele C is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.			= 0.001	OR			
1444842728	rs2740574	tacrolimus	Metabolism/PK	yes	Allele C is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.			= 0.011	OR			
827813802	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	C			Unknown			
827813794	rs1057868	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T		= 6.0E-4	Unknown			
1451116000	rs776746	lopinavir	Metabolism/PK	yes	Allele C is associated with increased trough concentration of lopinavir in people with HIV Infections as compared to allele T.	C		= 0.03				
1451230640	CYP2D6 poor metabolizers and intermediate metabolizers	n-desmethyltramadol	Metabolism/PK	yes	CYP2D6 poor metabolizers and intermediate metabolizers are associated with increased concentrations of n-desmethyltramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.			= 0.001				
1448496262	rs10012	exemestane	Metabolism/PK	no	Genotypes CC + CG are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to genotype GG.	C		= 0.59	OR			
1450935734	rs183701923	mephenytoin	Metabolism/PK	yes	Allele T is associated with decreased clearance of mephenytoin as compared to allele C.			< 0.05				
1451115963	rs776746	lopinavir	Metabolism/PK	no	Allele C is not associated with trough concentration of lopinavir in people with HIV Infections as compared to allele T.	C		= 0.45				
1451115963	rs776746	lopinavir	Metabolism/PK	no	Allele C is not associated with trough concentration of lopinavir in people with HIV Infections as compared to allele T.	C		= 0.9				
1450935739	rs140278421	mephenytoin	Metabolism/PK	yes	Allele A is associated with decreased clearance of mephenytoin as compared to allele G.			< 0.05				
827830139	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	C		< 1.0E-4	Unknown			
827830139	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	C		= 0.21	Unknown			
1450935745	rs1187513719	mephenytoin	Metabolism/PK	no	Allele G is associated with decreased clearance of mephenytoin as compared to allele A.			> 0.05				
827830124	rs776746	cyclosporine	Dosage,Metabolism/PK	no	Genotypes CT + TT are not associated with increased dose of cyclosporine in people with Kidney Transplantation as compared to genotype CC.	C			Unknown			
1451230740	CYP2D6 intermediate metabolizer	brexpiprazole	Metabolism/PK	not stated	CYP2D6 intermediate metabolizer is associated with decreased metabolism of brexpiprazole in people with Schizophrenia as compared to CYP2D6 normal metabolizer.							
1448266816	rs776746	carbamazepine	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.			= 0.006	OR			
1448266807	rs15524	carbamazepine	Metabolism/PK	yes	Genotype AA is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes AG + GG.			= 0.006	OR			
1449002543	rs1799971	opioids	Dosage,Efficacy	yes	Genotype AA is associated with decreased dose of opioids in people with Pain, Postoperative as compared to genotype GG.	A		= 0.001	Unknown	-0.27	-0.433	-0.108
1449166382	rs1045642	omeprazole	Metabolism/PK	yes	Genotypes AA + AG are associated with increased concentrations of omeprazole in infants with Gastroesophageal Reflux as compared to genotype GG.			< 0.01	OR			
1449002556	rs1045642	opioids	Dosage,Efficacy	no	Genotype GG is not associated with dose of opioids in people with Pain, Postoperative as compared to genotypes AA + AG.	G		= 0.239	Unknown	0.097	-0.064	0.258
1448266716	rs776746	carbamazepine	Metabolism/PK	no	Allele C is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele T.			= 0.356	OR			
1448266710	rs15524	carbamazepine	Metabolism/PK	no	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.			= 0.357	OR			
1448266704	rs1128503	carbamazepine	Metabolism/PK	no	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.			= 0.411	OR			
1448266698	rs10234411	carbamazepine	Metabolism/PK	no	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele T.			= 0.393	OR			
1448266687	rs2032582	carbamazepine	Metabolism/PK	no	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele C.			= 0.246	OR			
1448266671	rs1045642	carbamazepine	Metabolism/PK	no	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.			= 0.546	OR			
827551899	rs28399468	nicotine	Metabolism/PK	not stated	Allele A is associated with decreased metabolism of nicotine as compared to allele C.				Unknown			
769250129	rs776746	sirolimus	Dosage,Metabolism/PK	yes	Genotypes CT + TT are associated with increased dose of sirolimus in people with Kidney Transplantation as compared to genotype CC.			< 0.02	Unknown			
769250131	rs2740574	sirolimus	Dosage,Metabolism/PK	yes	Genotypes CC + CT are associated with increased dose of sirolimus in people with Kidney Transplantation as compared to genotype TT.	T		< 0.01	Unknown			
769250136	rs776746	sirolimus	Dosage,Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of sirolimus in people with Transplantation as compared to genotypes CT + TT.	C			Unknown			
1450985140	rs1128503	ritonavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AG + GG.			= 0.009	OR			
1450985140	rs1128503	ritonavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AG + GG.			< 0.03	OR			
1450985140	rs1128503	ritonavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AG + GG.			= 0.49	OR			
1450985140	rs1128503	ritonavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AG + GG.			= 0.54	OR			
1446906755	CYP2C19 poor metabolizers	clomipramine	Metabolism/PK	yes	CYP2C19 poor metabolizers are associated with decreased clearance of clomipramine in healthy individuals as compared to CYP2C19 normal metabolizers.			= 0.028	OR			
1450985160	rs2032582	ritonavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AC + CC.			= 0.009	OR			
1450985160	rs2032582	ritonavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AC + CC.			< 0.03	OR			
1450985160	rs2032582	ritonavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AC + CC.			= 0.49	OR			
1450985160	rs2032582	ritonavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AC + CC.			= 0.54	OR			
1444711216	CYP2D6 poor metabolizers	endoxifen	Metabolism/PK	yes	CYP2D6 poor metabolizers are associated with decreased concentrations of endoxifen in women Breast Neoplasms as compared to CYP2D6 normal metabolizers.			< 0.0001	OR			
1444711216	CYP2D6 poor metabolizers	endoxifen	Metabolism/PK	yes	CYP2D6 poor metabolizers are associated with decreased concentrations of endoxifen in women Breast Neoplasms as compared to CYP2D6 normal metabolizers.			< 0.0001	OR			
769250168	rs12782374	phenytoin	Dosage,Metabolism/PK	yes	Genotypes AA + AG are associated with decreased dose of phenytoin in people with Epilepsy as compared to genotype GG.			= 0.017	Unknown			
1184511673	rs3745274	efavirenz	Dosage,Metabolism/PK	no	Genotype TT is associated with decreased dose of efavirenz in men with HIV Infections.				OR			
769250171	rs71486745	phenytoin	Dosage,Metabolism/PK	yes	Genotypes GT/del + del/del are associated with decreased dose of phenytoin in people with Epilepsy as compared to genotype GTGT.			= 0.017	Unknown			
769250174	rs12782374	warfarin	Dosage,Metabolism/PK	no	Allele A is not associated with dose of warfarin in people with stable INRs in target range of 2-3 as compared to allele G.				Unknown			
769250177	rs71486745	warfarin	Dosage,Metabolism/PK	no	Allele del is not associated with dose of warfarin in people with stable INRs in target range of 2-3 as compared to allele GT.				Unknown			
1184511697	rs2279343	efavirenz	Dosage,Metabolism/PK	no	Genotype GG is associated with decreased dose of efavirenz in men with HIV Infections.				OR			
1450985200	rs1045642	ritonavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AG + GG.			= 0.009	OR			
1450985200	rs1045642	ritonavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AG + GG.			< 0.03	OR			
1450985200	rs1045642	ritonavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AG + GG.			= 0.49	OR			
1450985200	rs1045642	ritonavir	Metabolism/PK	yes	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AG + GG.			= 0.54	OR			
827813946	rs10264272	cyclosporine	Dosage,Metabolism/PK	no	Allele T is not associated with clearance of cyclosporine in people with Kidney Transplantation as compared to allele C.	T			Unknown			
1184135014	UGT1A1*60	axitinib	Metabolism/PK	no	UGT1A1 *60 is not associated with metabolism of axitinib in healthy individuals.			= 1	OR			
1451116369	rs4149032	lopinavir	Metabolism/PK	no	Allele T is not associated with trough concentration of lopinavir in people with HIV Infections as compared to allele C.	T		= 0.007				
1451116369	rs4149032	lopinavir	Metabolism/PK	no	Allele T is not associated with trough concentration of lopinavir in people with HIV Infections as compared to allele C.	T		= 0.414				
1448266539	rs1128503	risperidone	Metabolism/PK	no	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.			= 0.02	OR			
1448266512	rs9282564	risperidone	Metabolism/PK	no	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T.			= 0.02	OR			
1448266492	rs4253728	risperidone	Metabolism/PK	no	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.			= 0.02	OR			
827698684	rs776746	tacrolimus	Efficacy,Metabolism/PK	not stated	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T			Unknown			
1451116340	rs4149056	lopinavir	Metabolism/PK	yes	Allele C is associated with increased trough concentration of lopinavir in people with HIV Infections as compared to allele T.	C		= 0.001				
1451116340	rs4149056	lopinavir	Metabolism/PK	yes	Allele C is associated with increased trough concentration of lopinavir in people with HIV Infections as compared to allele T.	C		= 0.002				
827698683	CYP2A6*1A	tegafur	Metabolism/PK	not stated	CYP2A6 *1A/*1A is associated with increased metabolism of tegafur in people with Neoplasms.	*1A			Unknown			
981345098	CYP2C19*2	warfarin	Metabolism/PK	no	CYP2C19 *2 is not associated with decreased dose of warfarin in people with Cardiovascular Diseases.				Unknown			
1448266483	rs7643645	risperidone	Metabolism/PK	no	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.			= 0.02	OR			
769250028	rs1799853	phenytoin	Metabolism/PK	yes	Genotype CT is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype CC.	T		< 0.001	Unknown			
1444694702	rs1057910	warfarin	Metabolism/PK	no	Genotype AA is not associated with concentrations of warfarin in people with heart valve replacement as compared to genotype AC.	A	C	= 0.326	OR			
769250031	rs1057910	phenytoin	Other,Metabolism/PK	not stated	Genotype AC is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype AA.	C			Unknown			
1448266465	rs1057868	risperidone	Metabolism/PK	no	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T.			= 0.02	OR			
1447676621	CYP2D6 normal metabolizers	metoprolol	Metabolism/PK	yes	CYP2D6 normal metabolizers are associated with increased clearance of metoprolol in women with Pregnancy as compared to CYP2D6 intermediate metabolizers.			< 0.05	OR			
1448266456	rs776746	risperidone	Metabolism/PK	no	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T.			= 0.02	OR			
1448266447	rs4646437	risperidone	Metabolism/PK	no	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.			= 0.02	OR			
1444694728	rs9923231	warfarin	Metabolism/PK	yes	Genotype TT is associated with decreased concentrations of warfarin in people with as compared to genotype CT.	A	G	< 0.001	OR			
1448266438	rs2740574	risperidone	Metabolism/PK	no	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T.			= 0.02	OR			
982033269	rs1057910	warfarin	Dosage,Efficacy,Toxicity	not stated	Allele C is associated with decreased dose of warfarin as compared to allele A.				OR	6.21	2.48	15.6
1448266420	rs2276707	risperidone	Metabolism/PK	yes	Genotype CC is associated with decreased clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to genotypes CT + TT.			= 0.02	OR			
1448266403	rs1523130	risperidone	Metabolism/PK	yes	Genotype CC is associated with decreased clearance of risperidone in people with Bipolar Disorder, Depression or Substance-Related Disorders as compared to genotypes CT + TT.			= 0.01	OR			
1448266389	rs35599367	risperidone	Metabolism/PK	yes	Genotype AG is associated with decreased clearance of risperidone in people with as compared to genotype GG.			= 8.0E-3	OR			
1448266372	CYP2D6 poor metabolizer genotype	risperidone	Metabolism/PK	yes	CYP2D6 poor metabolizer genotype is associated with increased exposure to risperidone in people with Bipolar Disorder, Depression, Psychotic Disorders or Substance-Related Disorders as compared to CYP2D6 normal metabolizer and ultra-metabolizer genotypes.			< 0.0001	OR			
827698530	rs776746	tacrolimus	Efficacy,Metabolism/PK	yes	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T			Unknown			
827698530	rs776746	tacrolimus	Efficacy,Metabolism/PK	yes	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T			Unknown			
1184511955	rs2108622	warfarin	Metabolism/PK	yes	Genotypes CT + TT is associated with increased dose of warfarin in healthy individuals as compared to genotype CC.	C		= 0.04	OR			
1449576503	rs7604115	montelukast	Metabolism/PK	yes	Allele T is associated with decreased concentrations of montelukast in healthy individuals as compared to allele C.	T		= 1.83e-10	OR			
1450936406	rs1042028	acetaminophen	Metabolism/PK	no	Genotype TT is not associated with decreased metabolism of acetaminophen in healthy individuals as compared to genotypes CC + CT.			= 0.04	OR			
1450936406	rs1042028	acetaminophen	Metabolism/PK	no	Genotype TT is not associated with decreased metabolism of acetaminophen in healthy individuals as compared to genotypes CC + CT.			= 0.043	OR			
1450936406	rs1042028	acetaminophen	Metabolism/PK	no	Genotype TT is not associated with decreased metabolism of acetaminophen in healthy individuals as compared to genotypes CC + CT.			= 0.06	OR			
982033507	rs1045642	digoxin	Metabolism/PK	yes	Genotypes AA + AG are associated with decreased dose of digoxin in healthy individuals as compared to genotype GG.	G		< 0.05	Unknown			
1449576525	rs704212	montelukast	Metabolism/PK	yes	Allele T is associated with decreased concentrations of montelukast in healthy individuals as compared to allele C.	C		= 2.19e-4	OR			
1447676403	rs3957356	busulfan	Metabolism/PK	yes	Genotype CT is associated with decreased clearance of busulfan in people with hematopoietic stem cell transplantation as compared to genotype CC.			= 0.001	OR			
1451198580	rs2472297	caffeine	Metabolism/PK	yes	Allele T is associated with increased metabolism of caffeine as compared to allele C.	T		= 9.5e-22				
981345407	rs1042714	terbutaline	Metabolism/PK	yes	Genotype GG is associated with increased response to terbutaline in healthy individuals as compared to genotypes CC + CG.	G			Unknown			
1449003184	CYP2D6 poor metabolizer genotype	oxycodone	Metabolism/PK	yes	CYP2D6 poor metabolizer genotype is associated with increased exposure to oxycodone in healthy individuals as compared to CYP2D6 normal metabolizer genotype.			= 0.042	OR			
1184233704	rs1045642	efavirenz	Metabolism/PK	not stated	Genotype GG is not associated with clearance of efavirenz in children with HIV Infections.	A			OR			
1184233697	rs3745274	efavirenz	Metabolism/PK	not stated	Genotype TT is associated with decreased clearance of efavirenz in children with HIV Infections.	G			OR			
1449576644	CYP2D6 intermediate metabolizer and normal metabolizer	tamsulosin	Metabolism/PK	yes	CYP2D6 intermediate metabolizer and normal metabolizer are associated with decreased concentrations of tamsulosin in healthy individuals as compared to CYP2D6 poor metabolizers.			< 0.001	OR			
1449576644	CYP2D6 intermediate metabolizer and normal metabolizer	tamsulosin	Metabolism/PK	yes	CYP2D6 intermediate metabolizer and normal metabolizer are associated with decreased concentrations of tamsulosin in healthy individuals as compared to CYP2D6 poor metabolizers.			< 0.001	OR			
1449003217	CYP2D6 ultrarapid metabolizer genotype	noroxycodone	Metabolism/PK	yes	CYP2D6 ultrarapid metabolizer genotype is associated with decreased exposure to noroxycodone in healthy individuals as compared to CYP2D6 normal metabolizer genotype.			= 0.032	OR			
1446906191	CYP2C9*2	voriconazole	Metabolism/PK	not stated	CYP2C9 *2/*2 is not associated with concentrations of voriconazole.				OR			
827698783	rs28399433	tegafur	Metabolism/PK	no	Genotypes AC + CC are associated with decreased metabolism of tegafur as compared to genotype AA.	C		= 0.1241	Unknown			
1449560343	rs2231142	lamotrigine	Metabolism/PK	yes	Allele T is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to allele G.			< 0.006	OR			
1449560343	rs2231142	lamotrigine	Metabolism/PK	yes	Allele T is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to allele G.				Unknown			
1449560343	rs2231142	lamotrigine	Metabolism/PK	yes	Allele T is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to allele G.				OR			
827698754	rs8192725	tegafur	Metabolism/PK	no	Genotypes AG + GG are associated with increased metabolism of tegafur as compared to genotype AA.	G		= 0.1033	Unknown			
1449560363	rs6755571	lamotrigine	Metabolism/PK	no	Allele A is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele C.			> 0.0125	OR			
827698736	rs8192720	tegafur	Metabolism/PK	yes	Genotypes AA + AG are associated with increased metabolism of tegafur as compared to genotype GG.	A		= 0.0381	Unknown			
981794132	rs1060896	gemcitabine	Efficacy,Toxicity	no	Genotype AA is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AC + CC.	A		= 0.923	HR	1.02	0.71	1.47
1183689066	rs12248560	busulfan	Metabolism/PK	no	Genotype CC is not associated with clearance of busulfan in children with Transplantation as compared to genotype TT.			= 0.81	OR			
981794102	rs8187758	gemcitabine	Efficacy,Toxicity	no	Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + AC.	A		= 0.482	HR	1.14	0.8	1.62
981794096	rs2242048	gemcitabine	Efficacy,Toxicity	no	Genotype GG is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + AG.	G		= 0.465	HR	1.18	0.76	1.85
1449154915	CYP2D6 deficiency	o-desmethyltramadol	Metabolism/PK	not stated	CYP2D6 deficiency is associated with decreased exposure to o-desmethyl-tramadol in infants with Pain.				OR		1.58	1.94
1449171296	rs35599367	tacrolimus	Metabolism/PK	yes	Allele A is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	A			OR			
981794195	rs7867504	gemcitabine	Efficacy,Toxicity	no	Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	C		= 0.532	HR	1.16	0.73	1.84
1448532176	rs2032582	rivaroxaban	Metabolism/PK	no	Genotype CC is associated with decreased exposure to rivaroxaban in healthy individuals as compared to genotypes AA + AC.			= 0.15	OR			
981794170	rs7853758	gemcitabine	Efficacy,Toxicity	no	Genotype GG is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + AG.	A		= 0.455	HR	1.14	0.81	1.62
1448532160	rs1045642	rivaroxaban	Metabolism/PK	no	Genotypes AA + AG is associated with increased exposure to rivaroxaban in healthy individuals as compared to genotype GG.			= 0.15	OR			
1183689095	rs1050152	busulfan	Metabolism/PK	no	Genotype CC is not associated with clearance of busulfan in children with Transplantation as compared to genotype TT.			= 0.35	OR			
1183689075	rs7141505	busulfan	Metabolism/PK	no	Genotype AA is not associated with clearance of busulfan in children with Transplantation as compared to genotype CC.			= 0.35	OR			
1448532144	rs1045642	Dabigatran	Metabolism/PK	no	Genotypes AA + AG is associated with increased exposure to Dabigatran in healthy individuals as compared to genotype GG.			= 0.61	OR			
1449171398	rs1057868	tacrolimus	Metabolism/PK	no	Genotype CC is not associated with concentrations of tacrolimus in children with Kidney Transplantation as compared to genotypes CT + TT.	T			OR			
1449171411	rs1128503	tacrolimus	Metabolism/PK	no	Genotype AA is not associated with concentrations of tacrolimus in children with Kidney Transplantation as compared to genotypes AG + GG.	A			OR			
1449171405	rs1045642	tacrolimus	Metabolism/PK	no	Genotype AA is not associated with concentrations of tacrolimus in children with Kidney Transplantation as compared to genotypes AG + GG.	A			OR			
1449171419	rs2032582	tacrolimus	Metabolism/PK	no	Genotype AA is not associated with concentrations of tacrolimus in children with Kidney Transplantation.	T			OR			
981794226	rs324148	gemcitabine	Efficacy,Toxicity	no	Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	C		= 0.531	HR	1.12	0.79	1.6
1447680051	CYP2D6 poor metabolizers	atomoxetine	Metabolism/PK	not stated	CYP2D6 poor metabolizers are associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 normal metabolizers.				OR			
827847979	rs28399454	nevirapine	Toxicity,Metabolism/PK	no	Allele T is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele C.			= 0.48	Unknown			
1448531977	rs2032582	Dabigatran	Metabolism/PK	no	Genotype CC is associated with decreased exposure to Dabigatran in healthy individuals as compared to genotypes AA + AC.			= 0.61	OR			
1448531959	rs4149056	ticagrelor	Efficacy,Metabolism/PK	no	Genotype TT is not associated with response to ticagrelor in healthy individuals as compared to genotypes CC + CT.	C		= 0.714	OR			
1448531946	rs113681054	ticagrelor	Metabolism/PK	no	Allele C is not associated with increased exposure to ticagrelor in healthy individuals as compared to allele T.	C		= 0.093	OR			
1448531937	rs113681054	AR-C124910XX	Metabolism/PK	no	Genotype CT is associated with increased exposure to ar c124910xx in healthy individuals as compared to genotypes CC + TT.	C		= 0.093	OR			
981565062	rs11568820	midazolam	Metabolism/PK	yes	Genotypes CT + TT are associated with increased clearance of midazolam as compared to genotype CC.	T		= 0.04	Unknown			
1448531887	rs28365063	morphine	Metabolism/PK	no	Allele G is not associated with exposure to morphine in healthy individuals as compared to allele A.	A		= 0.51	OR			
1448531882	rs7438135	morphine	Metabolism/PK	no	Allele G is not associated with exposure to morphine in healthy individuals as compared to allele A.	A		= 0.32	OR			
1448531875	rs1045642	morphine	Metabolism/PK	no	Allele G is not associated with exposure to morphine in healthy individuals as compared to allele A.	A		= 0.15	OR			
1449171668	rs3740066	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T		< 0.05	OR			
1449171694	rs717620	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T		< 0.05	OR			
1449171720	rs3740066	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T		< 0.05	OR			
637880191	rs1138272	oxaliplatin	Toxicity,Metabolism/PK	no	Allele C is not associated with response to oxaliplatin in people with Gastrointestinal Neoplasms as compared to allele T.				Unknown			
1451105100	rs4149056	letermovir	Metabolism/PK	yes	Genotypes CC + CT are associated with increased exposure to letermovir as compared to genotype TT.	C		= 0.000595				
1451105113	rs4148323	letermovir	Metabolism/PK	yes	Genotypes AA + AG are associated with increased exposure to letermovir as compared to genotype GG.	A		= 0.0137				
1451154260	CYP2D6 poor metabolizer phenotype	ketobemidone	Metabolism/PK	no	CYP2D6 poor metabolizer phenotype is not associated with clearance of ketobemidone in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.							
1450826595	rs1045642	fentanyl	Metabolism/PK	no	Genotype AA is not associated with concentrations of fentanyl in children as compared to genotypes AG + GG.	A		= 0.958				
1184754574	rs2276706	repaglinide	Metabolism/PK	yes	Genotype GG is associated with increased metabolism of repaglinide in men as compared to genotype AA.	G	A	= 0.0009	OR			
1184754595	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	C	T	= 0.001	OR			
1184754595	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	T	C	= 0.004	OR			
1184754595	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	C	T	= 0.007	OR			
1451154245	CYP2C19 poor metabolizer phenotype	ketobemidone	Metabolism/PK	no	CYP2C19 poor metabolizer phenotype is not associated with clearance of ketobemidone in healthy individuals as compared to CYP2C19 normal metabolizer phenotype.							
769249016	rs28371686	phenytoin	Other,Metabolism/PK	yes	Allele G is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype CC.			= 0.001	Unknown			
1444714180	CYP2C19 intermediate metabolizers	voriconazole	Metabolism/PK	yes	Genotypes *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of voriconazole in people with Mycoses as compared to genotype *1/*1 (assigned as normal metabolizer phenotype) .			< 0.05	OR			
769249039	rs7900194	phenytoin	Other,Metabolism/PK	yes	Allele A is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype GG.			= 0.001	Unknown			
769249040	rs28371685	phenytoin	Other,Metabolism/PK	yes	Allele T is associated with increased metabolism of phenytoin in people with no disease as compared to genotype CC.			= 0.001	Unknown			
769249041	rs9332131	phenytoin	Other,Metabolism/PK	yes	Allele del is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype AA.			= 0.001	Unknown			
1448105661	rs20572	doxorubicin	Metabolism/PK	yes	Genotype CC is associated with decreased concentrations of doxorubicin in people with Breast Neoplasms as compared to genotype CT.	C	C	= 0.03	OR			
978614975	rs11212617	metformin	Efficacy,Metabolism/PK	no	Allele C is not associated with increased response to metformin as compared to allele A.			= 0.13	HR	1.17	0.96	1.42
1184754523	rs2276706	repaglinide	Metabolism/PK	yes	Genotype GG is associated with decreased metabolism of repaglinide in men as compared to genotype AA.	G	A	= 0.014	OR			
1184754523	rs2276706	repaglinide	Metabolism/PK	yes	Genotype GG is associated with decreased metabolism of repaglinide in men as compared to genotype AA.	G	A	= 0.026	OR			
1184754523	rs2276706	repaglinide	Metabolism/PK	yes	Genotype GG is associated with decreased metabolism of repaglinide in men as compared to genotype AA.	G	A	= 0.041	OR			
1184754529	rs3814058	repaglinide	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of repaglinide in men as compared to genotype TT.	C	T	= 0.014	OR			
1184754529	rs3814058	repaglinide	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of repaglinide in men as compared to genotype TT.	C	T	= 0.026	OR			
1184754529	rs3814058	repaglinide	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of repaglinide in men as compared to genotype TT.	C	T	= 0.041	OR			
1448105654	rs20572	doxorubicin	Metabolism/PK	yes	Genotype CC is associated with decreased exposure to doxorubicin in people with Breast Neoplasms as compared to genotype CT.	C	C	= 0.06	OR			
1444714094	CYP2C19 intermediate metabolizers	voriconazole	Metabolism/PK	not stated	Genotypes *1/*2 + *1/*3 + *2/*17 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of voriconazole as compared to genotype *1/*1 (assigned as normal metabolizers phenotype) .				OR			
981843937	rs3832043	SN-38	Metabolism/PK	yes	Genotype del/del is associated with decreased metabolism of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes T/del + TT.	T		= 0.001	Unknown			
981843937	rs3832043	SN-38	Metabolism/PK	yes	Genotype del/del is associated with decreased metabolism of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes T/del + TT.	T		= 0.046	Unknown			
1448613522	rs13120400	deferasirox	Metabolism/PK	yes	Genotypes CT + TT is associated with increased exposure to deferasirox in children with beta-Thalassemia as compared to genotype CC.			= 0.05	OR			
1448105620	rs9024	doxorubicin	Metabolism/PK	yes	Genotype GG is associated with decreased concentrations of doxorubicin in people with Breast Neoplasms as compared to genotype AG.	G	G	= 0.03	OR			
1448105610	rs9024	doxorubicin	Metabolism/PK	yes	Genotype GG is associated with increased clearance of doxorubicin in people with Breast Neoplasms as compared to genotype AG.	G	G	= 0.009	OR			
1448597114	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	C		< 0.001	OR			
1448613498	rs2231142	selumetinib	Metabolism/PK	no	Allele T is not associated with dose of selumetinib in healthy individuals as compared to allele G.	T	G	= 0.200	OR			
1448613498	rs2231142	selumetinib	Metabolism/PK	no	Allele T is not associated with dose of selumetinib in healthy individuals as compared to allele G.	T	G	= 0.305	OR			
1448613498	rs2231142	selumetinib	Metabolism/PK	no	Allele T is not associated with dose of selumetinib in healthy individuals as compared to allele G.	T	G	= 0.540	OR			
1448613498	rs2231142	selumetinib	Metabolism/PK	no	Allele T is not associated with dose of selumetinib in healthy individuals as compared to allele G.			= 0.546	OR		-0.063	0.118
981843914	rs4148323	SN-38	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	G		= 0.002	Unknown			
981843914	rs4148323	SN-38	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	G		= 0.002	Unknown			
1448597107	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	C		< 0.001	OR			
1448613490	rs12248560	selumetinib	Metabolism/PK	no	Allele T is not associated with dose of selumetinib in healthy individuals as compared to allele C.	T	A	= 0.557	OR			
1448613490	rs12248560	selumetinib	Metabolism/PK	no	Allele T is not associated with dose of selumetinib in healthy individuals as compared to allele C.	T	A	= 0.596	OR			
1448613490	rs12248560	selumetinib	Metabolism/PK	no	Allele T is not associated with dose of selumetinib in healthy individuals as compared to allele C.			= 0.718	OR		-0.162	0.235
1448613490	rs12248560	selumetinib	Metabolism/PK	no	Allele T is not associated with dose of selumetinib in healthy individuals as compared to allele C.	T	C	= 0.812	OR			
1448613482	rs4986893	selumetinib	Metabolism/PK	no	Allele G is not associated with dose of selumetinib in healthy individuals as compared to allele A.			= 0.419	OR		-0.174	0.418
1448613482	rs4986893	selumetinib	Metabolism/PK	no	Allele G is not associated with dose of selumetinib in healthy individuals as compared to allele A.	A	G	= 0.423	OR			
1448613482	rs4986893	selumetinib	Metabolism/PK	no	Allele G is not associated with dose of selumetinib in healthy individuals as compared to allele A.	A	G		OR			
1448613482	rs4986893	selumetinib	Metabolism/PK	no	Allele G is not associated with dose of selumetinib in healthy individuals as compared to allele A.	A	G		OR			
1184754606	rs1927907	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	T	C	< 0.001	OR			
1184754606	rs1927907	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	T	C	= 0.018	OR			
1448613474	rs4244285	selumetinib	Metabolism/PK	no	Allele G is not associated with dose of selumetinib in healthy individuals as compared to allele A.	A	G	= 0.256	OR			
1448613474	rs4244285	selumetinib	Metabolism/PK	no	Allele G is not associated with dose of selumetinib in healthy individuals as compared to allele A.	A	G	= 0.472	OR			
1448613474	rs4244285	selumetinib	Metabolism/PK	no	Allele G is not associated with dose of selumetinib in healthy individuals as compared to allele A.	A	G	= 0.630	OR			
1448613474	rs4244285	selumetinib	Metabolism/PK	no	Allele G is not associated with dose of selumetinib in healthy individuals as compared to allele A.			= 0.891	OR		-0.155	0.135
1449188355	rs1074287	cotinine	Metabolism/PK	yes	Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A.	G		= 0.002	OR			
1448613466	rs4148323	selumetinib	Metabolism/PK	no	Allele G is not associated with metabolism of selumetinib in healthy individuals as compared to allele A.	G	A	= 0.048	OR			
1448613466	rs4148323	selumetinib	Metabolism/PK	no	Allele G is not associated with metabolism of selumetinib in healthy individuals as compared to allele A.			= 0.363	OR		-0.07	0.192
1448613466	rs4148323	selumetinib	Metabolism/PK	no	Allele G is not associated with metabolism of selumetinib in healthy individuals as compared to allele A.	G	A		OR			
1448613466	rs4148323	selumetinib	Metabolism/PK	no	Allele G is not associated with metabolism of selumetinib in healthy individuals as compared to allele A.	G	A		OR			
1449188362	rs6912029	cotinine	Metabolism/PK	yes	Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele G.	T		= 0.01	OR			
1448613452	rs2273697	deferasirox	Metabolism/PK	yes	Genotype AG is associated with increased exposure to deferasirox in children with beta-Thalassemia as compared to genotype GG.			= 0.018	OR			
1448613452	rs2273697	deferasirox	Metabolism/PK	yes	Genotype AG is associated with increased exposure to deferasirox in children with beta-Thalassemia as compared to genotype GG.			= 0.038	OR			
1449188368	rs1799971	cotinine	Metabolism/PK	yes	Allele A is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele G.	A		= 0.029	OR			
1449188376	rs12209447	cotinine	Metabolism/PK	yes	Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.	T		= 0.009	OR			
1449270311	rs1002976	uric acid	Metabolism/PK	yes	Allele C is associated with increased concentrations of uric acid in people with Hypertension as compared to allele T.	A		= 2.3E-5	OR			
1449270311	rs1002976	uric acid	Metabolism/PK	yes	Allele C is associated with increased concentrations of uric acid in people with Hypertension as compared to allele T.	A		= 3.5E-4	OR			
1449188382	rs510769	cotinine	Metabolism/PK	yes	Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.	T		= 0.001	OR			
1449188394	rs553202	cotinine	Metabolism/PK	yes	Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.	T		= 0.02	OR			
1449188388	rs3798676	cotinine	Metabolism/PK	yes	Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.	T		= 0.007	OR			
1448613418	rs12248560	selumetinib	Metabolism/PK	no	Allele T is not associated with metabolism of selumetinib in healthy individuals as compared to allele C.	T	A	= 0.304	OR			
1448613418	rs12248560	selumetinib	Metabolism/PK	no	Allele T is not associated with metabolism of selumetinib in healthy individuals as compared to allele C.	T	C	= 0.410	OR			
1448613418	rs12248560	selumetinib	Metabolism/PK	no	Allele T is not associated with metabolism of selumetinib in healthy individuals as compared to allele C.	T	A	= 0.525	OR			
1448613418	rs12248560	selumetinib	Metabolism/PK	no	Allele T is not associated with metabolism of selumetinib in healthy individuals as compared to allele C.			= 0.956	OR		-0.136	0.144
1449188400	rs499796	cotinine	Metabolism/PK	no	Allele G is not associated with concentrations of cotinine in people with Heroin Dependence as compared to allele A.	G		= 0.101	OR			
1449270328	rs950569	uric acid	Metabolism/PK	yes	Allele T is associated with increased concentrations of uric acid in people with Hypertension as compared to allele G.	T		= 4.8E-5	OR			
1449270328	rs950569	uric acid	Metabolism/PK	yes	Allele T is associated with increased concentrations of uric acid in people with Hypertension as compared to allele G.	T		= 2.6E-3	OR			
1449188406	rs7748401	cotinine	Metabolism/PK	yes	Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele T.	G		= 0.006	OR			
1449270340	rs2477134	uric acid	Metabolism/PK	yes	Allele G is associated with increased concentrations of uric acid in people with Hypertension as compared to allele T.			= 0.016	OR			
1447990796	CYP2D6*17	debrisoquine	Metabolism/PK	not stated	CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine.				OR			
1448613398	rs4244285	selumetinib	Metabolism/PK	no	Allele G is not associated with metabolism of selumetinib in healthy individuals as compared to allele A.			= 0.101	OR			
1448613398	rs4244285	selumetinib	Metabolism/PK	no	Allele G is not associated with metabolism of selumetinib in healthy individuals as compared to allele A.			= 0.48	OR		-0.074	0.158
1448613398	rs4244285	selumetinib	Metabolism/PK	no	Allele G is not associated with metabolism of selumetinib in healthy individuals as compared to allele A.			= 0.753	OR			
1448613398	rs4244285	selumetinib	Metabolism/PK	no	Allele G is not associated with metabolism of selumetinib in healthy individuals as compared to allele A.			= 0.867	OR			
1449188412	rs495491	cotinine	Metabolism/PK	yes	Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A.	G		= 0.001	OR			
1449188424	rs589046	cotinine	Metabolism/PK	yes	Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.	T		= 0.001	OR			
1449188442	rs2075572	cotinine	Metabolism/PK	yes	Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.	G		= 0.03	OR			
1449188436	rs563649	cotinine	Metabolism/PK	yes	Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.	T		= 0.006	OR			
1184754859	rs776746	simvastatin	Metabolism/PK	not stated	Genotype TT is associated with increased clearance of simvastatin as compared to genotypes CC + CT.				OR			
1184754854	rs4149056	simvastatin acid	Metabolism/PK	not stated	Genotype CT is associated with decreased clearance of simvastatin acid as compared to genotype TT.				OR			
981483674	rs11045872	methotrexate	Efficacy,Toxicity,Metabolism/PK	no	Allele G is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.			= 2.42E-12				
981483674	rs11045872	methotrexate	Efficacy,Toxicity,Metabolism/PK	no	Allele G is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.			= 3.77E-7	Unknown			
981483686	rs11045879	methotrexate	Efficacy,Toxicity,Metabolism/PK	yes	Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.			= 3.13E-19				
981483686	rs11045879	methotrexate	Efficacy,Toxicity,Metabolism/PK	yes	Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	C		= 8.31E-10	Unknown			
1448285628	rs1045642	tacrolimus	Metabolism/PK	no	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	A		= 0.616	OR			
1448613303	rs1058930	imatinib	Metabolism/PK	no	Allele C is not associated with concentrations of imatinib in people with Neoplasms as compared to allele G.			= 0.452	OR			
1448613297	rs10509681	imatinib	Metabolism/PK	no	Allele C is not associated with concentrations of imatinib in people with Neoplasms as compared to allele T.			= 0.448	OR			
1448613291	rs11572080	imatinib	Metabolism/PK	no	Allele T is not associated with concentrations of imatinib in people with Neoplasms as compared to allele C.			= 0.448	OR			
827863717	rs2242480	warfarin	Other,Metabolism/PK	not stated	Genotype CT is associated with increased clearance of warfarin as compared to genotype CC.	T			Unknown			
1448613285	rs17110453	imatinib	Metabolism/PK	no	Allele C is not associated with concentrations of imatinib in people with Neoplasms as compared to allele A.			= 0.287	OR			
1451252940	CYP2D6 poor metabolizer phenotype	venlafaxine	Metabolism/PK	yes	CYP2D6 poor metabolizer phenotype is associated with decreased clearance of venlafaxine as compared to CYP2D6 normal metabolizer phenotype.			< 0.005				
1448613278	rs7909236	imatinib	Metabolism/PK	no	Allele T is not associated with concentrations of imatinib in people with Neoplasms as compared to allele G.			= 0.32	OR			
1451138275	rs797397	methadone	Metabolism/PK	yes	Genotype AA is associated with increased concentrations of methadone as compared to genotypes AG + GG.	G		= 0.0002				
827863702	rs3814637	warfarin	Other,Metabolism/PK	not stated	Allele T is associated with decreased clearance of warfarin as compared to allele C.	T			Unknown			
1448285592	rs1057868	tacrolimus	Metabolism/PK	no	Genotypes CT + TT are not associated with trough concentration of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T		> 0.05	OR			
1451138270	rs204047	methadone	Metabolism/PK	yes	Genotype GG is associated with increased concentrations of methadone as compared to genotypes GT + TT.	T		= 0.00002				
981844189	rs35599367	midazolam	Metabolism/PK	yes	Genotype AG is associated with decreased metabolism of midazolam in people with Neoplasms as compared to genotype GG.	A		< 0.001	Unknown			
1451138220	NAT2 slow acetylator	hydralazine	Metabolism/PK	yes	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.			< 0.001				
981483700	rs11045821	methotrexate	Efficacy,Toxicity,Metabolism/PK	yes	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.			= 5.59E-12				
981483700	rs11045821	methotrexate	Efficacy,Toxicity,Metabolism/PK	yes	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	A		= 3.33E-8	Unknown			
981483693	rs4149081	methotrexate	Efficacy,Toxicity,Metabolism/PK	yes	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.			= 9.74E-19				
981483693	rs4149081	methotrexate	Efficacy,Toxicity,Metabolism/PK	yes	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	A		< 1.58E-10	Unknown			
1184754864	rs12422149	simvastatin	Metabolism/PK	not stated	Genotype AA is associated with increased clearance of simvastatin as compared to genotypes AG + GG.				OR			
1448613226	rs4646437	tacrolimus	Metabolism/PK	yes	Genotype GG is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.	A		= 0.039	OR			
1448613220	rs2242480	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	C		< 0.001	OR			
1183690021	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with increased clearance of tacrolimus in healthy individuals as compared to genotype CC.			= 3.0E-4	OR			
1448613214	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	C		< 0.001	OR			
1184754871	rs4253728	simvastatin	Metabolism/PK	not stated	Genotypes AA + AG is associated with decreased clearance of simvastatin as compared to genotype GG.				OR			
1448613208	rs4646437	tacrolimus	Metabolism/PK	yes	Genotype GG is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.	G		= 0.01	OR			
1448613202	rs2242480	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	C		= 0.010	OR			
1447990618	rs2585428	telaprevir	Metabolism/PK	yes	Allele C is associated with decreased trough concentration of telaprevir in people with Hepatitis C as compared to allele T.	C		= 0.003	OR	-2567.0	-3933.0	-1202.0
1449188612	rs2231142	apixaban	Metabolism/PK	not stated	Genotypes GG + GT is associated with increased clearance of apixaban in people with Atrial Fibrillation as compared to genotype TT.	T	G		OR			
1449188622	rs2231142	methotrexate	Metabolism/PK	yes	Allele T is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele G.	T	G	= 0.037	OR	4.2	1.0	17.8
1448613188	rs4553808	tacrolimus	Metabolism/PK	yes	Genotypes AG + GG is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotype AA.	A		= 0.008	OR			
1449188634	rs7643038	methotrexate	Metabolism/PK	yes	Allele G is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele A.	A	G	= 0.02	OR	2.6	1.2	5.9
1448613179	rs181781	tacrolimus	Metabolism/PK	yes	Genotype AA is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	A		= 0.004	OR			
1449188641	rs3814055	methotrexate	Metabolism/PK	yes	Allele T is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele C.	T	C	= 0.03	OR	2.2	1.1	5.1
1449188647	rs9282564	methotrexate	Metabolism/PK	yes	Allele C is associated with increased concentrations of methotrexate in children with as compared to allele T.			= 0.01	OR	8.8	1.02	75.6
1449188647	rs9282564	methotrexate	Metabolism/PK	yes	Allele C is associated with increased concentrations of methotrexate in children with as compared to allele T.			= 0.04	OR	4.2	0.9	18.2
1449188656	rs4793665	methotrexate	Metabolism/PK	yes	Allele C is associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to allele T.	C	T	= 0.03	OR	0.2	0.1	0.9
1448613158	rs1128503	imatinib	Metabolism/PK	no	Genotype AA is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.	A	A	= 0.005	OR			
1449188665	rs3740066	methotrexate	Metabolism/PK	yes	Genotype TT is associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to genotypes CC + CT.	T	C	= 0.01	OR	0.1	0.01	0.8
1448613152	rs776746	imatinib	Metabolism/PK	yes	Genotype CC is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CT + TT.	C	C	< 0.001	OR			
981481812	rs2108622	warfarin	Dosage,Efficacy	yes	Allele T is associated with increased dose of warfarin as compared to allele C.	T	T		Unknown			
1448613146	rs2032582	imatinib	Metabolism/PK	no	Genotype AA is not associated with increased concentrations of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AT + CT.			= 0.297	OR			
1448613138	rs2032582	imatinib	Metabolism/PK	no	Genotype AA is not associated with increased concentrations of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AC + CC.			= 0.297	OR			
981481830	rs2108622	warfarin	Dosage,Efficacy	yes	Allele T is associated with increased dose of warfarin as compared to allele C.	T		< 0.05	Unknown			
1448613132	rs1045642	imatinib	Metabolism/PK	yes	Genotype AA is associated with increased concentrations of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.	A	A	= 0.013	OR			
1184755091	CYP2D6 poor metabolizer	venlafaxine	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine.			= 0.001	OR			
1184755091	CYP2D6 poor metabolizer	venlafaxine	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine.			= 0.002	OR			
1184755091	CYP2D6 poor metabolizer	venlafaxine	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine.			= 0.013	OR			
1184755091	CYP2D6 poor metabolizer	venlafaxine	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine.			= 0.018	OR			
1184755091	CYP2D6 poor metabolizer	venlafaxine	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine.			= 0.021	OR			
1448613124	rs1128503	imatinib	Metabolism/PK	no	Genotype AA is not associated with increased concentrations of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.	A	A	= 0.201	OR			
1183690054	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with increased metabolism of tacrolimus in healthy individuals as compared to genotype CC.			= 0.04	OR			
1448613117	rs776746	imatinib	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CT + TT.	C	C	= 0.016	OR			
1184755106	CYP2D6 heterozygous normal metabolizer	venlafaxine	Metabolism/PK	yes	CYP2D6 heterozygous normal metabolizer is associated with decreased metabolism of venlafaxine in Elderly Adult.			= 0.007	OR			
1184755106	CYP2D6 heterozygous normal metabolizer	venlafaxine	Metabolism/PK	yes	CYP2D6 heterozygous normal metabolizer is associated with decreased metabolism of venlafaxine in Elderly Adult.			= 0.008	OR			
1451138433	rs2298895	methadone	Metabolism/PK	no	Genotype AA is not associated with concentrations of methadone as compared to genotypes AT + TT.	T		= 0.480				
1451138429	rs12749204	methadone	Metabolism/PK	no	Genotype AA is not associated with concentrations of methadone as compared to genotypes AG + GG.	G		= 0.136				
1184755049	CYP2D6 poor metabolizer	venlafaxine	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine in Elderly Adult.			< 0.001	OR			
1184755049	CYP2D6 poor metabolizer	venlafaxine	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine in Elderly Adult.			< 0.001	OR			
1184755049	CYP2D6 poor metabolizer	venlafaxine	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine in Elderly Adult.			= 0.001	OR			
1184755049	CYP2D6 poor metabolizer	venlafaxine	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine in Elderly Adult.			= 0.001	OR			
1184755049	CYP2D6 poor metabolizer	venlafaxine	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine in Elderly Adult.			= 0.002	OR			
1448613027	rs2266780	sulindac	Metabolism/PK	yes	Genotype GG is associated with increased exposure to sulindac in healthy individuals as compared to genotype AA.			< 0.05	OR			
1448613020	rs2266782	sulindac	Metabolism/PK	yes	Genotype AA is associated with increased exposure to sulindac in healthy individuals as compared to genotype GG.			< 0.05	OR			
1451138505	rs204076	methadone	Metabolism/PK	no	Genotype AA is not associated with concentrations of methadone as compared to genotypes AT + TT.	T		= 0.664				
1451138500	rs678849	methadone	Metabolism/PK	no	Genotype TT is not associated with concentrations of methadone as compared to genotypes CC + CT.	C		= 0.663				
769248362	rs2032582	tipifarnib	Other,Metabolism/PK	no	Allele T is not associated with increased metabolism of tipifarnib.	A		= 0.92	Unknown			
1184755120	CYP2D6 normal metabolizer	venlafaxine	Metabolism/PK	yes	CYP2D6 normal metabolizer is associated with decreased metabolism of venlafaxine in Elderly Adult.			= 0.001	OR			
1184755120	CYP2D6 normal metabolizer	venlafaxine	Metabolism/PK	yes	CYP2D6 normal metabolizer is associated with decreased metabolism of venlafaxine in Elderly Adult.			< 0.001	OR			
769248365	rs1128503	tipifarnib	Other,Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of tipifarnib as compared to genotypes AG + GG.			= 0.047	Unknown			
769248368	rs1045642	tipifarnib	Other,Metabolism/PK	no	Allele G is not associated with decreased metabolism of tipifarnib.			= 0.92	Unknown			
769248371	rs2740574	tipifarnib	Other,Metabolism/PK	no	Allele C is not associated with decreased metabolism of tipifarnib.			= 0.46	Unknown			
1449188859	rs1799971	morphine	Dosage,Efficacy	yes	Genotype GG is associated with increased dose of morphine in women with Pain, Postoperative as compared to genotype AA.	G		= 0.02	OR			
1451122200	rs2461817	voriconazole	Metabolism/PK	yes	Genotype AA is associated with decreased concentrations of voriconazole as compared to genotype AC.			= 0.015				
1184755138	CYP2C19 heterozygous normal metabolizer	escitalopram	Metabolism/PK	yes	CYP2C19 heterozygous normal metabolizer is associated with decreased metabolism of escitalopram in Elderly Adult.			< 0.001	OR			
1184755138	CYP2C19 heterozygous normal metabolizer	escitalopram	Metabolism/PK	yes	CYP2C19 heterozygous normal metabolizer is associated with decreased metabolism of escitalopram in Elderly Adult.			= 0.018	OR			
1451122204	rs7643645	voriconazole	Metabolism/PK	yes	Genotype AA is associated with increased concentrations of voriconazole as compared to genotypes AG + GG.			= 0.015				
1451138603	NAT2 slow acetylator	hydralazine	Metabolism/PK	no	NAT2 slow acetylator is not associated with decreased metabolism of hydralazine in people with Neoplasms as compared to NAT2 rapid acetylator.							
1451122160	rs3814057	voriconazole	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of voriconazole as compared to genotypes AA + AC.			= 0.005				
1449188881	rs3732361	methotrexate	Metabolism/PK	yes	Allele A is associated with increased concentrations of methotrexate in children with Osteosarcoma as compared to allele G.	A	G	= 0.01	OR	2.6	1.2	5.9
1184755154	CYP2C19 normal metabolizer	escitalopram	Metabolism/PK	yes	CYP2C19 normal metabolizer is associated with decreased metabolism of escitalopram in Elderly Adult.			< 0.001	OR			
1184755154	CYP2C19 normal metabolizer	escitalopram	Metabolism/PK	yes	CYP2C19 normal metabolizer is associated with decreased metabolism of escitalopram in Elderly Adult.			= 0.018	OR			
1451138540	rs4654327	methadone	Metabolism/PK	no	Genotype AA is not associated with concentrations of methadone as compared to genotypes AG + GG.	G		= 0.873				
1449188891	rs6785049	methotrexate	Metabolism/PK	yes	Allele G is associated with increased concentrations of methotrexate in children with Osteosarcoma as compared to allele A.	A	G	= 0.006	OR	14.0	1.8	106.5
1451122165	rs2266780	voriconazole	Metabolism/PK	yes	Genotype AA is associated with increased concentrations of voriconazole as compared to genotypes AG + GG.			= 0.029				
1451122177	rs6785049	voriconazole	Metabolism/PK	yes	Genotype GG is associated with increased concentrations of voriconazole as compared to genotype AA.			= 0.014				
1184755166	CYP2C19 poor metabolizer	escitalopram	Metabolism/PK	no	CYP2C19 poor metabolizer is not associated with metabolism of escitalopram in Elderly Adult.				OR			
1451122180	rs10954732	voriconazole	Metabolism/PK	yes	Genotype GG is associated with increased concentrations of voriconazole as compared to genotype AA.			= 0.017				
827816234	rs3745274	methadone	Dosage,Metabolism/PK	yes	Genotype TT is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG.	T		< 5.0E-4	OR	0.13	0.04	0.42
1444828143	CYP2C19*17	voriconazole	Metabolism/PK	not stated	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer genotype phenotype) is associated with decreased concentrations of voriconazole.				OR			
1444828153	CYP2C19*2	voriconazole	Metabolism/PK	not stated	CYP2C19 *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with increased concentrations of voriconazole.				OR			
1451335271	rs10248420	olanzapine	Metabolism/PK	no	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	A		> 0.05				
1451335261	rs2032582	olanzapine	Metabolism/PK	no	Allele C is not associated with exposure to olanzapine in healthy individuals as compared to allele A.			> 0.05				
1451335266	rs2032582	olanzapine	Metabolism/PK	no	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele A.			> 0.05				
827848963	rs3745274	nevirapine	Toxicity,Metabolism/PK	yes	Genotype TT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.			= 0.001	Unknown			
1444828181	CYP2D6 normal metabolizer genotype	perphenazine	Metabolism/PK	not stated	CYP2D6 normal metabolizer genotype is associated with increased clearance of perphenazine as compared to CYP2D6 poor metabolizer genotype.				OR			
827848956	rs3745274	nevirapine	Toxicity,Metabolism/PK	yes	Genotype GT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.			= 0.008	Unknown			
1451122240	rs3745274	efavirenz	Metabolism/PK	yes	Allele T is associated with increased concentrations of efavirenz in women HIV Infections and Malaria as compared to genotype GG.			= 0.001				
1451122240	rs3745274	efavirenz	Metabolism/PK	yes	Allele T is associated with increased concentrations of efavirenz in women HIV Infections and Malaria as compared to genotype GG.			= 0.001				
827848942	rs3211371	nevirapine	Toxicity,Metabolism/PK	no	Genotype TT is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes CC + CT.				Unknown			
1448612852	rs2231142	rosuvastatin	Metabolism/PK	no	Genotype GT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype GG.			< 0.05	OR			
1451335320	rs13306278	olanzapine	Metabolism/PK	no	Genotype CT is not associated with exposure to olanzapine in healthy individuals as compared to genotype CC.	T		> 0.05				
827848927	rs776746	nevirapine	Toxicity,Metabolism/PK	no	Genotype CC is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes CT + TT.				Unknown			
1451335313	rs4520	olanzapine	Metabolism/PK	no	Allele C is not associated with exposure to olanzapine in healthy individuals as compared to allele T.	T		> 0.05				
827848921	rs2740574	nevirapine	Toxicity,Metabolism/PK	no	Genotype CC is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes CT + TT.				Unknown			
827848916	rs1128503	nevirapine	Toxicity,Metabolism/PK	no	Genotype AA is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes AG + GG.				Unknown			
981858976	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	T		= 0.002	Unknown			
981858976	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	T		= 0.005	Unknown			
981858976	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	T		= 0.013	Unknown			
1448432589	rs8187843	SN-38	Metabolism/PK	no	Genotypes AA + AG are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype GG.			= 0.061	OR			
827848906	rs2032582	nevirapine	Toxicity,Metabolism/PK	no	Genotype AA is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes AC + CC.				Unknown			
1451335288	rs12720067	olanzapine	Metabolism/PK	no	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	T		> 0.05				
1448432576	rs2373586	SN-38	Metabolism/PK	no	Genotypes AC + CC are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.			= 0.033	OR			
1451335276	rs10280101	olanzapine	Metabolism/PK	no	Allele C is not associated with exposure to olanzapine in healthy individuals as compared to allele A.			> 0.05				
827848898	rs1045642	nevirapine	Toxicity,Metabolism/PK	no	Genotype AA is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes AG + GG.				Unknown			
1451335283	rs11983225	olanzapine	Metabolism/PK	no	Allele C is not associated with exposure to olanzapine in healthy individuals as compared to allele T.			> 0.05				
1451335293	rs4148737	olanzapine	Metabolism/PK	no	Allele C is not associated with exposure to olanzapine in healthy individuals as compared to allele T.	C		> 0.05				
1451335298	rs4728709	olanzapine	Metabolism/PK	no	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	G		> 0.05				
1448432559	rs35621	SN-38	Metabolism/PK	yes	Genotypes CT + TT are associated with increased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype CC.			= 0.025	OR			
1451138770	NAT2 slow acetylator	hydralazine	Metabolism/PK	not stated	NAT2 slow acetylator is associated with increased concentrations of hydralazine in healthy individuals as compared to NAT2 rapid acetylator.							
1448432548	rs6498588	SN-38	Metabolism/PK	yes	Genotypes AT + TT are associated with increased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.			= 0.010	OR			
1448612764	rs2606345	deferasirox	Metabolism/PK	yes	Genotypes AC + CC is associated with increased trough concentration of deferasirox in children with beta-Thalassemia as compared to genotype AA.			= 0.001	OR			
1448612764	rs2606345	deferasirox	Metabolism/PK	yes	Genotypes AC + CC is associated with increased trough concentration of deferasirox in children with beta-Thalassemia as compared to genotype AA.			= 0.042	OR			
1451335402	CYP2C19 ultrarapid metabolizer	olanzapine	Metabolism/PK	no	CYP2C19 ultrarapid metabolizer are not associated with exposure to olanzapine in healthy individuals as compared to CYP2C19 normal metabolizers.			> 0.05				
1448432529	rs12720066	SN-38	Metabolism/PK	yes	Genotypes AC + CC are associated with decreased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.			= 0.005	OR			
1451335348	rs4803419	olanzapine	Metabolism/PK	no	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	T		> 0.05				
1451335340	rs4680	olanzapine	Metabolism/PK	no	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	A		> 0.05				
981858994	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	T		< 0.001	Unknown			
981858994	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	T		= 0.002	Unknown			
981858994	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	T		= 0.004	Unknown			
981858994	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	T		= 0.004	Unknown			
981858994	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	T		= 0.019	Unknown			
1451335358	CYP2C19 poor metabolizers and intermediate metabolizers	olanzapine	Metabolism/PK	no	CYP2C19 poor metabolizers and intermediate metabolizers are not associated with exposure to olanzapine in healthy individuals as compared to CYP2C19 normal metabolizers.			> 0.05				
1448530802	CYP2D6 poor metabolizers	risperidone	Metabolism/PK	yes	CYP2D6 poor metabolizers are associated with decreased metabolism of risperidone in children as compared to CYP2D6 intermediate metabolizer and normal metabolizer.			< 0.05	OR			
1451335361	rs2279345	olanzapine	Metabolism/PK	no	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	T		> 0.05				
1451335464	rs6313	olanzapine	Metabolism/PK	no	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	A		> 0.05				
1448530758	rs1045642	sunitinib	Metabolism/PK	no	Allele A is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele G.	A			OR			
1451335406	CYP2D6 ultrarapid metabolizer	olanzapine	Metabolism/PK	no	CYP2D6 ultrarapid metabolizer is not associated with exposure to olanzapine in healthy individuals as compared to CYP2D6 normal metabolizers.			> 0.05				
1451335410	CYP2D6 poor metabolizers and intermediate metabolizers	olanzapine	Metabolism/PK	no	CYP2D6 poor metabolizers and intermediate metabolizers is not associated with exposure to olanzapine in healthy individuals as compared to CYP2D6 normal metabolizers.			> 0.05				
1448530742	rs1128503	sunitinib	Metabolism/PK	no	Allele A is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele G.	A			OR			
1448530735	rs2622604	sunitinib	Metabolism/PK	no	Allele C is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele T.	T			OR			
1451335427	rs1799732	olanzapine	Metabolism/PK	no	Genotype GG is not associated with exposure to olanzapine in healthy individuals as compared to genotype G/del.	del		> 0.05				
1448530729	rs2231137	sunitinib	Metabolism/PK	no	Allele T is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele C.	T			OR			
1444827885	CYP2C19 ultrarapid metabolizer	voriconazole	Metabolism/PK	not stated	Genotypes *1/*17 + *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased concentrations of voriconazole as compared to genotype *1/*1 (assigned as normal metabolizer phenotype) .				OR			
1444827896	CYP2C19 poor metabolizer	voriconazole	Metabolism/PK	yes	Genotypes *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is associated with increased trough concentration of voriconazole in people with Mycoses as compared to genotype *1/*1 (assigned as normal metabolizer phenotype) .			< 0.05	OR			
1448530723	rs2231142	sunitinib	Metabolism/PK	no	Allele T is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele G.	T			OR			
1449140029	rs3814055	temsirolimus	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes CC + CT.	C	C	= 0.017	OR			
1184755593	rs2266780	itopride	Metabolism/PK	yes	Genotype GG is associated with decreased metabolism of itopride in healthy individuals as compared to genotype AA.			< 0.001	OR			
1449140043	rs2032582	temsirolimus	Metabolism/PK	yes	Genotype CC is associated with increased metabolism of temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AC.	C	C	= 0.033	OR			
1451138920	NAT2 slow acetylator	hydralazine	Metabolism/PK	not stated	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Neoplasms as compared to NAT2 rapid acetylator.							
1451138866	NAT2 slow acetylator	hydralazine	Metabolism/PK	not stated	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Neoplasms as compared to NAT2 rapid acetylator.							
1447990018	rs4149056	atorvastatin	Metabolism/PK	not stated	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotype TT.	C	T		Unknown			
1447990018	rs4149056	atorvastatin	Metabolism/PK	not stated	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotype TT.	C	T		OR			
1447990018	rs4149056	atorvastatin	Metabolism/PK	not stated	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotype TT.	C	T		OR			
1447990018	rs4149056	atorvastatin	Metabolism/PK	not stated	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotype TT.	C	T		OR			
1447990018	rs4149056	atorvastatin	Metabolism/PK	not stated	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotype TT.	C	T		OR			
1447990018	rs4149056	atorvastatin	Metabolism/PK	not stated	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotype TT.	C	T		OR			
1448530681	rs776746	sunitinib	Metabolism/PK	no	Allele C is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele T.	T			OR			
1184755616	rs3832043	mycophenolic acid	Metabolism/PK	yes	Allele del is associated with decreased metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T.	T	del	< 0.01	OR			
1450401621	rs7902257	omeprazole	Metabolism/PK	not stated	Allele A is not associated with decreased metabolism of omeprazole in healthy individuals as compared to allele G.				OR			
1448612598	rs4149056	simvastatin	Metabolism/PK	no	Genotype CT is not associated with increased exposure to simvastatin as compared to genotype TT.				OR			
1184755622	rs2306283	mycophenolic acid	Metabolism/PK	yes	Genotypes AA + AG is associated with decreased clearance of mycophenolic acid in people with Kidney Transplantation as compared to genotype GG.	G	A	< 0.01	OR			
1451335572	rs815147	olanzapine	Metabolism/PK	no	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele T.	T		> 0.05				
1451335577	rs7799039	olanzapine	Metabolism/PK	no	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	G		> 0.05				
1447989994	rs4149056	rosuvastatin	Metabolism/PK	not stated	Genotype CT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.	C	T		Unknown			
1447989994	rs4149056	rosuvastatin	Metabolism/PK	not stated	Genotype CT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.	C	T		OR			
1447989994	rs4149056	rosuvastatin	Metabolism/PK	not stated	Genotype CT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.	C	T		OR			
1447989994	rs4149056	rosuvastatin	Metabolism/PK	not stated	Genotype CT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.	C	T		OR			
1447989994	rs4149056	rosuvastatin	Metabolism/PK	not stated	Genotype CT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.	C	T		OR			
1447989994	rs4149056	rosuvastatin	Metabolism/PK	not stated	Genotype CT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.	C	T		OR			
1451335540	rs1414334	olanzapine	Metabolism/PK	no	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	C		> 0.05				
1447989951	CYP2D6 poor metabolizer	donepezil	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of donepezil in people with Alzheimer Disease as compared to CYP2D6 normal metabolizer.			= 0.023	OR			
1451335560	rs3813929	olanzapine	Metabolism/PK	no	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	T		> 0.05				
827815322	rs2234922	carbamazepine	Dosage,Metabolism/PK	yes	Allele G is associated with increased dose of carbamazepine in people with Epilepsy as compared to allele A.	G		= 0.027	Unknown			
827815311	rs1051740	carbamazepine	Dosage,Metabolism/PK	yes	Allele C is associated with increased dose of carbamazepine in people with Epilepsy as compared to allele T.	C		= 0.019	Unknown			
1184755634	rs17868323	mycophenolic acid	Metabolism/PK	no	Allele G is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T.	T	G	> 0.05	OR			
1450942480	rs2740574	tacrolimus	Metabolism/PK	no	Genotypes CC + CT is associated with decreased exposure to tacrolimus in people with Kidney Transplantation as compared to genotype TT.	C		= 0.962				
827848035	rs28399499	nevirapine	Toxicity,Metabolism/PK	yes	Genotypes CC + CT are not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype TT.			= 0.48	Unknown			
827700577	CYP2A6*4C	tegafur	Metabolism/PK	yes	CYP2A6 *4C is associated with decreased metabolism of tegafur in people with Carcinoma, Non-Small-Cell Lung.	*4C		< 0.05	Unknown			
1184755639	rs17863778	mycophenolic acid	Metabolism/PK	no	Allele A is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele C.	A	C	> 0.05	OR			
1184755649	rs2741045	mycophenolic acid	Metabolism/PK	no	Allele C is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T.	C	T	> 0.05	OR			
1184755644	rs2741046	mycophenolic acid	Metabolism/PK	no	Allele C is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T.	T	C	> 0.05	OR			
1448612434	rs2231142	talinolol	Metabolism/PK	no	Allele G is not associated with clearance of talinolol in healthy individuals as compared to allele T.	G			OR			
1184755659	rs717620	mycophenolic acid	Metabolism/PK	no	Allele C is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T.	T	C	> 0.05	OR			
827848013	rs3745274	nevirapine	Toxicity,Metabolism/PK	yes	Allele T is associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele G.			= 0.06	Unknown			
1448612429	rs2231137	talinolol	Metabolism/PK	no	Allele C is not associated with clearance of talinolol in healthy individuals as compared to allele T.	C			OR			
1184755654	rs73823859	mycophenolic acid	Metabolism/PK	no	Allele G is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele A.	A	G	> 0.05	OR			
1184755664	rs2273697	mycophenolic acid	Metabolism/PK	no	Allele G is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele A.	A	G	> 0.05	OR			
1448612419	rs717620	talinolol	Metabolism/PK	no	Allele C is not associated with clearance of talinolol in healthy individuals as compared to allele T.	C			OR			
827848004	rs12721655	nevirapine	Toxicity,Metabolism/PK	no	Allele G is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele A.			= 0.53	Unknown			
1184755674	rs4149056	mycophenolic acid	Metabolism/PK	no	Allele C is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T.	T	C	> 0.05	OR			
1184755669	rs3740066	mycophenolic acid	Metabolism/PK	no	Allele C is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T.	T	C	> 0.05	OR			
1448612409	rs2032582	talinolol	Metabolism/PK	no	Allele C is not associated with clearance of talinolol in healthy individuals as compared to allele A.	A			OR			
1448612403	rs1128503	talinolol	Metabolism/PK	no	Allele A is not associated with clearance of talinolol in healthy individuals as compared to allele G.	A			OR			
1451155460	CYP2D6*4	oxycodone	Metabolism/PK	not stated	CYP2D6 *4 is associated with increased concentrations of oxycodone.							
981793894	rs1048977	gemcitabine	Efficacy,Toxicity	no	Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	T		= 0.281	HR	1.22	0.85	1.76
1451155560	CYP2D6 poor metabolizer	tramadol	Metabolism/PK	not stated	CYP2D6 poor metabolizer is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer.							
1448612369	rs4149056	simvastatin acid	Metabolism/PK	yes	Genotype CT is associated with increased exposure to simvastatin acid as compared to genotype TT.			< 0.05	OR			
1183690838	rs9344	methotrexate	Efficacy,Toxicity	no	Genotype AA is not associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	A		= 0.007	OR			
1447678461	rs2298771	carbamazepine	Metabolism/PK	no	Genotype TT is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	C	T	= 0.97	OR	0.99	0.391	2.481
982023222	rs776746	cyclosporine	Metabolism/PK	yes	Genotypes CC + CT are associated with increased metabolism of cyclosporine in healthy individuals as compared to genotype TT.			= 0.011	Unknown			
982023222	rs776746	cyclosporine	Metabolism/PK	yes	Genotypes CC + CT are associated with increased metabolism of cyclosporine in healthy individuals as compared to genotype TT.			= 0.016	Unknown			
982023222	rs776746	cyclosporine	Metabolism/PK	yes	Genotypes CC + CT are associated with increased metabolism of cyclosporine in healthy individuals as compared to genotype TT.			= 0.025	Unknown			
982023222	rs776746	cyclosporine	Metabolism/PK	yes	Genotypes CC + CT are associated with increased metabolism of cyclosporine in healthy individuals as compared to genotype TT.			= 0.035	Unknown			
982023222	rs776746	cyclosporine	Metabolism/PK	yes	Genotypes CC + CT are associated with increased metabolism of cyclosporine in healthy individuals as compared to genotype TT.			= 0.037	Unknown			
982023222	rs776746	cyclosporine	Metabolism/PK	yes	Genotypes CC + CT are associated with increased metabolism of cyclosporine in healthy individuals as compared to genotype TT.			= 0.04	Unknown			
827815680	rs35599367	cyclosporine	Toxicity,Metabolism/PK	yes	Genotypes AA + AG are associated with decreased clearance of cyclosporine in people with Kidney Transplantation as compared to genotype GG.	A		= 0.019	Unknown			
1447678444	rs1051740	carbamazepine	Dosage,Metabolism/PK	no	Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype TT.	T			OR			
1448530413	rs2276707	sunitinib	Dosage,Toxicity	no	Genotype TT is associated with increased dose of sunitinib in people with Carcinoma, Renal Cell as compared to genotypes CC + CT.	T		= 0.063	HR	2.954	1.132	7.707
1183690913	rs1057910	celecoxib	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of celecoxib in children as compared to genotype AA.				OR			
769247726	rs762551	caffeine	Other,Metabolism/PK	yes	Genotype AA is associated with increased metabolism of caffeine as compared to genotype AC.			= 0.01	Unknown			
769247726	rs762551	caffeine	Other,Metabolism/PK	yes	Genotype AA is associated with increased metabolism of caffeine as compared to genotype AC.				Unknown			
1449713783	rs1799971	fentanyl	Dosage,Efficacy	yes	Genotype GG is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotype AA.	G		= 0.0398	OR			
1183690922	rs1799853	celecoxib	Metabolism/PK	no	Allele T is not associated with clearance of celecoxib in healthy individuals as compared to allele C.				OR			
1183690897	rs3957357	busulfan	Metabolism/PK	yes	Genotype AA is associated with increased clearance of busulfan in children with Transplantation as compared to genotypes AG + GG.			= 0.004	OR			
1448104400	rs35599367	methadone	Metabolism/PK	yes	Genotype AG is associated with decreased clearance of methadone in people with Opioid-Related Disorders as compared to genotype GG.	A		< 0.05	OR			
1448104407	rs1057868	methadone	Metabolism/PK	yes	Genotypes CT + TT are associated with increased clearance of methadone in people with Opioid-Related Disorders as compared to genotype CC.	C		< 0.01	OR			
1449713816	rs1045642	opioids	Dosage,Efficacy	yes	Genotype AA is associated with decreased dose of opioids in people with Neoplasms and Pain as compared to genotypes AG + GG.	A		= 0.028	OR			
1449713816	rs1045642	opioids	Dosage,Efficacy	yes	Genotype AA is associated with decreased dose of opioids in people with Neoplasms and Pain as compared to genotypes AG + GG.	A		= 0.057	OR			
1449713808	rs1799971	opioids	Dosage,Efficacy	yes	Genotypes AG + GG are associated with increased dose of opioids in people with Neoplasms and Pain as compared to genotype AA.	G		= 0.0004	OR			
1448530360	rs1128503	sunitinib	Dosage,Toxicity	yes	Genotype AA is associated with increased dose of sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.	A		= 0.012	HR	2.278	1.077	4.82
1449156764	rs3745274	efavirenz	Metabolism/PK	not stated	Genotype GT is associated with increased concentrations of efavirenz as compared to genotype GG.				OR			
1447678392	rs3812718	carbamazepine	Dosage,Metabolism/PK	no	Genotypes CT + TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	C		< 0.05	OR			
1451139280	NAT2 slow acetylator	hydralazine	Metabolism/PK	yes	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.			< 0.001				
1451139280	NAT2 slow acetylator	hydralazine	Metabolism/PK	yes	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.			< 0.01				
1449713837	rs4680	sufentanil	Dosage,Efficacy	yes	Genotype AA is associated with decreased dose of sufentanil in children as compared to genotypes AG + GG.	A		= 0.04	OR			
1447678334	rs2234922	carbamazepine	Metabolism/PK	no	Genotype GG is not associated with dose of carbamazepine in people with Epilepsy as compared to genotype AA.	A	G	> 0.05	OR			
1447678341	rs1051740	carbamazepine	Metabolism/PK	no	Genotype CC is not associated with dose of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	C	T	> 0.05	OR			
1183690931	rs1057910	celecoxib	Metabolism/PK	yes	Genotype CC is associated with decreased clearance of celecoxib in healthy individuals as compared to genotype AA.			= 0.046	OR			
1447678320	rs2298771	carbamazepine	Metabolism/PK	no	Genotype CC is not associated with dose of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	C	T	> 0.05	OR			
981793989	rs1042858	gemcitabine	Efficacy,Toxicity	no	Genotype AA is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG.	A		= 0.486	HR	1.14	0.79	1.63
1447678328	rs1045642	carbamazepine	Metabolism/PK	no	Genotype AG is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes AA + GG.	G	A	< 0.05	OR			
981793982	rs12648166	gemcitabine	Efficacy,Toxicity	no	Genotype AA is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG.	G		= 0.811	HR	1.05	0.73	1.5
1447678304	rs1045642	carbamazepine	Metabolism/PK	yes	Genotype AG is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes AA + GG.	G	A	< 0.05	OR			
1449271546	rs1045642	methadone	Metabolism/PK	not stated	Genotype AG is associated with decreased concentrations of methadone.				OR			
1447678311	rs2298771	carbamazepine	Metabolism/PK	no	Genotype CC is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	C	T	> 0.05	OR			
1448497497	rs162555	exemestane	Metabolism/PK	no	Genotypes CT + TT are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to genotype CC.			= 0.51	OR			
1447678288	rs1051740	carbamazepine	Metabolism/PK	yes	Genotype CC is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	C	T	< 0.05	OR			
1447678288	rs1051740	carbamazepine	Metabolism/PK	yes	Genotype CC is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	C	T	< 0.05	OR			
1447678268	rs2234922	carbamazepine	Metabolism/PK	yes	Genotype GG is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes AA + AG.	A	G	= 0.039	OR			
1447678268	rs2234922	carbamazepine	Metabolism/PK	yes	Genotype GG is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes AA + AG.	A	G	< 0.05	OR			
1447678268	rs2234922	carbamazepine	Metabolism/PK	yes	Genotype GG is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes AA + AG.	A	G	< 0.05	OR			
827784211	rs3745274	nevirapine	Other,Metabolism/PK	not stated	Allele T is associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele G.				Unknown			
827784189	rs12768009	nevirapine	Other,Metabolism/PK	not stated	Genotype AA is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes AG + GG.				Unknown			
1183621538	CYP2C9*3	trimipramine	Metabolism/PK	yes	CYP2C9 *3/*3 is associated with decreased metabolism of trimipramine in healthy individuals.			= 0.03	Unknown			
1445585092	rs1045642	daptomycin	Metabolism/PK	yes	Genotype AA is associated with increased concentrations of daptomycin as compared to genotypes AG + GG.	A		= 0.01	OR			
1445585099	rs1045642	daptomycin	Metabolism/PK	not stated	Genotype AA is associated with decreased clearance of daptomycin as compared to genotypes AG + GG.	A		= 0.012	OR			
1449005482	rs9332131	warfarin	Dosage,Efficacy	not stated	Allele del is associated with decreased dose of warfarin in Pulmonary Embolism as compared to allele A.				OR			
1448108212	rs776746	efavirenz	Metabolism/PK	no	Allele C is not associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.				OR			
1449005488	rs28371686	warfarin	Dosage,Efficacy	not stated	Allele G is associated with decreased dose of warfarin in Pulmonary Embolism as compared to allele C.				OR			
1449005494	rs9923231	warfarin	Dosage,Efficacy	not stated	Genotype GG is not associated with dose of warfarin in Pulmonary Embolism as compared to allele C.				OR			
1184997887	UGT1A9*3a	raltegravir	Metabolism/PK	yes	UGT1A9 *3a is associated with increased exposure to raltegravir in people with HIV.			= 4.18e-4	OR			
1184997887	UGT1A9*3a	raltegravir	Metabolism/PK	yes	UGT1A9 *3a is associated with increased exposure to raltegravir in people with HIV.			= 0.097	OR			
1448632458	rs762551	olanzapine	Metabolism/PK	yes	Genotype AA is associated with decreased concentrations of olanzapine in people with Schizophrenia as compared to genotypes AC + CC.	C		= 0.038	OR			
1448632458	rs762551	olanzapine	Metabolism/PK	yes	Genotype AA is associated with decreased concentrations of olanzapine in people with Schizophrenia as compared to genotypes AC + CC.	C		= 0.068	OR			
1448108161	rs776746	efavirenz	Metabolism/PK	no	Genotypes CC + CT are not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype TT.			= 0.296	OR			
1448108161	rs776746	efavirenz	Metabolism/PK	no	Genotypes CC + CT are not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype TT.			= 0.639	OR			
1448108161	rs776746	efavirenz	Metabolism/PK	no	Genotypes CC + CT are not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype TT.			= 0.692	OR			
1448108161	rs776746	efavirenz	Metabolism/PK	no	Genotypes CC + CT are not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype TT.			= 0.828	OR			
1183703487	CYP2D6 poor metabolizer	fluvoxamine	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased clearance of fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.			= 0.02	OR			
1448632450	rs2011425	olanzapine	Metabolism/PK	no	Allele G is not associated with decreased concentrations of olanzapine in people with Schizophrenia as compared to allele T.	G		= 0.638	OR			
1183703476	CYP2D6 poor metabolizer	fluvoxamine	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased clearance of fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.			= 0.033	OR			
1448632358	rs2011425	olanzapine	Metabolism/PK	yes	Genotype GT is associated with decreased concentrations of olanzapine in people with Schizophrenia as compared to genotype TT.	G		= 0.019	OR			
1448632358	rs2011425	olanzapine	Metabolism/PK	yes	Genotype GT is associated with decreased concentrations of olanzapine in people with Schizophrenia as compared to genotype TT.	G		= 0.22	OR			
1447682087	CYP2D6 poor metabolizer	aripiprazole	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of aripiprazole in people with schizoaffective disorder or Schizophrenia as compared to CYP2D6 normal metabolizer.			= 0.018	OR			
1447682087	CYP2D6 poor metabolizer	aripiprazole	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with decreased metabolism of aripiprazole in people with schizoaffective disorder or Schizophrenia as compared to CYP2D6 normal metabolizer.			> 0.05	OR			
1450807902	CYP2C19 poor metabolizers	omeprazole	Metabolism/PK	not stated	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.				OR			
1448665077	rs2279343	efavirenz	Metabolism/PK	no	Allele G is not associated with increased concentrations of efavirenz in children with HIV Infections as compared to allele A.	G		= 0.546	OR			
1447682043	CYP2D6 poor metabolizer	risperidone	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with increased concentrations of risperidone in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.			= 0.009	OR			
1447682043	CYP2D6 poor metabolizer	risperidone	Metabolism/PK	yes	CYP2D6 poor metabolizer is associated with increased concentrations of risperidone in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.			< 0.05	OR			
1451135630	rs4105144	3-hydroxycotinine	Metabolism/PK	yes	Genotypes CC + CT are associated with increased concentrations of 3-hydroxycotinine in people with Tobacco Use Disorder as compared to genotype TT.	T		= 0.003				
1451135636	rs3733829	3-hydroxycotinine	Metabolism/PK	yes	Genotypes AA + AG are associated with decreased concentrations of 3-hydroxycotinine in people with Tobacco Use Disorder as compared to genotype GG.	G		= 0.03				
1183703697	rs2740574	efavirenz	Metabolism/PK	no	Genotype TT is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype CT.	C		= 0.058	OR			
1183703693	rs28399433	efavirenz	Metabolism/PK	no	Genotype AA is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype CC.	C		= 0.612	OR			
1183703705	rs776746	efavirenz	Metabolism/PK	no	Genotype TT is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype CC.	C		= 0.525	OR			
1183703701	rs28371759	efavirenz	Metabolism/PK	no	Genotype AA is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype AG.	G		= 0.849	OR			
1183703687	rs2279345	efavirenz	Metabolism/PK	yes	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype CC.	C		< 0.001	OR			
1449169556	rs699	atorvastatin	Metabolism/PK	no	Genotype AG is not associated with exposure to atorvastatin in healthy individuals as compared to genotypes AA + GG.	A	G	> 0.05	OR			
1449169556	rs699	atorvastatin	Metabolism/PK	no	Genotype AG is not associated with exposure to atorvastatin in healthy individuals as compared to genotypes AA + GG.	A	G	> 0.05	OR			
1449169556	rs699	atorvastatin	Metabolism/PK	no	Genotype AG is not associated with exposure to atorvastatin in healthy individuals as compared to genotypes AA + GG.	A	G	> 0.05	OR			
1449169556	rs699	atorvastatin	Metabolism/PK	no	Genotype AG is not associated with exposure to atorvastatin in healthy individuals as compared to genotypes AA + GG.	A	G	> 0.05	OR			
1449169556	rs699	atorvastatin	Metabolism/PK	no	Genotype AG is not associated with exposure to atorvastatin in healthy individuals as compared to genotypes AA + GG.	A	G	> 0.05	OR			
1450807931	CYP2C19 poor metabolizers	omeprazole	Metabolism/PK	yes	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.			< 0.05	OR			
1449169583	rs1799722	atorvastatin	Metabolism/PK	yes	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes CC + TT.	C	T	= 0.01	OR			
1449169583	rs1799722	atorvastatin	Metabolism/PK	yes	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes CC + TT.	C	T	= 0.021	OR			
1449169583	rs1799722	atorvastatin	Metabolism/PK	yes	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes CC + TT.	C	C	= 0.023	OR			
1449169583	rs1799722	atorvastatin	Metabolism/PK	yes	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes CC + TT.	C	T	> 0.05	OR			
1449169583	rs1799722	atorvastatin	Metabolism/PK	yes	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes CC + TT.	C	T	> 0.05	OR			
1449169583	rs1799722	atorvastatin	Metabolism/PK	yes	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes CC + TT.	C	T	> 0.05	OR			
1184998169	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes CT + TT is associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	C		= 0.001	OR			
1448632196	rs1544410	rifampin	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of rifampin in people with Tuberculosis as compared to genotypes CC + CT.			= 0.006	OR			
1448632188	rs4646536	rifampin	Metabolism/PK	yes	Genotypes AG + GG is associated with increased concentrations of rifampin in people with Tuberculosis as compared to genotype AA.			= 0.024	OR			
1184998180	rs776746	tacrolimus	Dosage,Metabolism/PK	no	Genotypes CT + TT are not associated with metabolism of tacrolimus in children with liver transplantation as compared to genotype CC.	C		> 0.05	OR			
827784291	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.			< 0.001	Unknown			
1448107856	rs2740574	docetaxel	Metabolism/PK	yes	Allele C is associated with increased clearance of docetaxel in people with Neoplasms as compared to allele T.	T	C	= 0.055	OR			
1183703811	rs1695	olanzapine	Metabolism/PK	yes	Genotype AA is associated with increased clearance of olanzapine in healthy individuals as compared to genotypes AG + GG.			< 0.05	OR			
769165237	rs4920037	Arsenic compounds	Toxicity,Metabolism/PK	yes	Genotypes AA + AG are associated with increased metabolism of Arsenic compounds as compared to genotype GG.			= 0.005	Unknown			
769165235	rs234709	Arsenic compounds	Toxicity,Metabolism/PK	yes	Genotypes CT + TT are associated with increased metabolism of Arsenic compounds as compared to genotype CC.			= 0.006	Unknown			
981939971	NAT2*4	isoniazid	Metabolism/PK	not stated	NAT2 *4 is associated with increased metabolism of isoniazid in people with Tuberculosis.				Unknown			
1183703802	rs1799735	olanzapine	Metabolism/PK	yes	Genotype CCT/CCT is associated with increased clearance of olanzapine in healthy individuals as compared to genotypes CCT/del + del/del.			< 0.05	OR			
827849230	rs3745274	nevirapine	Toxicity,Metabolism/PK	yes	Genotype TT is associated with decreased clearance of nevirapine in children with HIV Infections as compared to genotypes GG + GT.			< 0.01	Unknown			
1448632071	rs4149056	rifampin	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of rifampin in people with Tuberculosis as compared to genotype TT.	T		= 0.019	OR			
1448632071	rs4149056	rifampin	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of rifampin in people with Tuberculosis as compared to genotype TT.			= 0.019	OR			
982022009	rs6295	risperidone	Dosage,Efficacy	yes	Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CG.	C		= 0.038	Unknown			
827816402	rs4648317	methadone	Dosage,Metabolism/PK	no	Genotype AA is not associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG.	A			Unknown			
1448435381	rs212082	SN-38	Metabolism/PK	no	Genotypes AG + GG are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.			= 0.142	OR			
1448435370	rs215095	SN-38	Metabolism/PK	no	Genotypes AG + GG are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.			= 0.109	OR			
1184654330	rs9923231	warfarin	Dosage,Efficacy	yes	Genotype CC is associated with increased dose of warfarin in children with Heart Diseases as compared to genotype TT.	T			OR			
1449595846	rs717620	voriconazole	Metabolism/PK	yes	Genotypes CT + TT is associated with increased trough concentration of voriconazole in children as compared to genotype CC.	T		= 0.025	OR			
1184998408	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	C		< 0.01	OR			
827816353	rs5443	methadone	Dosage,Metabolism/PK	no	Genotype TT is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype CC.	T			Unknown			
1448435351	rs3743527	SN-38	Metabolism/PK	no	Genotypes CT + TT are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype CC.			= 0.071	OR			
827816315	rs2279343	methadone	Dosage,Metabolism/PK	no	Genotype GG is not associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype AA.	G			Unknown			
1448255082	DPYD deficiency	fluorouracil	Metabolism/PK	yes	DPYD deficiency is associated with clearance of fluorouracil in people with Head and Neck Neoplasms.			= 0.002	OR			
827816268	rs6275	methadone	Dosage,Metabolism/PK	yes	Genotype AA is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG.	A		= 0.002	OR	0.27	0.11	10.64
1184998356	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	C		< 0.05	OR			
1184998363	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotype CC.	C		< 0.05	OR			
1184998375	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT are associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.	C		< 0.05	OR			
827816247	rs1799978	methadone	Dosage,Metabolism/PK	yes	Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype TT.			= 0.01	OR	0.07	0.009	0.00056
1184998369	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	C		< 0.05	OR			
1184998516	rs776746	tacrolimus	Metabolism/PK	yes	Allele C is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele T.	C		< 0.027	OR			
1445125617	rs1045642	tacrolimus	Metabolism/PK	no	Allele G is not associated with concentrations of tacrolimus as compared to allele A.	A		= 0.109	OR			
1445125617	rs1045642	tacrolimus	Metabolism/PK	no	Allele G is not associated with concentrations of tacrolimus as compared to allele A.	A		= 0.392	OR			
1184654456	rs2108622	warfarin	Dosage,Efficacy	no	Allele T is not associated with increased dose of warfarin in children with Heart Diseases as compared to allele C.	T			OR			
1184998539	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes CT + TT is associated with increased dose of tacrolimus in children with liver transplantation as compared to genotype CC.	C		< 0.05	OR			
1184998546	rs776746	tacrolimus	Metabolism/PK	not stated	Genotypes CT + TT is associated with increased clearance of tacrolimus in children with liver transplantation as compared to genotype CC.	C			OR			
1183491305	rs1523130	memantine	Metabolism/PK	yes	Genotypes CT + TT are associated with decreased clearance of memantine in people with Dementia as compared to genotype CC.	C		= 0.006	Unknown			
769246523	rs2069514	theophylline	Other,Metabolism/PK	yes	Genotypes AA + AG are associated with decreased metabolism of theophylline in people with Asthma as compared to genotype GG.			< 0.05	Unknown			
1184998684	rs4793665	morphine	Metabolism/PK	yes	Genotype CC is associated with increased metabolism of morphine in children as compared to genotypes CT + TT.			< 0.01	OR			
1184998684	rs4793665	morphine	Metabolism/PK	yes	Genotype CC is associated with increased metabolism of morphine in children as compared to genotypes CT + TT.			> 0.05	OR			
1184998684	rs4793665	morphine	Metabolism/PK	yes	Genotype CC is associated with increased metabolism of morphine in children as compared to genotypes CT + TT.			< 0.05	OR			
1448631654	CYP2D6 normal metabolizer genotype	olanzapine	Metabolism/PK	no	CYP2D6 normal metabolizer genotype is not associated with clearance of olanzapine in people with Schizophrenia as compared to CYP2D6 intermediate metabolizer genotype.				OR			
1183622437	rs2069521	escitalopram	Metabolism/PK	yes	Allele A is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele G.			= 0.05	Unknown			
769246583	rs2069514	caffeine	Other,Metabolism/PK	yes	Genotypes AA + AG are associated with decreased metabolism of caffeine as compared to genotype GG.			< 0.05	Unknown			
1451152645	CYP2D6 poor metabolizer phenotype	ethylmorphine	Metabolism/PK	not stated	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of ethylmorphine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.							
981479763	rs2213712	olanzapine	Metabolism/PK	no	Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
1183491421	rs3745274	efavirenz	Metabolism/PK	yes	Genotype GT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	G		< 0.001	Unknown			
981479756	rs9306356	olanzapine	Metabolism/PK	no	Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.				Unknown			
981479768	rs2859228	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
1183491430	rs8192709	efavirenz	Metabolism/PK	no	Genotype CC is not associated with clearance of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	C		= 0.105	Unknown			
1183491434	rs2279343	efavirenz	Metabolism/PK	yes	Genotype GG is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype AG.	A		< 0.001	Unknown			
981479778	rs1492899	olanzapine	Metabolism/PK	no	Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.				Unknown			
1183491412	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	G		< 0.001	Unknown			
1183491417	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GT.	G		< 0.001	Unknown			
981479783	rs929087	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
981479730	rs2069526	olanzapine	Metabolism/PK	no	Allele G is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.				Unknown			
981479724	rs2069522	olanzapine	Metabolism/PK	no	Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.				Unknown			
1183622464	rs762551	escitalopram	Metabolism/PK	no	Allele C is not associated with metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele A.			> 0.05	Unknown			
981479737	rs4646425	olanzapine	Metabolism/PK	no	Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.				Unknown			
1447959818	rs1533682	doxorubicin	Metabolism/PK	yes	Genotype TT is associated with increased clearance of doxorubicin in women with Breast Neoplasms as compared to genotypes CC + CT.			= 0.04	OR			
981479744	rs11631682	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
1183622452	rs2069526	escitalopram	Metabolism/PK	yes	Allele G is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele T.			= 0.05	Unknown			
981479749	rs6002616	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
1183622456	rs4646425	escitalopram	Metabolism/PK	yes	Allele T is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele C.			= 0.05	Unknown			
981479826	rs651430	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
1184998709	rs1045642	morphine	Metabolism/PK	yes	Genotype AA is associated with increased metabolism of morphine in children as compared to genotypes AG + GG.			> 0.05	OR			
1184998709	rs1045642	morphine	Metabolism/PK	yes	Genotype AA is associated with increased metabolism of morphine in children as compared to genotypes AG + GG.			< 0.05	OR			
1184998709	rs1045642	morphine	Metabolism/PK	yes	Genotype AA is associated with increased metabolism of morphine in children as compared to genotypes AG + GG.			> 0.05	OR			
982036882	CYP2D6*10	carvedilol	Metabolism/PK	yes	CYP2D6 *10 is associated with decreased metabolism of carvedilol in people with Angina Pectoris as compared to CYP2D6 *1.			< 0.05	Unknown			
978614496	rs699664	warfarin	Dosage,Metabolism/PK	not stated	Allele T is associated with dose of warfarin.				Unknown			
978614496	rs699664	warfarin	Dosage,Metabolism/PK	not stated	Allele T is associated with dose of warfarin.				Unknown			
1183491471	rs3211371	efavirenz	Metabolism/PK	no	Genotype CC is not associated with clearance of efavirenz in people with HIV Infections as compared to genotype CT.	C		= 0.5	Unknown			
1184998726	UGT1A1*28	raltegravir	Metabolism/PK	no	UGT1A1 *28 is not associated with metabolism of raltegravir in healthy individuals.			= 0.90	OR		0.8	1.44
981479840	rs12535293	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
1183491475	CYP2B6*1	efavirenz	Metabolism/PK	yes	CYP2B6 *1/*1 is associated with increased clearance of efavirenz in people with HIV.	*1		= 0.027	Unknown			
981479851	rs472660	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
1451152807	CYP2D6 ultrarapid metabolizer phenotype	codeine	Metabolism/PK	not stated	CYP2D6 ultrarapid metabolizer phenotype is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.							
981479790	rs10458360	olanzapine	Metabolism/PK	no	Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
981479802	rs2527887	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.				Unknown			
978614465	rs2108622	warfarin	Dosage,Metabolism/PK	not stated	Allele T is associated with dose of warfarin.				Unknown			
978614465	rs2108622	warfarin	Dosage,Metabolism/PK	not stated	Allele T is associated with dose of warfarin.				Unknown			
1183491467	rs2279343	efavirenz	Metabolism/PK	yes	Genotype AG is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype AA.	A		= 0.011	Unknown			
978614455	rs9923231	warfarin	Dosage,Metabolism/PK	not stated	Allele T is associated with dose of warfarin.				Unknown			
978614455	rs9923231	warfarin	Dosage,Metabolism/PK	not stated	Allele T is associated with dose of warfarin.				Unknown			
1448107184	rs17868320	mycophenolic acid	Metabolism/PK	no	Genotype CC is not associated with metabolism of mycophenolic acid as compared to genotype TT.				OR			
981479807	rs2525557	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
981479819	rs4729562	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
1448107192	rs10187694	mycophenolic acid	Metabolism/PK	no	Genotype GG is not associated with metabolism of mycophenolic acid as compared to genotype AA.				OR			
981479812	rs6960542	olanzapine	Metabolism/PK	no	Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.				Unknown			
978614436	CYP2C9*3	warfarin	Dosage,Metabolism/PK	not stated	CYP2C9 *3 is associated with dose of warfarin.	*3			Unknown			
978614436	CYP2C9*3	warfarin	Dosage,Metabolism/PK	not stated	CYP2C9 *3 is associated with dose of warfarin.	*3			Unknown			
981479884	rs2572023	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
1448107164	rs6714486	mycophenolic acid	Metabolism/PK	no	Genotype AA is not associated with metabolism of mycophenolic acid as compared to genotype TT.				OR			
981479892	rs2527927	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
978614420	CYP2C9*8	warfarin	Dosage,Metabolism/PK	not stated	CYP2C9 *8 is associated with dose of warfarin.	*8			Unknown			
978614420	CYP2C9*8	warfarin	Dosage,Metabolism/PK	not stated	CYP2C9 *8 is associated with dose of warfarin.	*8			Unknown			
982036911	CYP2D6*4	carvedilol	Metabolism/PK	no	CYP2D6 *4 is not associated with metabolism of carvedilol in people with Angina Pectoris as compared to CYP2D6 *1.				Unknown			
981479862	rs17161981	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
981479873	rs17161983	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
1448123512	CYP2C19 poor metabolizers and intermediate metabolizers	voriconazole	Metabolism/PK	yes	CYP2C19 poor metabolizers and intermediate metabolizers are associated with increased trough concentration of voriconazole as compared to CYP2C19 normal metabolizers.			< 0.0001	OR			
1448123512	CYP2C19 poor metabolizers and intermediate metabolizers	voriconazole	Metabolism/PK	yes	CYP2C19 poor metabolizers and intermediate metabolizers are associated with increased trough concentration of voriconazole as compared to CYP2C19 normal metabolizers.			< 0.0001	OR			
1448123512	CYP2C19 poor metabolizers and intermediate metabolizers	voriconazole	Metabolism/PK	yes	CYP2C19 poor metabolizers and intermediate metabolizers are associated with increased trough concentration of voriconazole as compared to CYP2C19 normal metabolizers.			= 0.005	OR			
982036924	CYP2D6*5	carvedilol	Metabolism/PK	no	CYP2D6 *5 is not associated with metabolism of carvedilol in people with Angina Pectoris as compared to CYP2D6 *1.				Unknown			
1450989080	rs2032582	erlotinib	Toxicity,Metabolism/PK	yes	Genotype AA is associated with decreased clearance of erlotinib in people with Carcinoma, Non-Small-Cell Lung.			= 0.021	Unknown			
1448615000	rs1045642	anastrozole	Metabolism/PK	no	Genotype GG is not associated with concentrations of anastrozole in women with Breast Neoplasms as compared to genotypes AA + AG.	A	G	> 0.05	OR			
1448614994	rs1128503	anastrozole	Metabolism/PK	no	Genotype GG is not associated with concentrations of anastrozole in women with Breast Neoplasms as compared to genotypes AA + AG.	A	G	> 0.05	OR			
1448614987	rs2032582	anastrozole	Metabolism/PK	yes	Genotype AA is associated with increased concentrations of anastrozole in women with Breast Neoplasms as compared to genotypes AC + CC.	C	A	= 0.037	OR			
1450989040	rs1128503	erlotinib	Toxicity,Metabolism/PK	yes	Genotype AA is associated with decreased clearance of erlotinib in people with Carcinoma, Non-Small-Cell Lung.			= 0.021	Unknown			
1444666354	rs187238	tacrolimus	Metabolism/PK	no	Genotype CC is not associated with concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CG + GG.			> 0.05	OR			
1450989140	rs1045642	crizotinib	Metabolism/PK	no	Genotype AA is associated with increased exposure to crizotinib in people with.				OR			
1444666368	rs1946518	tacrolimus	Metabolism/PK	yes	Genotypes GG + GT are associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT.	G	T	= 0.039	OR			
1444666368	rs1946518	tacrolimus	Metabolism/PK	yes	Genotypes GG + GT are associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT.	G	T	< 0.05	OR			
1450989160	rs1128503	crizotinib	Metabolism/PK	no	Genotype AA is associated with increased exposure to crizotinib in people with.				OR			
1183491630	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with liver transplantation as compared to genotype CC.			= 0.02	Unknown			
1183491630	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with liver transplantation as compared to genotype CC.			= 0.03	Unknown			
1444666410	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	C	T	< 0.05	OR			
1183491726	rs1045642	talinolol	Metabolism/PK	yes	Genotype AA is associated with increased clearance of talinolol in healthy individuals as compared to genotypes AG + GG.	G		= 0.028	Unknown			
1183491726	rs1045642	talinolol	Metabolism/PK	yes	Genotype AA is associated with increased clearance of talinolol in healthy individuals as compared to genotypes AG + GG.	G		= 0.030	Unknown			
1183491726	rs1045642	talinolol	Metabolism/PK	yes	Genotype AA is associated with increased clearance of talinolol in healthy individuals as compared to genotypes AG + GG.	G		= 0.032	Unknown			
1183491726	rs1045642	talinolol	Metabolism/PK	yes	Genotype AA is associated with increased clearance of talinolol in healthy individuals as compared to genotypes AG + GG.	G		= 0.106	Unknown			
1183491726	rs1045642	talinolol	Metabolism/PK	yes	Genotype AA is associated with increased clearance of talinolol in healthy individuals as compared to genotypes AG + GG.	G		= 0.229	Unknown			
1183491726	rs1045642	talinolol	Metabolism/PK	yes	Genotype AA is associated with increased clearance of talinolol in healthy individuals as compared to genotypes AG + GG.	G		= 0.326	Unknown			
1450186361	CYP2C8*4	paclitaxel	Metabolism/PK	no	CYP2C8 *4 is not associated with increased exposure to paclitaxel in women with Breast Neoplasms.			= 0.58	OR			
1448663995	rs3745274	efavirenz	Metabolism/PK	yes	Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	T		< 0.001	OR			
1451153020	CYP2D6 poor metabolizer phenotype	tramadol	Metabolism/PK	yes	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.			< 0.001				
1448106881	rs2740574	tacrolimus	Metabolism/PK	yes	Allele T is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele C.			< 0.05	OR			
1448614791	rs750165758	rocuronium	Metabolism/PK	no	Genotypes CC + CT are not associated with clearance of rocuronium in healthy individuals as compared to genotype TT.			= 0.20	OR			
1448614780	rs11568563	rocuronium	Metabolism/PK	no	Genotypes GT + TT are not associated with clearance of rocuronium in healthy individuals as compared to genotype GG.			= 0.33	OR			
1448614774	rs3834939	rocuronium	Metabolism/PK	yes	Genotypes T/del + TT are associated with decreased clearance of rocuronium in healthy individuals as compared to genotype del/del.			= 0.002	OR			
1448614774	rs3834939	rocuronium	Metabolism/PK	yes	Genotypes T/del + TT are associated with decreased clearance of rocuronium in healthy individuals as compared to genotype del/del.			= 0.047	OR			
1448614761	rs3764043	rocuronium	Metabolism/PK	no	Genotypes CT + TT are not associated with clearance of rocuronium in healthy individuals as compared to genotype CC.			= 0.35	OR			
1447680865	rs1054190	efavirenz	Metabolism/PK	no	Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	A		= 0.7802	OR			
1448614755	rs4148978	rocuronium	Metabolism/PK	no	Genotypes CT + TT are not associated with clearance of rocuronium in healthy individuals as compared to genotype CC.			= 0.19	OR			
1447680871	rs1054191	efavirenz	Metabolism/PK	no	Genotype GG is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AA + AG.			= 0.1553	OR			
1448106854	rs776746	tacrolimus	Metabolism/PK	yes	Allele C is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.			< 0.05	OR			
982037228	rs1045642	digoxin	Metabolism/PK	yes	Genotype AA is associated with decreased clearance of digoxin in healthy individuals as compared to genotypes AG + GG.	A		< 0.017	Unknown			
1447680819	rs1042389	efavirenz	Metabolism/PK	no	Genotype TT is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CC + CT.	C		= 0.0065	OR			
1447680825	rs2740574	efavirenz	Metabolism/PK	no	Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	C		= 0.8630	OR			
1447680778	rs28399499	efavirenz	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	C		< 0.0001	OR			
1447680752	rs2279343	efavirenz	Metabolism/PK	yes	Allele G is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele A.	A		< 0.0001	OR			
1447680733	rs35303484	efavirenz	Metabolism/PK	no	Genotype AA is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.	A		= 0.7802	OR			
982037396	rs1799853	fluvastatin	Metabolism/PK	no	Genotypes CT + TT are not associated with metabolism of fluvastatin in healthy individuals as compared to genotype CC.				Unknown			
1447680740	rs4803419	efavirenz	Metabolism/PK	no	Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.			= 0.0045	OR			
1447680746	rs3745274	efavirenz	Metabolism/PK	yes	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.	T		< 0.0001	OR			
1447680719	rs45564134	efavirenz	Metabolism/PK	no	Allele G is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes G/del + del/del.			= 0.8789	OR			
982037414	rs1799853	fluvastatin	Metabolism/PK	no	Allele T is not associated with response to fluvastatin in healthy individuals as compared to allele C.			= 0.1	Unknown			
1447680725	rs28399454	efavirenz	Metabolism/PK	no	Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.			= 0.1920	OR			
982037405	rs1057910	fluvastatin	Metabolism/PK	no	Genotype CC is not associated with response to fluvastatin in healthy individuals as compared to genotype AA.			= 0.1	Unknown			
1449564044	rs1057868	bupropion	Metabolism/PK	yes	Genotypes CT + TT are not associated with metabolism of bupropion in healthy individuals as compared to genotype CC.			< 0.05	OR			
1449170836	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	endoxifen	Metabolism/PK	yes	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with concentrations of endoxifen in women with Breast Neoplasms.			= 0.0008	OR			
982037386	rs1057910	fluvastatin	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of fluvastatin in healthy individuals as compared to genotype AA.			< 0.001	Unknown			
1444698851	rs3745274	efavirenz	Metabolism/PK	yes	Allele T is associated with decreased clearance of efavirenz in people with HIV Infections as compared to allele G.			= 2e-10	OR			
1444698851	rs3745274	efavirenz	Metabolism/PK	yes	Allele T is associated with decreased clearance of efavirenz in people with HIV Infections as compared to allele G.			= 0.0018	OR			
1449170850	CYP3A5 poor metabolizer and intermediate metabolizer genotypes	endoxifen	Metabolism/PK	no	CYP3A5 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of endoxifen in women with Breast Neoplasms.			= 0.9607	OR			
1447680695	rs762551	efavirenz	Metabolism/PK	no	Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AA + AC.	A		= 0.2734	OR			
1184753650	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes CT + TT is associated with increased clearance of tacrolimus in children with liver transplantation as compared to genotype CC.	C		< 0.001	OR			
1184753650	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes CT + TT is associated with increased clearance of tacrolimus in children with liver transplantation as compared to genotype CC.	C		= 0.038	OR			
1451136987	rs1045642	dexlansoprazole	Metabolism/PK	no	Allele A is not associated with metabolism of dexlansoprazole in healthy individuals as compared to allele G.							
827784609	rs7311358	docetaxel	Other,Metabolism/PK	yes	Allele A is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms.			= 0.025	Unknown			
1184753658	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes CT + TT is associated with increased metabolism of tacrolimus in children with liver transplantation as compared to genotype CC.	C		= 0.001	OR			
1184753658	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes CT + TT is associated with increased metabolism of tacrolimus in children with liver transplantation as compared to genotype CC.	C		= 0.049	OR			
827784603	rs4149118	docetaxel	Other,Metabolism/PK	yes	Allele G is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms.			= 0.025	Unknown			
1449564102	rs2248359	daclatasvir	Metabolism/PK	yes	Genotypes CT + TT is associated with increased concentrations of daclatasvir in people with Hepatitis C as compared to genotype CC.			= 0.04	OR			
1449170887	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	n-desmethyltamoxifen	Metabolism/PK	no	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of n-desmethyltamoxifen in women with Breast Neoplasms.			= 0.5916	OR			
1449564095	rs11568820	daclatasvir	Metabolism/PK	yes	Genotype TT is associated with decreased concentrations of daclatasvir in people with Hepatitis C as compared to genotypes CC + CT.			= 0.01	OR			
1449170899	CYP3A5 poor metabolizer and intermediate metabolizer genotypes	n-desmethyltamoxifen	Metabolism/PK	no	CYP3A5 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of n-desmethyltamoxifen in women with Breast Neoplasms.			= 0.9713	OR			
1449170899	CYP3A5 poor metabolizer and intermediate metabolizer genotypes	n-desmethyltamoxifen	Metabolism/PK	no	CYP3A5 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of n-desmethyltamoxifen in women with Breast Neoplasms.				OR			
1184753676	rs2032582	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes AA + TT is associated with decreased clearance of tacrolimus in children with liver transplantation.			= 0.038	OR			
1449170905	CYP2C9 poor metabolizer and intermediate metabolizer genotypes	n-desmethyltamoxifen	Metabolism/PK	no	CYP2C9 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of n-desmethyltamoxifen in women with Breast Neoplasms.			= 0.5451	OR			
1449170917	CYP3A4 poor metabolizer and intermediate metabolizer genotypes	tamoxifen	Metabolism/PK	no	CYP3A4 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of tamoxifen in women with Breast Neoplasms.			= 0.3876	OR			
1451137042	CYP2C19 poor metabolizer	dexlansoprazole	Metabolism/PK	not stated	CYP2C19 poor metabolizer is associated with decreased metabolism of dexlansoprazole in healthy individuals as compared to CYP2C19 normal metabolizer.							
1448106601	rs1127354	mercaptopurine	Metabolism/PK	yes	Allele A is associated with metabolism of mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.			= 3.0E-4	OR			
1448106601	rs1127354	mercaptopurine	Metabolism/PK	yes	Allele A is associated with metabolism of mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.			= 0.0057	OR			
1184753631	rs35599367	tacrolimus	Metabolism/PK	yes	Genotypes AA + AG is associated with decreased clearance of tacrolimus in children with liver transplantation as compared to genotype GG.	A		= 0.035	OR			
1444665867	CYP2D6 poor metabolizers	vortioxetine	Metabolism/PK	not stated	CYP2D6 poor metabolizers is associated with decreased clearance of vortioxetine in healthy individuals as compared to CYP2D6 normal metabolizers.				OR			
1449171049	rs3211371	methadone	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of methadone as compared to genotypes CC + CT.	T	T	< 0.05	OR			
1449171059	rs8192709	S-EDDP	Metabolism/PK	yes	Genotype CT is associated with increased concentrations of (S)-EDDP as compared to genotype CC.	T	T	< 0.05	OR			
613976745	rs2234922	carbamazepine	Dosage,Metabolism/PK	yes	Allele G is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to allele A.	G		= 0.0351	Unknown			
1449171064	rs2279344	methadone	Metabolism/PK	no	Allele A is not associated with concentrations of methadone as compared to allele G.	A	A		OR			
1451251861	CYP2D6 intermediate metabolizer phenotype	aripiprazole	Metabolism/PK	yes	CYP2D6 intermediate metabolizer phenotype is associated with decreased metabolism of aripiprazole as compared to genotypes *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as intermediate metabolizer phenotype) .			< 0.01				
1451251861	CYP2D6 intermediate metabolizer phenotype	aripiprazole	Metabolism/PK	yes	CYP2D6 intermediate metabolizer phenotype is associated with decreased metabolism of aripiprazole as compared to genotypes *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as intermediate metabolizer phenotype) .			< 0.01				
1451251861	CYP2D6 intermediate metabolizer phenotype	aripiprazole	Metabolism/PK	yes	CYP2D6 intermediate metabolizer phenotype is associated with decreased metabolism of aripiprazole as compared to genotypes *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as intermediate metabolizer phenotype) .			< 0.05				
1447680461	rs2307024	efavirenz	Metabolism/PK	no	Genotype TT is not associated with concentrations of efavirenz in people with HIV Infections.	T		= 0.175	OR			
1449171069	rs3745274	methadone	Metabolism/PK	no	Allele T is not associated with concentrations of methadone as compared to allele G.	T	T		OR			
1449171079	rs8192709	methadone	Metabolism/PK	no	Allele T is not associated with concentrations of methadone as compared to allele C.	T	T		OR			
1449171089	rs2279344	S-EDDP	Metabolism/PK	no	Allele A is not associated with concentrations of (S)-EDDP as compared to allele G.	A	A		OR			
1447680448	rs7439366	efavirenz	Metabolism/PK	no	Genotype TT is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CC + CT.	C		= 0.849	OR			
1451251823	CYP2D6 intermediate metabolizer phenotype	risperidone	Metabolism/PK	yes	CYP2D6 intermediate metabolizer phenotype is associated with decreased metabolism of risperidone as compared to genotypes *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as intermediate metabolizer phenotype) .			= 0.01				
1451251823	CYP2D6 intermediate metabolizer phenotype	risperidone	Metabolism/PK	yes	CYP2D6 intermediate metabolizer phenotype is associated with decreased metabolism of risperidone as compared to genotypes *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as intermediate metabolizer phenotype) .			< 0.05				
1449171099	rs3745274	S-EDDP	Metabolism/PK	no	Allele T is not associated with concentrations of (S)-EDDP as compared to allele G.	T	T		OR			
1447680454	rs6785049	efavirenz	Metabolism/PK	no	Genotype AA is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.	A		= 0.766	OR			
1449171094	rs3211371	S-EDDP	Metabolism/PK	no	Allele T is not associated with concentrations of (S)-EDDP as compared to allele C.	T	T	< 0.05	OR			
1447680428	rs8192726	efavirenz	Metabolism/PK	no	Genotype AA is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AC + CC.	A		= 0.692	OR			
1449171104	rs4803419	S-EDDP	Metabolism/PK	no	Allele T is not associated with concentrations of (S)-EDDP as compared to allele C.	T	T		OR			
1447680436	rs28399454	efavirenz	Metabolism/PK	no	Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotype CT.	C		= 0.471	OR			
1449171109	rs8192719	S-EDDP	Metabolism/PK	no	Allele T is not associated with concentrations of (S)-EDDP as compared to allele C.	T	T		OR			
1447680442	rs28365062	efavirenz	Metabolism/PK	no	Genotype AA is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.	A		= 0.83	OR			
1447680398	rs1128503	efavirenz	Metabolism/PK	no	Genotype AA is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.	A		= 0.087	OR	0.49	0.19	1.26
1447680404	rs1884613	efavirenz	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes CG + GG.	C		= 0.042	OR	0.71	0.33	1.53
1447680386	rs1045642	efavirenz	Metabolism/PK	yes	Genotype AA is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.	A		= 0.029	OR	0.39	0.17	0.9
1183492294	rs1045642	tacrolimus	Metabolism/PK	yes	Genotypes AG + GG are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype AA.	G		< 0.05	Unknown			
1447680392	rs2032582	efavirenz	Metabolism/PK	yes	Genotype AA is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotypes AC + CC.	A		= 0.016	OR	0.39	0.14	1.05
1447680365	CYP2C19*9	omeprazole	Metabolism/PK	not stated	CYP2C19 *9 is associated with decreased metabolism of omeprazole in healthy individuals.	*9			OR			
1447680376	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	G		< 0.001	OR	22.79	4.78	108.79
1447680349	CYP2C19*15	omeprazole	Metabolism/PK	not stated	CYP2C19 *15 is associated with decreased metabolism of omeprazole in healthy individuals.	*15			OR			
1447680341	CYP2C19*17	omeprazole	Metabolism/PK	not stated	CYP2C19 *17 is not associated with increased metabolism of omeprazole in healthy individuals.	*17			OR			
1449171233	rs1045642	tacrolimus	Metabolism/PK	no	Genotype AG is not associated with concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.				OR			
827807158	CYP2C19*2	carvedilol	Other,Metabolism/PK	no	CYP2C19 *2/*2 is not associated with metabolism of carvedilol in healthy individuals.				Unknown			
981479773	rs2859229	olanzapine	Metabolism/PK	no	Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.				Unknown			
1447680801	rs707265	efavirenz	Metabolism/PK	no	Genotype AA is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.	A		= 0.7919	OR			
981474995	rs17222723	methotrexate	Metabolism/PK	no	Allele A is not associated with clearance of methotrexate in people with Lymphoma.	A			Unknown			
1448639969	rs8330	acetaminophen	Metabolism/PK	no	Allele C is not associated with metabolism of acetaminophen in healthy individuals as compared to allele G.			> 0.05	OR			
1447680859	rs3732360	efavirenz	Metabolism/PK	no	Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.			= 0.9843	OR			
1449165203	rs2252281	metformin	Metabolism/PK	no	Allele C is not associated with exposure to metformin as compared to allele T.	T	C	> 0.15	OR			
1449310942	rs4244285	clopidogrel	Efficacy,Other	yes	Allele A is associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele G.	A	G	= 0.03	HR	0.68	0.47	0.97
981479797	rs2527894	olanzapine	Metabolism/PK	no	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.				Unknown			
1450045085	rs3740065	methotrexate	Metabolism/PK	no	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	G		> 0.0001	OR			
1450814759	rs3740066	pitavastatin	Metabolism/PK	no	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele C.	T		= 0.045				
1450814759	rs3740066	pitavastatin	Metabolism/PK	no	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele C.	T		= 0.097				
1450814759	rs3740066	pitavastatin	Metabolism/PK	no	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele C.	T		= 0.154				
1450814759	rs3740066	pitavastatin	Metabolism/PK	no	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele C.	T		= 0.154				
1450814759	rs3740066	pitavastatin	Metabolism/PK	no	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele C.	T		= 0.174				
1450814759	rs3740066	pitavastatin	Metabolism/PK	no	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele C.	T		= 0.738				
982035432	CYP2D6*10	bepridil	Metabolism/PK	yes	CYP2D6 *10 is associated with increased clearance of bepridil in people with Arrhythmias, Cardiac.				Unknown			
1451129611	rs3842	efavirenz	Metabolism/PK	no	Allele C is not associated with exposure to efavirenz in healthy individuals as compared to allele T.	C		> 0.05				
1448530349	rs2231142	sunitinib	Metabolism/PK	no	Genotype TT is associated with increased exposure to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.				OR			
1449165138	rs622342	metformin	Metabolism/PK	no	Allele A is not associated with exposure to metformin as compared to allele C.	A	C	> 0.15	OR			
1449188418	rs10457090	cotinine	Metabolism/PK	yes	Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A.	G		= 0.004	OR			
1449271581	rs1128503	S-EDDP	Metabolism/PK	not stated	Genotype AG is associated with increased concentrations of (S)-EDDP.				OR			
1447680877	rs3814057	efavirenz	Metabolism/PK	no	Genotype AA is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AC + CC.	A		= 0.3185	OR			
827783823	CYP2B6*4	propofol	Other,Metabolism/PK	no	CYP2B6 *4 is not associated with metabolism of propofol.				Unknown			
827807173	CYP2C9*1	carvedilol	Other,Metabolism/PK	no	CYP2C9 *1/*1 is not associated with metabolism of carvedilol in healthy individuals.				Unknown			
827783818	CYP2B6*6	propofol	Other,Metabolism/PK	no	CYP2B6 *6 is not associated with metabolism of propofol.				Unknown			
1448993700	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.			< 0.001	OR			
1183701883	rs1799853	warfarin	Metabolism/PK	not stated	Allele T is associated with decreased metabolism of warfarin as compared to allele C.				OR			
1448573551	rs71647871	methylphenidate	Metabolism/PK	yes	Allele T is associated with decreased metabolism of methylphenidate in healthy individuals as compared to allele C.			< 0.0001	OR			
1448993691	rs3745274	efavirenz	Metabolism/PK	yes	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.			= 0.01	OR			
1183685450	G6PD A- 202A_376G	daunorubicin	Metabolism/PK	yes	G6PD A-202A_376G is associated with decreased metabolism of daunorubicin.			< 0.001	OR			
769278041	rs5031016	nicotine	Other,Metabolism/PK	no	Allele G is associated with decreased metabolism of nicotine as compared to allele A.				Unknown			
827803602	CYP2A6*2	efavirenz	Other,Metabolism/PK	yes	CYP2A6 *2 is associated with decreased metabolism of efavirenz in people with HIV.	*2		< 0.05	Unknown			
827892687	rs1801265	fluorouracil	Toxicity,Metabolism/PK	no	Genotypes AG + GG are not associated with clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.	G		= 0.549	Unknown			
827783832	CYP2B6*7	propofol	Other,Metabolism/PK	no	CYP2B6 *7 is not associated with metabolism of propofol.				Unknown			
981474986	rs2273697	methotrexate	Metabolism/PK	no	Allele A is not associated with clearance of methotrexate in people with Lymphoma.	A			Unknown			
981848260	NAT2*4	isoniazid	Metabolism/PK	not stated	NAT2 *4 is associated with increased clearance of isoniazid in healthy individuals.	*4			Unknown			
981862003	CYP2C9*3	ibuprofen	Metabolism/PK	yes	CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.			= 0.005	Unknown			
981862003	CYP2C9*3	ibuprofen	Metabolism/PK	yes	CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.			= 0.025	Unknown			
769248355	rs776746	tipifarnib	Other,Metabolism/PK	no	Allele T is not associated with decreased metabolism of tipifarnib.			= 0.52	Unknown			
981501615	NAT2*6A	sulfapyridine	Metabolism/PK	yes	NAT2 *6A/*6A is associated with decreased metabolism of sulfapyridine in healthy individuals.			< 0.05	Unknown			
981501615	NAT2*6A	sulfapyridine	Metabolism/PK	yes	NAT2 *6A/*6A is associated with decreased metabolism of sulfapyridine in healthy individuals.			< 0.05	Unknown			
981501880	rs3814055	carbamazepine	Metabolism/PK	yes	Allele T is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to allele C.			= 0.04	Unknown			
981501880	rs3814055	carbamazepine	Metabolism/PK	yes	Allele T is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to allele C.				Unknown			
1043859014	CYP2C19*3	metoprolol	Metabolism/PK	no	CYP2C19 *3 is not associated with decreased clearance of metoprolol as compared to CYP2C19 *1.				Unknown			
981501404	NAT2*4	sulfasalazine	Metabolism/PK	no	NAT2 *4/*4 is not associated with clearance of sulfasalazine in healthy individuals.				Unknown			
1183631242	CYP2D6*1	clozapine	Metabolism/PK	no	CYP2D6 *1 is not associated with metabolism of clozapine in people with Schizophrenia.				Unknown			
981345093	CYP2C9*3	warfarin	Metabolism/PK	yes	CYP2C9 *3 is associated with decreased dose of warfarin in people with Cardiovascular Diseases.	*3			Unknown			
1183622033	CYP2C19*1	mephenytoin	Metabolism/PK	not stated	CYP2C19 *1/*1 is associated with increased metabolism of mephenytoin in healthy individuals.				Unknown			
982015573	rs13280604	nicotine	Efficacy,Other	yes	Allele G is associated with increased response to nicotine in smokers as compared to allele A.			< 0.007	Unknown			
982015573	rs13280604	nicotine	Efficacy,Other	yes	Allele G is associated with increased response to nicotine in smokers as compared to allele A.			= 0.044	Unknown			
982047409	CYP2C9*1	warfarin	Dosage,Metabolism/PK	not stated	CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *2/*2.			< 0.001	Unknown			
1451098100	rs34130495	sumatriptan	Metabolism/PK	yes	Allele A (assigned as low activity phenotype) is associated with increased exposure to sumatriptan in healthy individuals as compared to allele G (assigned as high activity phenotype) .			= 3.1e-4	OR			
1451101175	rs79983226	tramadol	Metabolism/PK	not stated	Allele C is associated with decreased metabolism of tramadol as compared to allele G.	C		= 1.703E-11				
1451101175	rs79983226	tramadol	Metabolism/PK	not stated	Allele C is associated with decreased metabolism of tramadol as compared to allele G.			> 0.05				
1451098090	rs34130495	fenoterol	Metabolism/PK	yes	Allele A are associated with increased exposure to fenoterol in healthy individuals as compared to allele G.			= 4e-6	OR			
1448266722	rs4646440	carbamazepine	Metabolism/PK	no	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.			= 0.765	OR			
982023752	NAT2*4	caffeine	Metabolism/PK	yes	NAT2 *4 is associated with increased metabolism of caffeine in healthy individuals.			= 1.0E-4	Unknown			
982023752	NAT2*4	caffeine	Metabolism/PK	yes	NAT2 *4 is associated with increased metabolism of caffeine in healthy individuals.			= 0.02	Unknown			
981794086	rs4742	gemcitabine	Efficacy,Toxicity	no	Genotype GG is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + AG.	G		= 0.729	HR	1.07	0.74	1.55
655388073	rs7294	warfarin	Dosage,Metabolism/PK	yes	Allele T is associated with increased dose of warfarin.			< 0.001	Unknown			
1448998441	rs3745274	efavirenz	Metabolism/PK	no	Genotype TT is associated with increased concentrations of efavirenz in women with HIV Infections as compared to genotype GG.				OR			
655388076	rs9934438	warfarin	Dosage,Metabolism/PK	yes	Allele A is associated with decreased dose of warfarin.			< 0.001	Unknown			
1444703287	rs2273697	tenofovir	Metabolism/PK	no	Genotypes AA + AG is not associated with concentrations of tenofovir in people with HIV Infections as compared to genotype GG.			= 0.984	OR			
1448104256	rs3745274	efavirenz	Metabolism/PK	yes	Genotype GG is associated with increased clearance of efavirenz in people with HIV Infections as compared to genotypes GT + TT.	G		= 0.041	OR			
1449188852	rs1799971	morphine	Dosage,Efficacy	yes	Genotype GG is associated with increased dose of morphine in people with Pain, Postoperative as compared to genotypes AA + AG.	G		< 0.05	OR			
769170863	rs28399499	efavirenz	Metabolism/PK	not stated	Allele C is associated with decreased metabolism of efavirenz in people with HIV Infections.				Unknown			
827848042	rs35979566	nevirapine	Toxicity,Metabolism/PK	no	Allele A is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele T.			= 0.83	Unknown			
769170865	rs4149056	pravastatin	Metabolism/PK	not stated	Allele C is associated with decreased metabolism of pravastatin in healthy individuals as compared to allele T.				Unknown			
981844204	rs35599367	erythromycin	Metabolism/PK	yes	Genotype AG is associated with decreased metabolism of erythromycin in people with Neoplasms as compared to genotype GG.	A		= 0.032	Unknown			
1449271551	rs1128503	methadone	Metabolism/PK	not stated	Genotype AG is associated with decreased concentrations of methadone.				OR			
981862045	CYP2C9*3	ibuprofen	Metabolism/PK	yes	CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.			< 0.001	Unknown			
981862045	CYP2C9*3	ibuprofen	Metabolism/PK	yes	CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.			< 0.001	Unknown			
981862045	CYP2C9*3	ibuprofen	Metabolism/PK	yes	CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.			< 0.001	Unknown			
982029511	CYP2D6*4	venlafaxine	Metabolism/PK	yes	CYP2D6 *4/*4 is associated with decreased metabolism of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.			< 0.05	Unknown			
1447680853	rs7668258	efavirenz	Metabolism/PK	no	Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	C		= 0.2885	OR			
827816329	rs45482602	methadone	Dosage,Metabolism/PK	no	Genotype AA is not associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype CC.	A			Unknown			
769250034	rs4244285	phenytoin	Other,Metabolism/PK	yes	Genotype AG is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype GG.	A		< 0.001	Unknown			
827848049	rs3892097	nevirapine	Toxicity,Metabolism/PK	no	Allele T is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele C.			= 0.39	Unknown			
769235413	rs2069526	leflunomide	Other,Metabolism/PK	no	Allele G is not associated with metabolism of leflunomide in people with Arthritis as compared to genotype TT.				Unknown			
769218883	rs762551	clozapine	Other,Metabolism/PK	no	Genotype AA is not associated with metabolism of clozapine.			= 0.38	Unknown			
827566674	rs2018417	ethanol	Toxicity,Metabolism/PK	yes	Allele A is associated with metabolism of ethanol.	A	C	= 0.015	Unknown			
1448105627	rs9024	doxorubicin	Metabolism/PK	yes	Genotype GG is associated with decreased exposure to doxorubicin in people with Breast Neoplasms as compared to genotype AG.	G	G	= 0.024	OR			
827698457	CYP1A2*1F	caffeine	Metabolism/PK	yes	CYP1A2 *1F/*1F is associated with increased metabolism of caffeine in people with Tobacco Use Disorder.	*1F		= 0.02	Unknown			
827698390	CYP1A2*1K	caffeine	Metabolism/PK	yes	CYP1A2 *1K is associated with decreased metabolism of caffeine in healthy individuals.	*1K		< 0.02	Unknown			
827698827	CYP2A6*4C	tegafur	Metabolism/PK	not stated	CYP2A6 *4C is associated with decreased metabolism of tegafur in people with Stomach Neoplasms.				Unknown			
827698809	CYP2A6*1B1	tegafur	Metabolism/PK	no	CYP2A6 *1B1 is associated with increased metabolism of tegafur.	*1B1		= 0.1308	Unknown			
827807143	CYP2C19*17	carvedilol	Other,Metabolism/PK	no	CYP2C19 *17/*17 is not associated with metabolism of carvedilol in healthy individuals.				Unknown			
827824071	rs2234922	carbamazepine	Dosage,Metabolism/PK	no	Allele G is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele A.	A			Unknown			
1449295921	rs4680	morphine	Dosage,Efficacy	no	Allele G is not associated with dose of morphine in people with Pain, Postoperative as compared to allele A.	A			OR			
827823858	rs2472677	nevirapine	Dosage,Metabolism/PK	no	Genotypes CT + TT are not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype CC.			= 0.3883	Unknown			
1450045199	rs2900476	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	C		> 0.0001	OR			
1450045223	rs2417955	methotrexate	Metabolism/PK	no	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	A		> 0.0001	OR			
1450045235	rs10444413	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	C		> 0.0001	OR			
1450045229	rs4149035	methotrexate	Metabolism/PK	no	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	T		> 0.0001	OR			
1449271576	rs1045642	S-EDDP	Metabolism/PK	not stated	Genotype AG is associated with increased concentrations of (S)-EDDP.				OR			
1449733152	rs16980091	rosuvastatin	Metabolism/PK	yes	Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele C.			= 0.04	OR			
1449733162	rs17216198	rosuvastatin	Metabolism/PK	yes	Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele C.			= 0.015	OR			
1449733189	rs17216177	rosuvastatin	Metabolism/PK	yes	Allele C is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele T.			= 0.006	OR			
827824096	rs2032582	carbamazepine	Dosage,Metabolism/PK	no	Allele T is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.	C			Unknown			
1185235665	CYP2C19 poor metabolizers	atomoxetine	Metabolism/PK	yes	CYP2C19 poor metabolizers are associated with increased concentrations of atomoxetine as compared to CYP2C19 intermediate metabolizer and normal metabolizer.			< 0.001	OR			
978639890	rs3750117	gemcitabine	Other,Metabolism/PK	yes	Genotype AA is associated with increased clearance of gemcitabine in people with Neoplasms as compared to genotype GG.			= 0.02	Unknown			
827783829	CYP2B6*5	propofol	Other,Metabolism/PK	no	CYP2B6 *5 is not associated with metabolism of propofol.				Unknown			
827783826	CYP2B6*9	propofol	Other,Metabolism/PK	no	CYP2B6 *9 is not associated with metabolism of propofol.				Unknown			
827824182	rs28365062	carbamazepine	Dosage,Metabolism/PK	no	Allele G is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele A.	G			Unknown			
827830265	rs1045642	tacrolimus	Dosage,Metabolism/PK	no	Allele G is not associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to allele A.	G			Unknown			
827784616	rs11045585	docetaxel	Other,Metabolism/PK	yes	Allele G is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms.			= 0.025	Unknown			
1449557344	rs11574077	irinotecan	Metabolism/PK	yes	Genotype TT is associated with increased metabolism of irinotecan in people with Colorectal Neoplasms as compared to genotype CT.	C	T	= 0.012	OR			
1449557344	rs11574077	irinotecan	Metabolism/PK	yes	Genotype TT is associated with increased metabolism of irinotecan in people with Colorectal Neoplasms as compared to genotype CT.	C	T	= 0.036	OR			
1183620362	rs2032582	risperidone	Metabolism/PK	no	Allele C is not associated with increased metabolism of risperidone in people with Schizophrenia as compared to allele A.	C			Unknown			
1448567737	rs4253728	sirolimus	Metabolism/PK	no	Genotype GG are not associated with metabolism of sirolimus in people with Kidney Transplantation as compared to genotypes AA + AG.				OR			
981502148	CYP2B6*6	mirtazapine	Metabolism/PK	yes	CYP2B6 *6/*6 is associated with increased metabolism of mirtazapine in people with Depression.			= 0.01	Unknown			
981501598	NAT2*5B	sulfapyridine	Metabolism/PK	yes	NAT2 *5B/*5B is associated with decreased metabolism of sulfapyridine in healthy individuals.			< 0.05	Unknown			
981501598	NAT2*5B	sulfapyridine	Metabolism/PK	yes	NAT2 *5B/*5B is associated with decreased metabolism of sulfapyridine in healthy individuals.			< 0.05	Unknown			
981501619	NAT2*7B	sulfapyridine	Metabolism/PK	yes	NAT2 *7B/*7B is associated with decreased metabolism of sulfapyridine in healthy individuals.			< 0.05	Unknown			
981501619	NAT2*7B	sulfapyridine	Metabolism/PK	yes	NAT2 *7B/*7B is associated with decreased metabolism of sulfapyridine in healthy individuals.			< 0.05	Unknown			
981239981	rs1051740	carbamazepine	Dosage,Metabolism/PK	yes	Allele C is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele T.	C		= 0.0241	Unknown			
1451116362	rs11045819	lopinavir	Metabolism/PK	no	Allele A is not associated with trough concentration of lopinavir in people with HIV Infections as compared to allele C.	A		= 0.005				
1451116362	rs11045819	lopinavir	Metabolism/PK	no	Allele A is not associated with trough concentration of lopinavir in people with HIV Infections as compared to allele C.	A		= 0.262				
981345416	rs1042713	terbutaline	Metabolism/PK	no	Genotype AA is not associated with increased response to terbutaline in healthy individuals as compared to genotypes AG + GG.	A			Unknown			
981240151	rs4646244	isoniazid	Toxicity,Metabolism/PK	yes	Genotype AT is associated with decreased clearance of isoniazid in people with Tuberculosis as compared to genotype TT.			= 0.001	Unknown			
1449716606	rs1799971	fentanyl	Dosage,Efficacy	yes	Genotype GG is associated with increased dose of fentanyl in women with Pain, Postoperative as compared to genotypes AA + AG.	G		= 0.04	OR			
981419964	rs2032582	antipsychotics	Dosage,Metabolism/PK	yes	Genotype CC is associated with increased dose of antipsychotics in people with Schizophrenia as compared to genotype AA.			= 0.0093	Unknown			
981345061	CYP2C9*2	warfarin	Metabolism/PK	yes	CYP2C9 *2 is associated with decreased dose of warfarin in people with Cardiovascular Diseases.	*2			Unknown			
981939860	NAT2*4	isoniazid	Metabolism/PK	yes	NAT2 *4 is associated with increased metabolism of isoniazid in healthy individuals.			< 0.05	OR	7.78	0.87	87.97
981794008	rs183484	gemcitabine	Efficacy,Toxicity	yes	Genotype AC is associated with decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + CC.	A		= 0.042	HR	1.46	1.02	2011.0
981750833	rs1051730	nicotine	Metabolism/PK	yes	Allele A is associated with increased dose of nicotine as compared to allele G.	A		= 4.7E-5	Unknown			
981851591	NAT2*4	isoniazid	Metabolism/PK	yes	NAT2 *4/*4 is associated with increased metabolism of isoniazid in people with Tuberculosis.	*4		= 1.6E-4	Unknown			
981851586	NAT2*4	isoniazid	Metabolism/PK	yes	NAT2 *4/*4 is associated with increased metabolism of isoniazid in people with Tuberculosis.	*4		= 4.2E-4	Unknown			
981862010	CYP2C9*2	ibuprofen	Metabolism/PK	no	CYP2C9 *2 is not associated with clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.				Unknown			
981862049	CYP2C8*3	ibuprofen	Metabolism/PK	yes	CYP2C8 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C8 *1A.			< 0.001	Unknown			
981862049	CYP2C8*3	ibuprofen	Metabolism/PK	yes	CYP2C8 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C8 *1A.			< 0.001	Unknown			
981862049	CYP2C8*3	ibuprofen	Metabolism/PK	yes	CYP2C8 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C8 *1A.			= 0.002	Unknown			
827785547	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.			= 0.011	Unknown			
827699040	rs776746	tacrolimus	Efficacy,Metabolism/PK	not stated	Genotype CT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T			Unknown			
982015587	rs13280604	ethanol	Dosage,Efficacy	no	Allele G is not associated with increased response to ethanol as compared to allele A.				Unknown			
827813960	rs776746	cyclosporine	Dosage,Metabolism/PK	no	Allele C is not associated with clearance of cyclosporine in people with Kidney Transplantation as compared to allele T.	C			Unknown			
1043859395	CYP2D6*10	metoprolol	Metabolism/PK	yes	CYP2D6 *10 is associated with decreased metabolism of metoprolol in healthy individuals as compared to CYP2D6 *1.	*10		< 0.05	Unknown			
1043859002	CYP2D6*2	metoprolol	Metabolism/PK	no	CYP2D6 *2 is not associated with decreased clearance of metoprolol as compared to CYP2D6 *1.	*2			Unknown			
1043859008	CYP2C19*2	metoprolol	Metabolism/PK	no	CYP2C19 *2 is not associated with decreased clearance of metoprolol as compared to CYP2C19 *1.				Unknown			
1043858995	CYP2D6*10	metoprolol	Metabolism/PK	yes	CYP2D6 *10 is associated with decreased clearance of metoprolol as compared to CYP2D6 *1.	*10			Unknown			
1184470178	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotype CC.	C		< 0.001	OR			
1184470178	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotype CC.	C		< 0.01	OR			
982033292	rs1799853	warfarin	Dosage,Efficacy,Toxicity	not stated	Allele T is associated with decreased dose of warfarin as compared to allele C.				OR	6.21	2.48	15.6
1043859140	CYP2D6*2	metoprolol	Toxicity,Metabolism/PK	no	CYP2D6 *2 is not associated with decreased metabolism of metoprolol in people with Hypertension as compared to CYP2D6 *1.			< 0.007	Unknown			
1183617585	CYP2D6*1	clozapine	Metabolism/PK	no	CYP2D6 *1 is not associated with metabolism of clozapine in people with Schizophrenia.				Unknown			
1183619871	CYP2C19*1	omeprazole	Metabolism/PK	no	CYP2C19 *1/*1 is not associated with metabolism of omeprazole in people with Gastroesophageal Reflux.	*2		= 0.97	Unknown			
1183629465	CYP2D6*2xN	debrisoquine	Metabolism/PK	not stated	CYP2D6 *2xN is associated with increased metabolism of debrisoquine.				Unknown			
1446900797	rs1695	gemcitabine	Metabolism/PK	no	Allele G is not associated with clearance of gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	G		< 1.0E-5	OR			
1184514835	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	C		< 0.05	OR			
1450374166	CYP2D6 poor and ultrarapid metabolizers	(S)-methadone	Metabolism/PK	no	CYP2D6 poor and ultrarapid metabolizers are not associated with concentrations of (S)-methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizers.			= 0.79	OR			
1450374166	CYP2D6 poor and ultrarapid metabolizers	(S)-methadone	Metabolism/PK	no	CYP2D6 poor and ultrarapid metabolizers are not associated with concentrations of (S)-methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizers.			= 0.95	OR			
982036394	rs776746	amlodipine	Metabolism/PK	no	Genotype CC is not associated with clearance of amlodipine in healthy individuals as compared to genotypes CT + TT.	C		= 0.063	Unknown			
982044327	CYP2D6*10	carvedilol	Metabolism/PK	yes	CYP2D6 *10/*10 is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to CYP2D6 *1/*1.			< 0.001	Unknown			
1448997449	rs3745274	efavirenz	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.			< 0.05	OR			
1184515029	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotype CT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	T		= 0.01	OR			
1184515181	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T		= 0.003	OR			
1183703481	CYP2C19 poor metabolizer	fluvoxamine	Metabolism/PK	no	CYP2C19 poor metabolizer is not associated with clearance of fluvoxamine in healthy individuals as compared to CYP2C19 normal metabolizer.			= 0.033	OR			
1183622460	rs4646427	escitalopram	Metabolism/PK	yes	Allele C is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele T.			= 0.05	Unknown			
1183623082	CYP2D6*4	amitriptyline	Toxicity,Metabolism/PK	not stated	CYP2D6 *4/*4 is associated with decreased clearance of amitriptyline in one suicide case.				Unknown			
1183617637	CYP2D6*1	clozapine	Metabolism/PK	no	CYP2D6 *1 is not associated with metabolism of clozapine in healthy individuals.				Unknown			
1184514498	rs776746	tacrolimus	Other,Metabolism/PK	yes	Genotype CT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	C		< 0.04	OR			
1184515270	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	C		< 0.001	OR			
1183700614	rs1057910	warfarin	Dosage,Efficacy	yes	Genotypes AC + CC is associated with decreased dose of warfarin in men as compared to genotype AA.	C		< 0.001	OR			
1184514537	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.			< 0.05	OR			
1183682179	CYP2D6 poor metabolizers	imipramine	Metabolism/PK	not stated	CYP2D6 poor metabolizers is associated with decreased clearance of imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.			< 0.01	OR			
1183682179	CYP2D6 poor metabolizers	imipramine	Metabolism/PK	not stated	CYP2D6 poor metabolizers is associated with decreased clearance of imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.			< 0.05	OR			
1183689638	CYP2D6 poor metabolizers	tolterodine	Metabolism/PK	yes	CYP2D6 poor metabolizers are associated with decreased clearance of tolterodine in healthy individuals as compared to CYP2D6 normal metabolizers.			< 0.001	OR			
1183684364	CYP2C19 poor metabolizers	imipramine	Metabolism/PK	yes	CYP2C19 poor metabolizers is associated with decreased clearance of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.			< 0.01	OR			
1183684364	CYP2C19 poor metabolizers	imipramine	Metabolism/PK	yes	CYP2C19 poor metabolizers is associated with decreased clearance of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.			< 0.05	OR			
1183698887	CYP2D6 poor metabolizers	nortriptyline	Metabolism/PK	yes	CYP2D6 poor metabolizers are associated with decreased metabolism of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.			< 0.05	OR			
1183690829	rs11545078	methotrexate	Efficacy,Toxicity	no	Genotype GG is not associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AG.	A		= 0.007	OR			
1184754437	rs2011425	lamotrigine	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes GG + GT.	G	T	< 0.000	OR			
1183682640	CYP2D6 normal metabolizer genotype	dextromethorphan	Metabolism/PK	yes	CYP2D6 normal metabolizer genotype is associated with increased metabolism of dextromethorphan in children as compared to CYP2D6 poor metabolizer genotype.			= 0.003	OR			
1451138485	rs482387	methadone	Metabolism/PK	no	Genotype AA is not associated with concentrations of methadone as compared to genotypes AG + GG.	G		= 0.043				
1451138489	rs508448	methadone	Metabolism/PK	no	Genotype GG is not associated with concentrations of methadone as compared to genotypes AA + AG.	A		= 0.678				
1183682332	rs316019	metformin	Metabolism/PK	yes	Genotype CC is associated with increased clearance of metformin in healthy individuals as compared to genotype AC.	A		= 0.005	OR			
1183682332	rs316019	metformin	Metabolism/PK	yes	Genotype CC is associated with increased clearance of metformin in healthy individuals as compared to genotype AC.	A		= 0.007	OR			
1183682332	rs316019	metformin	Metabolism/PK	yes	Genotype CC is associated with increased clearance of metformin in healthy individuals as compared to genotype AC.	A		= 0.012	OR			
1183684640	CYP2D6 ultrarapid metabolizer genotype	tramadol	Metabolism/PK	yes	CYP2D6 ultra-metabolizer genotype is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer genotype.			= 0.005	OR			
1444706064	rs776746	tacrolimus	Metabolism/PK	yes	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.				OR			
1183682189	CYP2D6 poor metabolizers	desipramine	Metabolism/PK	not stated	CYP2D6 poor metabolizers is associated with decreased clearance of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.			< 0.01	OR			
1183682189	CYP2D6 poor metabolizers	desipramine	Metabolism/PK	not stated	CYP2D6 poor metabolizers is associated with decreased clearance of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.			< 0.01	OR			
1183682248	rs776746	nifedipine	Metabolism/PK	yes	Genotypes CT + TT are associated with increased clearance of nifedipine in women with Pregnancy as compared to genotype CC.			= 0.000095	OR			
1183682248	rs776746	nifedipine	Metabolism/PK	yes	Genotypes CT + TT are associated with increased clearance of nifedipine in women with Pregnancy as compared to genotype CC.			= 0.002	OR			
1183682248	rs776746	nifedipine	Metabolism/PK	yes	Genotypes CT + TT are associated with increased clearance of nifedipine in women with Pregnancy as compared to genotype CC.			= 0.02	OR			
1183683979	CYP2D6 normal metabolizer phenotype	hydrocodone	Metabolism/PK	no	CYP2D6 normal metabolizer phenotype is associated with increased metabolism of hydrocodone as compared to CYP2D6 poor metabolizer phenotype.				OR			
1183697428	rs2032582	axitinib	Metabolism/PK	no	Genotype CC is not associated with metabolism of axitinib in healthy individuals.			= 0.49	OR			
1183697477	rs4149056	axitinib	Metabolism/PK	no	Genotype CC is not associated with metabolism of axitinib in healthy individuals as compared to genotypes CT + TT.			= 1	OR			
1183699447	rs4646437	risperidone	Metabolism/PK	no	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele G.	A			OR			
1448107849	rs776746	docetaxel	Metabolism/PK	yes	Allele T is associated with increased clearance of docetaxel in people with Neoplasms as compared to allele C.	T	C	= 0.020	OR			
1184998389	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	C		< 0.01	OR			
1183704875	rs11045819	rifampin	Metabolism/PK	not stated	Genotype AC is associated with increased clearance of rifampin in healthy individuals as compared to genotype CC.				OR			
1184137275	CYP2C19 poor metabolizers	escitalopram	Metabolism/PK	yes	CYP2C19 poor metabolizers is associated with decreased metabolism of escitalopram as compared to CYP2C19 normal metabolizers.			= 0.002	OR			
1184137275	CYP2C19 poor metabolizers	escitalopram	Metabolism/PK	yes	CYP2C19 poor metabolizers is associated with decreased metabolism of escitalopram as compared to CYP2C19 normal metabolizers.			= 0.0026	OR			
1184137275	CYP2C19 poor metabolizers	escitalopram	Metabolism/PK	yes	CYP2C19 poor metabolizers is associated with decreased metabolism of escitalopram as compared to CYP2C19 normal metabolizers.			= 0.0046	OR			
1184137275	CYP2C19 poor metabolizers	escitalopram	Metabolism/PK	yes	CYP2C19 poor metabolizers is associated with decreased metabolism of escitalopram as compared to CYP2C19 normal metabolizers.			= 0.0046	OR			
982047415	CYP2C9*1	warfarin	Dosage,Metabolism/PK	not stated	CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *2/*3.			< 0.001	Unknown			
1449171084	rs8192719	methadone	Metabolism/PK	no	Allele T is not associated with concentrations of methadone as compared to allele C.	T	T		OR			
982047403	CYP2C9*1	warfarin	Dosage,Metabolism/PK	no	CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *1/*2.			= 0.28	Unknown			
1183704865	rs2306283	rifampin	Metabolism/PK	not stated	Genotype GG is associated with decreased clearance of rifampin in healthy individuals as compared to genotypes AA + AG.				OR			
1451140400	NAT2 slow acetylator	hydralazine	Metabolism/PK	yes	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in men with Hypertension as compared to NAT2 rapid acetylator.			< 0.001				
1448997218	rs3745274	efavirenz	Metabolism/PK	yes	Genotypes GT + TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.			< 0.0001	OR			
1183703398	CYP2D6 poor metabolizers	pridopidine	Metabolism/PK	yes	CYP2D6 poor metabolizers are associated with decreased metabolism of pridopidine in healthy individuals as compared to CYP2D6 normal metabolizers.			< 0.001	OR			
1183703398	CYP2D6 poor metabolizers	pridopidine	Metabolism/PK	yes	CYP2D6 poor metabolizers are associated with decreased metabolism of pridopidine in healthy individuals as compared to CYP2D6 normal metabolizers.			< 0.001	OR			
1183703398	CYP2D6 poor metabolizers	pridopidine	Metabolism/PK	yes	CYP2D6 poor metabolizers are associated with decreased metabolism of pridopidine in healthy individuals as compared to CYP2D6 normal metabolizers.			< 0.001	OR			
1183703398	CYP2D6 poor metabolizers	pridopidine	Metabolism/PK	yes	CYP2D6 poor metabolizers are associated with decreased metabolism of pridopidine in healthy individuals as compared to CYP2D6 normal metabolizers.			< 0.001	OR			
1183703398	CYP2D6 poor metabolizers	pridopidine	Metabolism/PK	yes	CYP2D6 poor metabolizers are associated with decreased metabolism of pridopidine in healthy individuals as compared to CYP2D6 normal metabolizers.			= 0.012	OR			
1183703398	CYP2D6 poor metabolizers	pridopidine	Metabolism/PK	yes	CYP2D6 poor metabolizers are associated with decreased metabolism of pridopidine in healthy individuals as compared to CYP2D6 normal metabolizers.			= 0.028	OR			
1184473233	rs8192709	efavirenz	Metabolism/PK	yes	Genotype CC is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype CT.			= 0.012	OR			
1448098938	rs1128503	lamotrigine	Metabolism/PK	no	Genotype GG are associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes AA + AG.	A		= 0.033	OR			
1184349353	rs3745274	nevirapine	Metabolism/PK	no	Genotypes GT + TT is not associated with metabolism of nevirapine in people with HIV Infections as compared to genotype GG.			= 0.087	OR			
1448602097	rs2266782	nicotine	Metabolism/PK	no	Allele G is not associated with metabolism of nicotine in people with Tobacco Use Disorder as compared to allele A.	G		= 0.11	OR			
1448602091	rs2266782	cotinine	Metabolism/PK	no	Allele G is not associated with metabolism of cotinine in people with Tobacco Use Disorder as compared to allele A.	G		= 0.09	OR			
1184470358	rs4823613	tacrolimus	Metabolism/PK	yes	Allele G is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele A.	G	A	= 0.02	OR			
1184516561	TPMT low activity	azathioprine	Metabolism/PK	yes	TPMT low activity phenotype is associated with decreased dose of azathioprine as compared to TPMT high activity phenotype.			< 0.001	OR			
1184754582	rs3814058	repaglinide	Metabolism/PK	yes	Genotype CC is associated with increased metabolism of repaglinide in men as compared to genotype TT.	C	T	= 0.0009	OR			
1448266521	rs2229109	risperidone	Metabolism/PK	no	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T.			= 0.02	OR			
1184754844	rs776746	sunitinib	Metabolism/PK	yes	Genotype CC is associated with decreased clearance of sunitinib as compared to genotypes CT + TT.			= 0.01	OR			
1184470196	rs11584174	tacrolimus	Metabolism/PK	no	Allele C is not associated with metabolism of tacrolimus in people with liver transplantation as compared to allele T.	C			OR			
1184470196	rs11584174	tacrolimus	Metabolism/PK	no	Allele C is not associated with metabolism of tacrolimus in people with liver transplantation as compared to allele T.	C			OR			
1184470208	rs55802895	tacrolimus	Metabolism/PK	no	Allele C is not associated with metabolism of tacrolimus in people with liver transplantation as compared to allele T.	C			OR			
1184470208	rs55802895	tacrolimus	Metabolism/PK	no	Allele C is not associated with metabolism of tacrolimus in people with liver transplantation as compared to allele T.	C			OR			
1183959847	rs2032582	tacrolimus	Toxicity,Metabolism/PK	no	Genotypes CC + CT is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes AC + AT.	A		> 0.05	OR			
827816224	rs1045642	methadone	Dosage,Metabolism/PK	yes	Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.	G		< 1.0E-4	OR	7.95	2.96	21.33
1184755585	rs2266782	itopride	Metabolism/PK	yes	Genotype AA is associated with decreased metabolism of itopride in healthy individuals as compared to genotype GG.			< 0.001	OR			
1448099986	rs9282564	tacrolimus	Metabolism/PK	no	Genotype CT is associated with increased concentrations of tacrolimus in people with lung transplantation as compared to genotype TT.	C		= 0.036	OR			
982035840	rs1045642	verapamil	Metabolism/PK	yes	Genotype GG is associated with decreased metabolism of verapamil in healthy individuals as compared to genotypes AA + AG.			< 0.03	Unknown			
1184514719	rs776746	tacrolimus	Metabolism/PK	yes	Genotypes CT + TT is associated with increased clearance of tacrolimus in people with liver transplantation as compared to genotype CC.	T			OR			
1449188430	rs3778152	cotinine	Metabolism/PK	yes	Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A.	G		= 0.006	OR			
1184511088	rs1045642	donepezil	Metabolism/PK	no	Genotype GG is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype AA.			> 0.01	OR			
1184514528	rs776746	tacrolimus	Dosage,Metabolism/PK	yes	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.			< 0.024	OR			
1184514665	rs776746	tacrolimus	Metabolism/PK	no	Allele T is not associated with metabolism of tacrolimus in people with heart transplantation as compared to allele C.			> 0.05	OR			
1448997587	rs70950385	efavirenz	Metabolism/PK	yes	Genotype CA/CA is associated with decreased metabolism of efavirenz in healthy individuals as compared to genotype AG/AG.	CA		< 0.05	OR			
1449163317	rs4253730	tacrolimus	Metabolism/PK	no	Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.				OR			
1444696308	rs71647871	clopidogrel	Metabolism/PK	yes	Genotypes CT + TT are associated with increased exposure to clopidogrel in healthy individuals as compared to genotype CC.			= 0.009	OR	1.67	1.23	2.26
1444711202	CYP2D6 intermediate metabolizers	endoxifen	Metabolism/PK	yes	CYP2D6 intermediate metabolizers are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.			< 0.0001	OR			
1444711202	CYP2D6 intermediate metabolizers	endoxifen	Metabolism/PK	yes	CYP2D6 intermediate metabolizers are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.			< 0.0001	OR			
1444711202	CYP2D6 intermediate metabolizers	endoxifen	Metabolism/PK	yes	CYP2D6 intermediate metabolizers are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.			< 0.0001	OR			
1444711202	CYP2D6 intermediate metabolizers	endoxifen	Metabolism/PK	yes	CYP2D6 intermediate metabolizers are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.			< 0.0001	OR			
1444711202	CYP2D6 intermediate metabolizers	endoxifen	Metabolism/PK	yes	CYP2D6 intermediate metabolizers are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.			< 0.0001	OR			
1444711202	CYP2D6 intermediate metabolizers	endoxifen	Metabolism/PK	yes	CYP2D6 intermediate metabolizers are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.			= 0.0004	OR			
1444711202	CYP2D6 intermediate metabolizers	endoxifen	Metabolism/PK	yes	CYP2D6 intermediate metabolizers are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.			= 0.0016	OR			
1444711202	CYP2D6 intermediate metabolizers	endoxifen	Metabolism/PK	yes	CYP2D6 intermediate metabolizers are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.			= 0.033	OR			
1185234754	rs1045642	clopidogrel	Metabolism/PK	yes	Genotype AA is associated with decreased exposure to clopidogrel as compared to genotypes AG + GG.			= 0.012	OR			
1185023386	rs4253728	tacrolimus	Metabolism/PK	no	Allele A is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to allele G.	A		= 0.05	OR			
1185023386	rs4253728	tacrolimus	Metabolism/PK	no	Allele A is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to allele G.	A			OR			
1444828207	CYP2C19*2	voriconazole	Metabolism/PK	not stated	CYP2C19 *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with increased concentrations of voriconazole.				OR			
1448612336	rs1045642	tacrolimus	Metabolism/PK	no	Genotype GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Arthritis, Rheumatoid or Lupus Erythematosus, Systemic as compared to genotypes AA + AG.	A		< 0.05	OR			
1448573364	rs1045642	tacrolimus	Metabolism/PK	no	Genotypes AG + GG are not associated with metabolism of tacrolimus in people with Colitis, Ulcerative as compared to genotype AA.	A			OR			
1449171488	rs1045642	opioids	Dosage,Efficacy	yes	Genotype AA is associated with decreased dose of opioids in people with Pain, Postoperative as compared to genotypes AG + GG.	A		= 0.041	OR			
1444828173	CYP2C19*17	voriconazole	Metabolism/PK	not stated	CYP2C19 *17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased concentrations of voriconazole.				OR			
1444935576	rs3738046	carbamazepine	Metabolism/PK	yes	Genotype CG is associated with concentrations of carbamazepine in people with Epilepsy as compared to genotype GG.	C		= 0.017	OR			
981238227	rs1128503	antipsychotics	Dosage,Metabolism/PK	yes	Genotype AA is associated with increased dose of antipsychotics in people with Schizophrenia.			= 0.033	Unknown			
1448636673	rs1128503	everolimus	Metabolism/PK	no	Genotypes AA + AG are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype GG.	A	G	> 0.05	OR			
1444935858	rs846908	tacrolimus	Metabolism/PK	yes	Genotype AA is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	A		= 0.0204	OR			
1447680831	rs776746	efavirenz	Metabolism/PK	no	Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	C		= 0.1855	OR			
1446896579	rs2472304	erlotinib	Metabolism/PK	yes	Genotypes AA + AG is associated with increased concentrations of erlotinib in healthy individuals as compared to genotype GG.	A		= 0.015	OR			
1446767367	rs2291834	vancomycin	Metabolism/PK	no	Allele T is not associated with trough concentration of vancomycin as compared to allele C.	T	C	= 0.01	OR			
1448820619	rs2032582	tacrolimus	Metabolism/PK	yes	Allele T is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation.	A		< 0.05	OR			
1448573370	rs2032582	tacrolimus	Metabolism/PK	no	Genotype AA is not associated with metabolism of tacrolimus in people with Colitis, Ulcerative.	C			OR			
1446899459	rs71647871	enalapril	Metabolism/PK	no	Genotype CT is not associated with clearance of enalapril in healthy individuals as compared to genotype CC.	C	T	= 0.178	OR			
1444841854	CYP2D6 poor metabolizer genotype	perphenazine	Metabolism/PK	yes	CYP2D6 poor metabolizer genotype is associated with increased concentrations of perphenazine as compared to CYP2D6 normal metabolizer genotype.			< 0.01	OR			
1446906141	rs4646437	voriconazole	Metabolism/PK	yes	Genotype AG is associated with increased concentrations of voriconazole in people with Mycoses as compared to genotype GG.	A		= 0.033	OR	2.832	1.086	7.384
1446907896	rs2279343	cyclophosphamide	Metabolism/PK	no	Allele G is not associated with metabolism of cyclophosphamide in people with as compared to allele A.	G	A	= 0.683	OR			
1447680419	rs717620	efavirenz	Metabolism/PK	no	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes CC + CT.	C		= 0.175	OR			
1447947823	rs72558187	irbesartan	Metabolism/PK	yes	Genotype CT is associated with decreased metabolism of irbesartan in healthy individuals as compared to genotype TT.			< 0.001	OR			
1447947823	rs72558187	irbesartan	Metabolism/PK	yes	Genotype CT is associated with decreased metabolism of irbesartan in healthy individuals as compared to genotype TT.			< 0.01	OR			
1447676158	rs246221	cyclophosphamide	Efficacy,Toxicity,Metabolism/PK	no	Genotype CC is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype CT.	C		= 0.73	OR			
1447947627	CYP3A5 deficiency	atazanavir	Metabolism/PK	no	CYP3A5 deficiency is not associated with concentrations of atazanavir in people with HIV as compared to CYP3A5 non-deficient.			= 0.14	OR			
1184470054	rs4244285	clopidogrel	Dosage,Efficacy	yes	Genotypes AA + AG is associated with dose of clopidogrel in people with percutaneous coronary intervention as compared to genotype GG.	A		= 0.03	OR			
1448266503	rs2032582	risperidone	Metabolism/PK	no	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele A.			= 0.02	OR			
1448266474	rs2472677	risperidone	Metabolism/PK	no	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T.			= 0.02	OR			
1448266530	rs1045642	risperidone	Metabolism/PK	no	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.			= 0.02	OR			
1448266728	rs2242480	carbamazepine	Metabolism/PK	no	Allele C is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele T.			= 0.723	OR			
1447986082	rs2740574	lopinavir	Metabolism/PK	no	Genotypes CT + TT is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype CC.	C			OR			
1448265740	rs2032582	azithromycin	Metabolism/PK	yes	Genotype AA is associated with decreased concentrations of azithromycin in healthy individuals as compared to genotype CC.	A		= 0.013	OR			
1183622472	rs3743484	escitalopram	Metabolism/PK	no	Allele C is not associated with metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele G.			> 0.05	Unknown			
1184473337	rs28399454	efavirenz	Metabolism/PK	no	Allele T is not associated with metabolism of efavirenz in people with HIV Infections as compared to allele C.	T		= 0.001	OR			
827848949	rs28399499	nevirapine	Toxicity,Metabolism/PK	no	Genotype CC is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes CT + TT.				Unknown			
1448262619	rs1127354	azathioprine	Metabolism/PK	yes	Genotype AC is associated with increased metabolism of azathioprine in people with Inflammatory Bowel Diseases as compared to genotype CC.			= 0.051	OR			
1450936706	rs17376019	acetaldehyde	Metabolism/PK	no	Genotype CT is not associated with concentrations of acetaldehyde in healthy individuals as compared to genotype CC.	C		> 0.2422				
1184512504	rs3003596	efavirenz	Metabolism/PK	yes	Genotype GG is associated with increased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.			= 0.015	OR			
1446896361	CYP2D6 ultrarapid metabolizer genotype	ondansetron	Metabolism/PK	no	CYP2D6 ultrarapid metabolizer genotype is not associated with increased concentrations of ondansetron as compared to CYP2D6 normal metabolizer genotype.				OR			
1448104433	rs1128503	methadone	Metabolism/PK	yes	Genotype AG is associated with increased concentrations of methadone in men with Opioid-Related Disorders as compared to genotypes AA + GG.	A		= 0.033	OR			
1448124372	rs17376848	fluorouracil	Metabolism/PK	yes	Genotypes AG + GG is associated with increased concentrations of fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.			= 0.01	OR			
1448124372	rs17376848	fluorouracil	Metabolism/PK	yes	Genotypes AG + GG is associated with increased concentrations of fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.			= 0.046	OR			
1448423969	rs1128503	tacrolimus	Metabolism/PK	no	Allele A is not associated with metabolism of tacrolimus in people with liver transplantation as compared to allele G.				OR			
1449003516	rs28399499	lumefantrine	Metabolism/PK	no	Allele C is not associated with concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele T.			= 0.85	OR			
1448635307	rs2231142	sorafenib	Metabolism/PK	yes	Genotype GT is associated with concentrations of sorafenib in people with Carcinoma, Hepatocellular as compared to genotype GG.	T		= 0.007	OR			
1448997456	rs2279343	efavirenz	Metabolism/PK	yes	Genotype GG is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes AA + AG.			< 0.05	OR			
1448997462	rs3745274	efavirenz	Metabolism/PK	yes	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.			< 0.01	OR			
1448636667	rs1045642	everolimus	Metabolism/PK	no	Genotypes AG + GG are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype AA.	A	G	> 0.05	OR			
1448636654	rs776746	everolimus	Metabolism/PK	no	Genotypes CT + TT are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype CC.	T	C	> 0.05	OR			
1448613164	rs1045642	imatinib	Metabolism/PK	yes	Genotype AA is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.	A	A	< 0.001	OR			
1448612414	rs17143212	talinolol	Metabolism/PK	no	Allele T is not associated with clearance of talinolol in healthy individuals as compared to allele C.	C			OR			
1448997381	rs776746	cyclosporine	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of cyclosporine in people with Kidney Transplantation as compared to genotypes CT + TT.	T		= 0.015	OR			
1448997408	rs2257401	cyclosporine	Metabolism/PK	yes	Genotype CC is associated with increased concentrations of cyclosporine in people with Kidney Transplantation as compared to genotypes CG + GG.	G		= 0.017	OR			
1448997416	rs4646437	cyclosporine	Metabolism/PK	yes	Genotype GG is associated with increased concentrations of cyclosporine in people with Kidney Transplantation as compared to genotype AA.	A		= 0.005	OR			
1448495164	rs2606345	exemestane	Metabolism/PK	no	Genotypes AA + AC are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to genotype CC.			= 1.0	OR			
1448493593	rs17134592	exemestane	Metabolism/PK	no	Genotypes CG + GG are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to genotype CC.	G		= 0.42	OR			
1448996481	rs12459249	nicotine	Metabolism/PK	yes	Allele C is associated with decreased metabolism of nicotine as compared to allele T.	C		= 1.47E-39	OR			
1449003206	CYP2D6 poor metabolizer genotype	noroxymorphone	Metabolism/PK	yes	CYP2D6 poor metabolizer genotype is associated with decreased concentrations of noroxymorphone in healthy individuals as compared to CYP2D6 ultrarapid metabolizer genotype.			= 2.8E-5	OR			
1448530379	rs2032582	sunitinib	Dosage,Toxicity	yes	Genotypes AA + AT is associated with increased dose of sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC.			= 0.024	HR	2.106	1.015	4.371
1448603564	rs1800871	tacrolimus	Metabolism/PK	no	Genotypes AG + GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype AA.	A		> 0.05	OR			
1448613410	rs4986893	selumetinib	Metabolism/PK	no	Allele G is not associated with metabolism of selumetinib in healthy individuals as compared to allele A.			= 0.063	OR		-0.117	0.243
1448613410	rs4986893	selumetinib	Metabolism/PK	no	Allele G is not associated with metabolism of selumetinib in healthy individuals as compared to allele A.	A	G	= 0.497	OR			
1448613410	rs4986893	selumetinib	Metabolism/PK	no	Allele G is not associated with metabolism of selumetinib in healthy individuals as compared to allele A.	A	G		OR			
1448613410	rs4986893	selumetinib	Metabolism/PK	no	Allele G is not associated with metabolism of selumetinib in healthy individuals as compared to allele A.	A	G		OR			
1448624859	rs2254638	clopidogrel	Metabolism/PK	yes	Allele G is associated with decreased metabolism of clopidogrel as compared to genotype AA.			= 0.0166	OR			
1448612424	rs2273697	talinolol	Metabolism/PK	no	Allele A is not associated with clearance of talinolol in healthy individuals as compared to allele G.	A			OR			
1448639044	rs4244285	bupropion	Metabolism/PK	no	Genotype AA is not associated with metabolism of bupropion in healthy individuals as compared to genotypes AG + GG.	A	G	> 0.05	OR			
1449002579	rs2032582	opioids	Dosage,Efficacy	no	Allele C is not associated with dose of opioids in people with Pain, Postoperative.	A		= 0.218	Unknown	-0.276	-0.715	0.163
1448530748	rs2032582	sunitinib	Metabolism/PK	no	Allele C is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele T.	C			OR			
1448997158	rs28399499	efavirenz	Metabolism/PK	yes	Genotypes CC + CT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype TT.			< 0.001	OR			
1448632439	rs35694136	olanzapine	Metabolism/PK	yes	Genotype T/del is associated with increased concentrations of olanzapine in people with Schizophrenia as compared to genotype TT.	del		= 0.009	OR			
1449146940	CYP2C19 ultrarapid metabolizer	voriconazole	Metabolism/PK	yes	CYP2C19 ultrarapid metabolizer is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 normal metabolizer.			= 0.027	OR			
1448999777	rs12208357	metformin	Metabolism/PK	yes	Genotype TT is associated with decreased exposure to metformin in healthy individuals as compared to genotype CC.			< 0.05	OR			
1449165208	rs2289669	metformin	Metabolism/PK	no	Allele A is not associated with exposure to metformin as compared to allele G.	A	G	> 0.15	OR			
1449749382	rs3814055	tacrolimus	Metabolism/PK	no	Genotypes CT + TT is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	T			OR			
1449170856	CYP2C9 poor metabolizer and intermediate metabolizer genotypes	endoxifen	Metabolism/PK	no	CYP2C9 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of endoxifen in women with Breast Neoplasms.			= 0.4771	OR			
1449163533	rs4646450	tacrolimus	Metabolism/PK	yes	Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.	A		= 3.46E-38	OR			
1449163533	rs4646450	tacrolimus	Metabolism/PK	yes	Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.	A		= 4.91E-07	OR			
1449733121	rs2287622	rosuvastatin	Metabolism/PK	yes	Allele G is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele A.			= 0.003	OR			
1449295963	rs7668258	morphine	Dosage,Efficacy	no	Allele C is not associated with dose of morphine in people with Pain, Postoperative as compared to allele T.	C			OR			
1449295957	rs7438135	morphine	Dosage,Efficacy	no	Allele G is not associated with dose of morphine in people with Pain, Postoperative as compared to allele A.	A			OR			
1449295969	rs73823859	morphine	Dosage,Efficacy	no	Allele G is not associated with dose of morphine in people with Pain, Postoperative as compared to allele A.	G			OR			
1449171313	CYP2D6 ultrarapid metabolizer phenotype	morphine	Dosage,Efficacy	yes	CYP2D6 ultrarapid metabolizer phenotype is associated with decreased dose of morphine in women with Pain, Postoperative.			= 0.0091	OR			
1449165091	rs9923231	warfarin	Metabolism/PK	yes	Allele C is associated with increased dose of warfarin as compared to allele T.	A	G	< 0.001	OR			
1449165085	rs9923231	warfarin	Metabolism/PK	yes	Allele C is associated with increased steady-state concentration of warfarin as compared to allele T.	A	G	< 0.001	OR			
1449311424	rs4149056	conjugated estrogens	Metabolism/PK	yes	Genotype TT is associated with decreased concentrations of conjugated estrogens in women with Menopause as compared to genotypes CC + CT.	C	C	= 0.008	OR			
1449311424	rs4149056	conjugated estrogens	Metabolism/PK	yes	Genotype TT is associated with decreased concentrations of conjugated estrogens in women with Menopause as compared to genotypes CC + CT.	C	C	= 0.010	OR			
1449311424	rs4149056	conjugated estrogens	Metabolism/PK	yes	Genotype TT is associated with decreased concentrations of conjugated estrogens in women with Menopause as compared to genotypes CC + CT.	C	C	= 0.032	OR			
1449560356	rs2011425	lamotrigine	Metabolism/PK	no	Allele G is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele T.			> 0.0125	OR			
1449732418	CYP2C19 intermediate metabolizer and normal metabolizer	voriconazole	Metabolism/PK	no	Genotypes *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) are not associated with metabolism of voriconazole in people with Mycoses.			= 0.086	OR	0.48	0.21	1.1
1449732418	CYP2C19 intermediate metabolizer and normal metabolizer	voriconazole	Metabolism/PK	no	Genotypes *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) are not associated with metabolism of voriconazole in people with Mycoses.			= 0.6	OR	0.81	0.37	1.79
1449732409	CYP2C19 poor metabolizers	voriconazole	Metabolism/PK	yes	Genotypes *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of voriconazole in people with Mycoses.			= 0.011	OR	42.76	2.32	786.69
1449565316	CYP2C19*2	phenytoin	Dosage,Metabolism/PK	no	CYP2C19 *2 is associated with increased concentrations of phenytoin.				OR			
1449565307	CYP2C9*3	phenytoin	Dosage,Metabolism/PK	no	CYP2C9 *3 is associated with increased concentrations of phenytoin.				OR			
1449310602	rs2032582	axitinib	Metabolism/PK	yes	Allele T is associated with concentrations of axitinib in people with Carcinoma, Renal Cell as compared to allele C.				OR			
1449162619	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	desvenlafaxine	Metabolism/PK	not stated	CYP2D6 poor metabolizer and intermediate metabolizer genotypes is associated with increased concentrations of desvenlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizer and ultra-metabolizer genotypes.				OR			
1449163088	rs1128503	tacrolimus	Metabolism/PK	no	Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.				OR			
1449161678	CYP3A poor metabolizers	fentanyl	Metabolism/PK	yes	CYP3A poor metabolizers are associated with decreased metabolism of fentanyl in people with Pain.			= 0.015	OR			
1449733079	rs56903885	rosuvastatin	Metabolism/PK	yes	Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.			= 0.007	OR			
1449733054	rs11045873	rosuvastatin	Metabolism/PK	yes	Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele T.			= 0.002	OR			
1449733062	rs11045874	rosuvastatin	Metabolism/PK	yes	Allele C is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.			= 0.002	OR			
1449171074	rs4803419	methadone	Metabolism/PK	no	Allele T is not associated with concentrations of methadone as compared to allele C.	T	T		OR			
1450044766	rs2231142	ceftriaxone	Metabolism/PK	no	Allele T is not associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to allele G.				OR			
1450377018	rs2273897	emtricitabine	Metabolism/PK	yes	Genotype TT is associated with increased concentrations of emtricitabine in people with HIV Infections and Pregnancy as compared to genotypes CC + CT.	T		= 0.028	OR			
1450806633	CYP2C19 poor metabolizers	rabeprazole	Metabolism/PK	yes	CYP2C19 poor metabolizers are associated with decreased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.			< 0.05	OR			
1446767291	rs3002143	vancomycin	Metabolism/PK	no	Allele C is not associated with trough concentration of vancomycin as compared to allele T.	T	C	= 4.98E-5	OR			
1450935725	rs61311738	mephenytoin	Metabolism/PK	yes	Allele T is associated with decreased clearance of mephenytoin as compared to allele C.			< 0.05				
1450935708	rs149158426	tolbutamide	Metabolism/PK	no	Allele T is not associated with clearance of tolbutamide as compared to allele C.			> 0.05				
1449733134	rs3212207	rosuvastatin	Metabolism/PK	yes	Allele C is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele G.			= 0.01	OR			
1450935691	rs762081829	tolbutamide	Metabolism/PK	yes	Allele T is associated with decreased clearance of tolbutamide as compared to allele C.			< 0.01				
1450045067	rs2756109	methotrexate	Metabolism/PK	no	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	G		> 0.0001	OR			
1450045091	rs3740074	methotrexate	Metabolism/PK	no	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	C		> 0.0001	OR			
1450045073	rs2273697	methotrexate	Metabolism/PK	no	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.	A		> 0.0001	OR			
1450045079	rs717620	methotrexate	Metabolism/PK	no	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	T		> 0.0001	OR			
1451105117	rs2231142	letermovir	Metabolism/PK	no	Allele T is not associated with exposure to letermovir as compared to allele G.	T		= 0.696				
1450342285	SLC22A1 low activity	codeine	Metabolism/PK	no	SLC22A1 low activity is not associated with increased concentrations of codeine in healthy individuals as compared to SLC22A1 high activity.			= 0.6	OR			
1450112752	rs7662029	mycophenolic acid	Metabolism/PK	yes	Allele G is associated with increased dose-adjusted trough concentrations of mycophenolic acid in people with Kidney Transplantation as compared to allele A.			= 0.028	OR			
1184512540	rs2472677	efavirenz	Metabolism/PK	no	Genotype CC is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype TT.			> 0.05	OR			
1184512544	rs6785049	efavirenz	Metabolism/PK	no	Genotype AG is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype GG.			> 0.05	OR			
1450807038	rs11648166	anastrozole	Metabolism/PK	yes	Allele G is associated with increased concentrations of anastrozole in women with Breast Neoplasms as compared to allele A.	G		= 2.3e-8	OR			
1450989046	rs1045642	erlotinib	Toxicity,Metabolism/PK	yes	Genotype AA is associated with decreased clearance of erlotinib in people with Carcinoma, Non-Small-Cell Lung.			= 0.021	Unknown			
1450989200	rs2032582	crizotinib	Metabolism/PK	no	Genotype AA is associated with increased exposure to crizotinib in people with.				OR			
1451094960	rs4633	morphine	Dosage,Efficacy	yes	Allele C is associated with increased dose of morphine in people with Pain, Postoperative and Coronary Artery Disease as compared to allele T.			= 0.009				
1451094960	rs4633	morphine	Dosage,Efficacy	yes	Allele C is associated with increased dose of morphine in people with Pain, Postoperative and Coronary Artery Disease as compared to allele T.			= 0.025				
1451094980	rs4680	morphine	Dosage,Efficacy	yes	Allele G is associated with increased dose of morphine in people with Pain, Postoperative and Coronary Artery Disease as compared to allele A.			= 0.009				
1451094980	rs4680	morphine	Dosage,Efficacy	yes	Allele G is associated with increased dose of morphine in people with Pain, Postoperative and Coronary Artery Disease as compared to allele A.			= 0.025				
1451122208	rs3732359	voriconazole	Metabolism/PK	yes	Genotype GG is associated with increased concentrations of voriconazole as compared to genotype AA.			= 0.013				
1451097945	rs12208357	cycloguanil	Metabolism/PK	yes	Allele T are associated with increased concentrations of cycloguanil in healthy individuals as compared to allele C.			= 0.02	OR			
1451098246	rs34059508	o-desmethyltramadol	Metabolism/PK	yes	Allele A is associated with increased concentrations of o-desmethyltramadol in people with Pain as compared to allele G.			< 0.03	OR			
1449563883	rs11212617	metformin	Metabolism/PK	no	Allele C is associated with decreased concentrations of metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	C		= 0.0128	OR			
1183685478	CYP3A5*3	voriconazole	Metabolism/PK	no	CYP3A5 *3 is not associated with metabolism of voriconazole in healthy individuals.	*3			OR			
1451105120	rs2306283	letermovir	Metabolism/PK	no	Allele G is not associated with exposure to letermovir as compared to allele A.	G		= 0.632				
1449169568	rs5186	atorvastatin	Metabolism/PK	yes	Genotype AC is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes AA + CC.	A	C	= 0.015	OR			
1449169568	rs5186	atorvastatin	Metabolism/PK	yes	Genotype AC is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes AA + CC.	A	C	= 0.015	OR			
1449169568	rs5186	atorvastatin	Metabolism/PK	yes	Genotype AC is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes AA + CC.	A	C	= 0.015	OR			
1449169568	rs5186	atorvastatin	Metabolism/PK	yes	Genotype AC is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes AA + CC.	A	C	> 0.05	OR			
1449169568	rs5186	atorvastatin	Metabolism/PK	yes	Genotype AC is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes AA + CC.	A	C	> 0.05	OR			
1449169568	rs5186	atorvastatin	Metabolism/PK	yes	Genotype AC is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes AA + CC.	A	C	> 0.05	OR			
1451114623	rs4149056	lopinavir	Metabolism/PK	yes	Genotypes CC + CT are associated with increased trough concentration of lopinavir in men with HIV Infections as compared to genotype TT.	C		= 0.03				
1448613196	rs4553808	tacrolimus	Metabolism/PK	yes	Genotype AA is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	A		= 0.041	OR			
1447987295	rs62471956	ticagrelor	Metabolism/PK	yes	Allele G is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele A.	A		= 1.32E-14	OR			
1449165223	rs784892	metformin	Metabolism/PK	no	Allele A is not associated with exposure to metformin as compared to allele G.	A	G	> 0.15	OR			
1448636647	rs35599367	everolimus	Metabolism/PK	yes	Genotype AG is associated with increased concentrations of everolimus in women with Breast Neoplasms as compared to genotype GG.	A	G	= 0.019	OR			
1449163518	rs41303343	tacrolimus	Metabolism/PK	yes	Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele del.	A		= 1.18E-09	OR			
1448613514	rs4148323	selumetinib	Metabolism/PK	no	Allele G is not associated with dose of selumetinib in healthy individuals as compared to allele A.			= 0.507	OR		-0.143	0.289
1448613514	rs4148323	selumetinib	Metabolism/PK	no	Allele G is not associated with dose of selumetinib in healthy individuals as compared to allele A.	G	A	= 0.511	OR			
1448613514	rs4148323	selumetinib	Metabolism/PK	no	Allele G is not associated with dose of selumetinib in healthy individuals as compared to allele A.	G	A		OR			
1448613514	rs4148323	selumetinib	Metabolism/PK	no	Allele G is not associated with dose of selumetinib in healthy individuals as compared to allele A.	G	A		OR			
1450807049	rs28845026	anastrozole	Metabolism/PK	yes	Allele T is associated with increased concentrations of anastrozole in women with Breast Neoplasms as compared to allele C.	T		= 5.4e-8	OR			
1449752066	rs11030918	ara-CTP	Metabolism/PK	yes	Genotypes CT + TT is associated with decreased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype CC.	C		= 0.0025	OR			
982017795	rs11568482	cefotaxime	Metabolism/PK	yes	Genotype AT is associated with decreased clearance of cefotaxime in healthy individuals as compared to genotype TT.	T	T	= 0.006	Unknown			
1448435387	rs10929302	SN-38	Metabolism/PK	no	Genotypes AG + GG are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.			= 0.033	OR			
1449750697	rs1142345	thioguanine	Metabolism/PK	no	Allele C is not associated with concentrations of thioguanine in people with Autoimmune Diseases, Lupus Erythematosus, Systemic and Sjogren's Syndrome as compared to allele T.				OR			
827816359	rs1799971	methadone	Dosage,Metabolism/PK	no	Genotype GG is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype AA.	G			Unknown			
1450821136	rs1799971	opioids	Dosage,Efficacy	yes	Genotypes AG + GG are associated with increased dose of opioids in people with Pain, Postoperative as compared to genotype AA.			= 0.003				
1450821136	rs1799971	opioids	Dosage,Efficacy	yes	Genotypes AG + GG are associated with increased dose of opioids in people with Pain, Postoperative as compared to genotype AA.							
1450821136	rs1799971	opioids	Dosage,Efficacy	yes	Genotypes AG + GG are associated with increased dose of opioids in people with Pain, Postoperative as compared to genotype AA.							
1451118400	rs1799971	opioids	Dosage,Efficacy	yes	Genotypes AG + GG are associated with increased dose of opioids in people with Pain or Pain, Postoperative as compared to genotype AA.			< 0.001				
1451118400	rs1799971	opioids	Dosage,Efficacy	yes	Genotypes AG + GG are associated with increased dose of opioids in people with Pain or Pain, Postoperative as compared to genotype AA.			= 0.005				
1451118400	rs1799971	opioids	Dosage,Efficacy	yes	Genotypes AG + GG are associated with increased dose of opioids in people with Pain or Pain, Postoperative as compared to genotype AA.			= 0.143				
769170744	rs1801133	methotrexate	Toxicity,Metabolism/PK	no	Allele A is not associated with response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.				Unknown			
1448634598	rs717620	mycophenolic acid	Metabolism/PK	yes	Allele T is associated with exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele C.			= 0.024	OR			
1448634598	rs717620	mycophenolic acid	Metabolism/PK	yes	Allele T is associated with exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele C.			= 0.048	OR			
1448634590	rs717620	mycophenolic acid	Metabolism/PK	yes	Allele T is associated with exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele C.			= 0.018	OR			
1451105105	rs4149032	letermovir	Metabolism/PK	yes	Genotype TT is associated with decreased exposure to letermovir as compared to genotypes CC + CT.	T		= 0.0057				
1450823509	rs4149056	fluvastatin	Metabolism/PK	yes	Allele C is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele T.			= 8.15e-8				
1451115920	rs4149056	saquinavir	Metabolism/PK	no	Allele C is not associated with trough concentration of saquinavir in people with HIV Infections as compared to allele T.	C		= 0.98				
1448105647	rs20572	doxorubicin	Metabolism/PK	yes	Genotype CC is associated with increased clearance of doxorubicin in people with Breast Neoplasms as compared to genotype CT.	C	C	= 0.028	OR			
1448613426	rs2231142	selumetinib	Metabolism/PK	no	Allele T is not associated with metabolism of selumetinib in healthy individuals as compared to allele G.	T	G	= 0.400	OR			
1448613426	rs2231142	selumetinib	Metabolism/PK	no	Allele T is not associated with metabolism of selumetinib in healthy individuals as compared to allele G.	T	G	= 0.471	OR			
1448613426	rs2231142	selumetinib	Metabolism/PK	no	Allele T is not associated with metabolism of selumetinib in healthy individuals as compared to allele G.			= 0.546	OR		-0.063	0.118
1448613426	rs2231142	selumetinib	Metabolism/PK	no	Allele T is not associated with metabolism of selumetinib in healthy individuals as compared to allele G.	T	G	= 0.947	OR			
1296598942	rs2231142	methotrexate	Metabolism/PK	no	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.			= 0.591	OR	0.7	0.19	12.59
1296598942	rs2231142	methotrexate	Metabolism/PK	no	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.			= 0.922	OR	0.94	0.27	23.36
1185235766	rs2250242	atrasentan	Metabolism/PK	no	Genotype AA is not associated with clearance of atrasentan in men with Prostatic Neoplasms as compared to genotypes AG + GG.			= 0.16	OR			
1446899416	rs71647871	enalapril	Metabolism/PK	yes	Genotype CT is associated with decreased metabolism of enalapril in healthy individuals as compared to genotype CC.	C	T	= 0.044	OR			
1446899416	rs71647871	enalapril	Metabolism/PK	yes	Genotype CT is associated with decreased metabolism of enalapril in healthy individuals as compared to genotype CC.	C	T	= 0.049	OR			
1448109930	rs1801133	methotrexate	Metabolism/PK	yes	Genotype AA is associated with increased concentrations of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.			= 0.028	OR			
1447947806	rs1057910	irbesartan	Metabolism/PK	yes	Genotype AC is associated with increased concentrations of irbesartan in healthy individuals as compared to genotype AA.			< 0.01	OR			
1448997496	rs3745274	efavirenz	Metabolism/PK	not stated	Genotypes GT + TT are associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.				OR			
1449733168	rs3740066	rosuvastatin	Metabolism/PK	yes	Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele C.			= 0.01	OR			
1448997209	rs3745274	efavirenz	Metabolism/PK	yes	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.			= 1.9e-9	OR			
1448998426	rs3745274	efavirenz	Metabolism/PK	not stated	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	T			OR			
1450807575	rs2472677	isoniazid	Metabolism/PK	yes	Genotype TT is associated with increased exposure to isoniazid in people with HIV Infections and Tuberculosis as compared to genotypes CC + CT.			= 0.005	OR			
